<SEC-DOCUMENT>0001144204-19-040329.txt : 20190816
<SEC-HEADER>0001144204-19-040329.hdr.sgml : 20190816
<ACCEPTANCE-DATETIME>20190816083624
ACCESSION NUMBER:		0001144204-19-040329
CONFORMED SUBMISSION TYPE:	SUPPL
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20190816
DATE AS OF CHANGE:		20190816
EFFECTIVENESS DATE:		20190816

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SUPPL
		SEC ACT:		
		SEC FILE NUMBER:	333-224432
		FILM NUMBER:		191031587

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>SUPPL
<SEQUENCE>1
<FILENAME>tv527785_suppl.htm
<DESCRIPTION>SUPPL
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Filed pursuant to General Instruction
II.L of Form F-10</B><BR>
<B>File No. 333-224432</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(To Base Shelf Prospectus dated May
4, 2018)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tv527785_img01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>5,312,738 Common Shares</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are hereby qualifying for distribution
the issuance of: (i) up to 4,619,773 common shares (&quot;<B>Common Shares</B>&quot;) of the Corporation, issuable from time to
time, on exercise of up to 4,619,773 Common Share purchase warrants (expected to be issued by us on or about August 16, 2019 pursuant
to the Unit Offering (as defined herein), (ii) up to 692,965 Common Shares issuable from time to time, on exercise of 692,965 Common
Share purchase warrants that may be issued on the exercise of the over-allotment option (&ldquo;<B>Over-Allotment Option</B>&rdquo;)
granted to the underwriter pursuant to the Unit Offering; and (iii) such indeterminate number of additional Common Shares that
may be issuable by reason of the anti-dilution provisions contained in the Warrant Agency Agreement (as defined herein). The Common
Shares issuable upon exercise of Warrants, including any Warrants issued pursuant to the Over-Allotment Option are referred to
herein as the &ldquo;<B>Warrant Shares</B>&rdquo;. See &quot;<I>Terms of Warrants</I>&quot; for additional information on the terms
of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 14, 2019, we filed a prospectus
supplement to the Prospectus with the Alberta Securities Commission and a registration statement on Form F-10 (File No. 333224432),
principally filed on April 25, 2018, as amended May 4, 2018, with the United States Securities and Exchange Commission (the &quot;<B>SEC</B>&quot;)
relating to the offering (the &quot;<B>Unit Offering</B>&quot;) by us in the of up 4,619,773 units of the Corporation (the &quot;<B>Units</B>&quot;),
each Unit consisting of one Common Share and one Common Share purchase warrant (each, a &quot;<B>Warrant</B>&quot;) at a price
of US$0.80 per Unit. Each Warrant will entitle the holder to purchase one Warrant Share upon payment of US$0.90, subject to adjustment,
at any time until 5:00 p.m. (New York City time) on the date that is five years from the date of the closing of the Unit Offering.
The exercise price of the Warrants was determined by negotiation between us and the underwriter for the Unit Offering. See &quot;<I>Plan
of Distribution</I>&quot; for additional information on the Unit Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Common Shares are listed on Nasdaq
under the symbol &ldquo;ONCY&rdquo; and on the Toronto Stock Exchange (&ldquo;<B>TSX</B>&rdquo;) under the symbol &ldquo;ONC&rdquo;.
On August 14, 2019, the closing price of our Common Shares on Nasdaq was US$0.58 per Common Share and on the TSX was C$0.76 per
Common Share. We have applied to list the Common Shares issuable qualified by this Prospectus Supplement on Nasdaq and the TSX.
Listing will be subject to us fulfilling the listing requirements of Nasdaq and the TSX, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>An investment in the Warrant Shares
is speculative and bears certain risks. See &ldquo;<I>Risk Factors</I>&rdquo; in this Prospectus Supplement and the Prospectus.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>This offering is made by a Canadian
issuer that is permitted, under a multijurisdictional disclosure system adopted by the United States and Canada (&ldquo;MJDS&rdquo;),
to prepare this Prospectus Supplement and the Prospectus in accordance with Canadian disclosure requirements. Prospective investors
in the United States should be aware that such requirements are different from those of the United States. Financial statements
included or incorporated by reference in the Prospectus have been prepared in accordance with International Financial Reporting
Standards (&ldquo;IFRS&rdquo;) as issued by the International Accounting Standards Board (&ldquo;IASB&rdquo;) and may not be comparable
to financial statements of United States companies. Such financial statements are subject to the standards of the Public Company
Accounting Oversight Board (United States) and the United States Securities and Exchange Commission (&ldquo;SEC&rdquo;) independence
standards.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Prospective investors should be aware
that the acquisition of Warrant Shares described herein and the exercise of the Warrants may have tax consequences both in the
United States and in Canada. Such consequences for investors who are resident in, or citizens of, the United States may not be
described fully herein. This Prospectus Supplement and the Prospectus may not describe these tax consequences fully. You should
read the tax discussion under the headings &ldquo;<I>Certain U.S. Federal Income Tax Considerations</I>&rdquo; and &ldquo;<I>Certain
Canadian Federal Income Tax Considerations</I>&rdquo; in this Prospectus Supplement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The enforcement by investors of civil
liabilities under the United States federal securities laws may be affected adversely by the fact that the Corporation is incorporated
under the laws of Alberta, Canada, that the majority of its officers and directors are residents of Canada, that many of the experts
named in this Prospectus Supplement and the Prospectus are not residents of the United States, and that a substantial portion of
the assets of the Corporation and said persons are located outside the United States. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NEITHER THE SEC NOR ANY STATE OR CANADIAN
SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED THE SECURITIES OFFERED HEREBY OR DETERMINED IF THIS PROSPECTUS SUPPLEMENT OR
THE ACCOMPANYING PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENCE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial information of the Corporation
incorporated by reference in the Prospectus is presented in Canadian dollars. Unless otherwise noted herein, all references to
&ldquo;US$&rdquo;, &ldquo;United States dollars&rdquo; or &ldquo;US dollars&rdquo; are to United States dollars and all references
to &ldquo;C$&rdquo; or &ldquo;$&rdquo;, are to Canadian dollars. See &ldquo;<I>Exchange Rate</I>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our head office and principal place of
business is located at 210, 1167 Kensington Crescent N.W., Calgary, Alberta, T2N 1X7. Our registered office is located at 4000,
421 - 7<SUP>th</SUP> Avenue S.W., Calgary, Alberta, T2P 4K9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this Prospectus Supplement
is August 15, 2019.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal"><U>Prospectus
Supplement</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%"><A HREF="#main_001">IMPORTANT NOTICE ABOUT INFORMATION IN THIS PROSPECTUS SUPPLEMENT</A></TD>
    <TD STYLE="width: 10%; text-align: right"><A HREF="#main_001">S-4</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#main_002">FORWARD-LOOKING STATEMENTS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#main_002">S-4</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#main_003">DOCUMENTS INCORPORATED BY REFERENCE</A></TD>
    <TD STYLE="text-align: right"><A HREF="#main_003">S-6</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#main_004">DOCUMENTS FILED AS PART OF THE REGISTRATION STATEMENT</A></TD>
    <TD STYLE="text-align: right"><A HREF="#main_004">S-7</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#main_005">CURRENCY AND EXCHANGE RATE INFORMATION</A></TD>
    <TD STYLE="text-align: right"><A HREF="#main_005">S-7</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#main_006">RISK FACTORS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#main_006">S-8</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#main_007">THE CORPORATION</A></TD>
    <TD STYLE="text-align: right"><A HREF="#main_007">S-9</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#main_008">RECENT DEVELOPMENTS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#main_008">S-10</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#main_009">BUSINESS OF THE CORPORATION</A></TD>
    <TD STYLE="text-align: right"><A HREF="#main_009">S-10</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#main_010">USE OF PROCEEDS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#main_010">S-15</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#main_011">COMMON SHARES</A></TD>
    <TD STYLE="text-align: right"><A HREF="#main_011">S-15</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#main_012">TERMS OF WARRANTS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#main_012">S-15</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#main_013">CONSOLIDATED CAPITALIZATION</A></TD>
    <TD STYLE="text-align: right"><A HREF="#main_013">S-17</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#main_014">TRADING PRICE AND VOLUME</A></TD>
    <TD STYLE="text-align: right"><A HREF="#main_014">S-17</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#main_015">PRIOR SALES</A></TD>
    <TD STYLE="text-align: right"><A HREF="#main_015">S-18</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#main_016">PLAN OF DISTRIBUTION</A></TD>
    <TD STYLE="text-align: right"><A HREF="#main_016">S-19</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#main_017">CERTAIN UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#main_017">S-20</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#main_018">CERTAIN CANADIAN FEDERAL INCOME TAX CONSIDERATIONS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#main_018">S-28</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#main_019">LEGAL MATTERS AND INTEREST OF EXPERTS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#main_019">S-30</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#main_020">AGENT FOR SERVICE OF PROCESS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#main_020">S-30</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#main_021">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></TD>
    <TD STYLE="text-align: right"><A HREF="#main_021">S-30</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal"><U>Base
Shelf Prospectus dated May 4, 2018</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_001">ABOUT
    THIS PROSPECTUS AND OTHER MATTERS</A></FONT></TD>
    <TD STYLE="width: 10%; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_001">4</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_002">FORWARD-LOOKING
    STATEMENTS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_002">4</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_003">RISK
    FACTORS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_003">6</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_004">DOCUMENTS
    INCORPORATED BY REFERENCE</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_004">6</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_005">DOCUMENTS
    FILED AS PART OF THE REGISTRATION STATEMENT</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_005">7</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_006">ADDITIONAL
    INFORMATION</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_006">8</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_007">THE
    CORPORATION</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_007">8</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_008">BUSINESS
    OF THE CORPORATION</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_008">8</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_009">CONSOLIDATED
    CAPITALIZATION</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_009">9</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_010">USE
    OF PROCEEDS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_010">9</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_011">DESCRIPTION
    OF SHARE CAPITAL</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_011">9</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_012">DESCRIPTION
    OF SUBSCRIPTION RECEIPTS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_012">10</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_013">DESCRIPTION
    OF WARRANTS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_013">11</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_014">DESCRIPTION
    OF UNITS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_014">12</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_015">PLAN
    OF DISTRIBUTION</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_015">12</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_016">PRIOR
    SALES</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_016">13</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_017">TRADING
    PRICE AND VOLUME</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_017">13</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_018">CERTAIN
    INCOME TAX CONSIDERATIONS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_018">14</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_019">LEGAL
    MATTERS AND INTERESTS OF EXPERTS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_019">14</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_020">AUDITORS,
    TRANSFER AGENT AND REGISTRAR</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_020">14</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_021">AGENT
    FOR SERVICE OF PROCESS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_021">14</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_022">ENFORCEABILITY
    OF CIVIL LIABILITIES AGAINST NON-U.S. PERSONS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_022">14</A></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="main_001"></A>IMPORTANT NOTICE
ABOUT INFORMATION IN THIS PROSPECTUS SUPPLEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This document is in two parts. The first
part is this Prospectus Supplement, which describes the specific terms of the Warrant Shares and also supplements and updates information
regarding Oncolytics Biotech Inc. contained and incorporated by reference in the Prospectus. The second part is the accompanying
Prospectus, which gives more general information, some of which may not apply to the Warrant Shares. Both documents contain important
information you should consider when making your investment decision. If the description of the Warrant Shares and Warrants varies
between this Prospectus Supplement and the accompanying Prospectus, investors should rely on the information in this Prospectus
Supplement. This Prospectus Supplement is deemed to be incorporated by reference into the Prospectus solely for the purpose of
the offering of Warrant Shares on the exercise of Warrants. If information in this Prospectus Supplement is inconsistent with the
Prospectus or the information incorporated by reference in the Prospectus, you should rely on this Prospectus Supplement. You should
read both this Prospectus Supplement and the accompanying Prospectus, together with the additional information about us to which
we refer you in the section of this Prospectus Supplement entitled &ldquo;<I>Where You Can Find Additional Information</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>You should rely only on the information
contained in this Prospectus Supplement, the Prospectus and the documents incorporated by reference in the Prospectus. The Corporation
has not authorized anyone to provide you with different information. If anyone provides you with any different or inconsistent
information, you should not rely on it. The Corporation is offering the Warrant Shares only in jurisdictions where such offers
are permitted by law.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>You should assume that the information
contained in this Prospectus Supplement, the Prospectus and the documents incorporated by reference in the Prospectus is accurate
only as of their respective dates, regardless of the time of delivery of this Prospectus Supplement and the accompanying Prospectus.
</B>Our business, financial condition, results of operations and prospects may have changed since those dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Market data and certain industry forecasts
used in this Prospectus Supplement, the Prospectus and the documents incorporated by reference in the Prospectus were obtained
from market research, publicly available information and industry publications. We believe that these sources are generally reliable,
but the accuracy and completeness of this information is not guaranteed. We have not independently verified such information, and
we do not make any representation as to the accuracy of such information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this Prospectus Supplement, &ldquo;<B>Oncolytics</B>,&rdquo;
the &ldquo;<B>Corporation</B>,&rdquo; &ldquo;<B>we</B>,&rdquo; &ldquo;<B>us</B>,&rdquo; and &ldquo;<B>our</B>&rdquo; refer to Oncolytics
Biotech Inc. and its subsidiaries.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="main_002"></A>FORWARD-LOOKING STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Prospectus Supplement, the Prospectus
and the documents incorporated by reference in the Prospectus contain certain statements relating to future events or the Corporation&rsquo;s
future performance which constitute forward-looking statements. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause the actual results, performance or achievements of the Corporation, or industry
results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking
statements. Forward-looking statements are statements that are not historical facts, and include, but are not limited to, estimates
and their underlying assumptions; statements regarding plans, objectives and expectations with respect to the efficacy of our technologies;
the timing and results of clinical studies related to our technologies; future operations, products and services; the impact of
regulatory initiatives on our operations; the size of and opportunities related to the markets for our technologies; general industry
and macroeconomic growth rates; expectations related to possible joint and/or strategic ventures and statements regarding future
performance. Forward-looking statements generally, but not always, are identified by the words &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo;
&ldquo;believes,&rdquo; &ldquo;intends,&rdquo; &ldquo;estimates,&rdquo; &ldquo;projects&rdquo;, &ldquo;potential&rdquo;, &ldquo;possible&rdquo;
and similar expressions, or that events or conditions &ldquo;will,&rdquo; &ldquo;may,&rdquo; &ldquo;could&rdquo; or &ldquo;should&rdquo;
occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The forward-looking statements in this
Prospectus Supplement, the Prospectus and the documents incorporated by reference in the Prospectus are subject to various risks
and uncertainties, most of which are difficult to predict and generally beyond the Corporation&rsquo;s control, including without
limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to all of our products, including pelareorep, being in the research and development
stage and requiring further development and testing before they can be marketed commercially;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks inherent in pharmaceutical research and development;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to timing and possible delays in our clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to some of our clinical trials being conducted in, and subject to the laws of, foreign
countries;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our pharmaceutical products being subject to intense regulatory approval processes
in the United States and other foreign jurisdictions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to being subject to government manufacturing and testing regulations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the extremely competitive biotechnology industry and our competition with larger
companies with greater resources;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our reliance on patents and proprietary rights to protect our technology;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to potential product liability claims;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our limited manufacturing experience and reliance on third parties to commercially
manufacture our products, if and when developed;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our new products not being accepted by the medical community or consumers;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our technologies becoming obsolete;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our dependence on third party relationships for research and clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our license, development, supply and distribution agreement with Adlai Nortye
Biopharma Co. Ltd.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our lack of operating revenues and history of losses;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">uncertainty regarding our ability to obtain third-party reimbursement for the costs of our product;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to other third-party arrangements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our ability to obtain additional financing to fund future research and development
of our products and to meet ongoing capital requirements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to potential increases in the cost of director and officer liability insurance;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our dependence on key employees and collaborators;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to Barbados law, including those relating to the enforcement of judgments obtained
in Canada or the United States;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the effect of changes in the law on our corporate structure;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to expenses in foreign currencies and our exposure to foreign currency exchange rate
fluctuations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to fluctuations in interest rates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to information technology systems; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our Common Shares, including the Warrant Shares, and Warrants.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This list is not exhaustive of the factors
that may affect any of the Corporation&rsquo;s forward-looking statements. Some of the important risks and uncertainties that could
affect forward-looking statements are described further under the heading &ldquo;<I>Risk Factors</I>&rdquo; in this Prospectus
Supplement, in the Prospectus and in the Corporation&rsquo;s Annual Report (as defined below). If one or more of these risks or
uncertainties materializes, or if underlying assumptions prove incorrect, our actual results may vary materially from those expected,
estimated or projected. Forward-looking statements in this document are not a prediction of future events or circumstances, and
those future events or circumstances may not occur. Given these uncertainties, users of the information included herein, including
investors and prospective investors, are cautioned not to place undue reliance on such forward-looking statements. Investors should
consult our quarterly and annual filings with the securities commissions or similar regulatory authorities in Canada and the SEC
for additional information on risks and uncertainties relating to forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation cautions that the foregoing
list of factors that may affect future results is not exhaustive. The forward-looking information contained in this Prospectus
Supplement, the Prospectus and the documents incorporated by reference in the Prospectus is made as of the date of such documents.
The forward-looking information contained in this Prospectus Supplement, the Prospectus and in the documents incorporated by reference
in the Prospectus is expressly qualified by this cautionary statement. The Corporation does not undertake any obligation to publicly
update or revise any forward-looking information except as required pursuant to applicable securities laws.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="main_003"></A>DOCUMENTS INCORPORATED
BY REFERENCE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>This Prospectus Supplement is deemed
to be incorporated by reference into the Prospectus solely for the purposes of the offering of Warrant Shares issuable on the exercise
of Warrants.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Information has been incorporated by
reference in the Prospectus from documents filed with securities commissions or similar authorities in Canada. </B>Copies of the
documents incorporated herein by reference may be obtained on request without charge from our Corporate Secretary at 210, 1167
Kensington Crescent N.W., Calgary, Alberta, T2N 1X7 telephone (403) 670-7377, and are available electronically under the Corporation&rsquo;s
profile on SEDAR (<U>www.sedar.com</U>) and on EDGAR (<U>www.sec.gov/edgar.shtml</U>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following documents, filed with the
securities commissions or similar regulatory authorities in each of the provinces of Canada and filed with, or furnished to, the
SEC are specifically incorporated by reference into, and form an integral part of, the Prospectus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our annual report on Form 20-F (&ldquo;<B>Annual Report</B>&rdquo;) dated March 15, 2019, for the
year ended December 31, 2018 (filed in Canada with the Canadian securities regulatory authorities in lieu of an annual information
form);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our management information circular dated March 7, 2019 relating to the annual general meeting
of shareholders held on May 2, 2019;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our audited consolidated financial statements, together with the notes thereto, as at December
31, 2018 and 2017, which comprise the consolidated statements of financial position as at December 31, 2018 and 2017, and the consolidated
statements of loss and comprehensive loss, changes in equity, and cash flows for the years ended December 31, 2018, 2017 and 2016,
together with the independent auditors&rsquo; report thereon;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our management&rsquo;s discussion and analysis of financial condition and results of operations
dated March 7, 2019, for the year ended December 31, 2018;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our unaudited interim consolidated financial statements, together with the notes thereto, as at
June 30, 2019 and 2018, which comprise the interim consolidated statements of financial position as at June 30, 2019 and 2018,
and the interim consolidated statements of loss and comprehensive loss, changes in equity, and cash flows for the three and six
months ended June 30, 2019 and 2018;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our management&rsquo;s discussion and analysis of financial condition and results of operations
dated August 2, 2019, for the three and six months ended June 30, 2019; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our material change report dated August 15, 2019 in respect of the Unit Offering.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any documents of the type required by National
Instrument 44-101 - <I>Short Form Prospectus Distributions</I> to be incorporated by reference in a short form prospectus, including
any annual information form, annual report on Form 20-F, comparative annual consolidated financial statements and the auditors&rsquo;
report thereon, comparative interim consolidated financial statements, management&rsquo;s discussion and analysis of financial
condition and results of operations, material change report (except a confidential material change report), business acquisition
report and information circular, if filed by us with the securities commissions or similar authorities in Canada after the date
of this Prospectus Supplement and prior to the date on which the offering of Warrant Shares under this Prospectus Supplement ends,
shall be deemed to be incorporated by reference in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, to the extent that any document
or information incorporated by reference in the Prospectus is included in any report filed with or furnished to the SEC pursuant
to the <I>United States Securities Exchange Act of 1934, as amended</I> (the &ldquo;<B>U.S. Exchange Act</B>&rdquo;), after the
date of this Prospectus Supplement and prior to the date on which the offering of Warrant Shares under this Prospectus Supplement
ends, such document or information shall be deemed to be incorporated by reference as an exhibit to the registration statement
of which this Prospectus Supplement and the Prospectus forms a part (in the case of documents or information deemed furnished on
Form 6-K or Form 8-K, only to the extent specifically stated therein).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Any statement contained in this Prospectus
Supplement, the Prospectus or in a document incorporated or deemed to be incorporated by reference in the Prospectus shall be deemed
to be modified or superseded for the purposes of this Prospectus Supplement and the Prospectus to the extent that a statement contained
herein or in any other subsequently filed document which also is, or is deemed to be, incorporated by reference in the Prospectus
or therein modifies or supersedes such statement. The modifying or superseding statement need not state that it has modified or
superseded a prior statement or include any other information set forth in the document that it modifies or supersedes. The making
of a modifying or superseding statement shall not be deemed an admission for any purposes that the modified or superseded statement,
when made, constituted a misrepresentation, an untrue statement of a material fact or an omission to state a material fact that
was required to be stated or that was necessary to make a statement not misleading in light of the circumstances in which it was
made. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of
this Prospectus Supplement or the Prospectus.</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="main_004"></A>DOCUMENTS FILED AS
PART OF THE REGISTRATION STATEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following documents have been or will
be filed with the SEC as part of the registration statement of which this Prospectus Supplement and the Prospectus forms a part:
(i) the documents set out under the heading &ldquo;<I>Documents Incorporated by Reference</I>&rdquo; in this Prospectus Supplement
and the Prospectus; (ii) the consents of the Corporation&rsquo;s auditor and legal counsels; (iii) the powers of attorney from
the directors and certain officers of the Corporation; (iv) the Underwriting Agreement described in this Prospectus Supplement;
and (v) the Warrant Agency Agreement described in this Prospectus Supplement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="main_005"></A>CURRENCY AND EXCHANGE
RATE INFORMATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this Prospectus Supplement and the accompanying
Prospectus, unless otherwise indicated, all dollar amounts and references to &ldquo;$&rdquo; and &ldquo;US$&rdquo; are to U.S.
dollars and references to &ldquo;C$&rdquo; are to Canadian dollars. This Prospectus Supplement and the accompanying Prospectus
and the documents incorporated by reference in the Prospectus contain translations of some Canadian dollar amounts into U.S. dollars
solely for your convenience.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth, for the periods indicated, the
high, low, average and period-end rates of exchange for US$1.00, expressed in Canadian dollars, posted by the Bank of Canada:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended December 31</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>2018<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>2017<SUP>(2)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>2016<SUP>(2)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; text-align: left">Highest rate during the period</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">C</TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">1.3642</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">C$</TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">1.3743</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">C$</TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">1.4589</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Lowest rate during the period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">C</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.2288</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">C$</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.2128</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">C$</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.2544</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Average rate for the period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">C</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.2957</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">C$</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.2986</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">C$</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.3248</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Rate at the end of the period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">C</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.3642</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">C$</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.2545</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">C$</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.3427</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Notes:</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">2018 and 2017 data from the Bank of Canada reflects the
daily average noon rates.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">2016 data from the Bank of Canada reflects the noon exchange
rates.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 13, 2019, the daily average exchange
rate posted by the Bank of Canada for conversion of U.S. dollars into Canadian dollars was US$1.00 = C$1.3311. Unless otherwise
indicated, currency translation in this Prospectus Supplement reflect the August 13, 2019 rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="main_006"></A>RISK FACTORS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prospective purchasers of Warrant Shares
should consider carefully the risk factors set out in this Prospectus Supplement, the Prospectus and the documents incorporated
by reference in the Prospectus. Discussions of certain risks affecting Oncolytics in connection with its business are set forth
under &ldquo;<I>Risk Factors</I>&rdquo; in the Prospectus and in our annual disclosure documents filed with the various securities
regulatory authorities which are incorporated by reference in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Volatility of market price of the Common
Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The market price of the Common Shares may
be volatile. The volatility may affect the ability of holders of Common Shares to sell the Common Shares at an advantageous price.
Market price fluctuations in the Common Shares may be due to the Corporation&rsquo;s operating results failing to meet the expectations
of securities analysts or investors in any quarter, downward revision in securities analysts&rsquo; estimates, governmental regulatory
action, adverse change in general market conditions or economic trends, acquisitions, dispositions or other material public announcements
by the Corporation or its competitors, along with a variety of additional factors, including, without limitation, those set forth
under &ldquo;<I>Special Notice Regarding Forward-Looking Statements</I>&rdquo; in this Prospectus Supplement. In addition, the
market price for securities in the stock markets, including the Nasdaq and the TSX, recently experienced significant price and
trading fluctuations. These fluctuations have resulted in volatility in the market prices of securities that often has been unrelated
or disproportionate to changes in operating performance. These broad market fluctuations may adversely affect the market price
of the Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Corporation will have broad discretion
over the use of the net proceeds from the offering of the Common Shares issuable on the exercise of Warrants and the Corporation
may not use these proceeds in a manner desired by the Corporation&rsquo;s shareholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management will have broad discretion with
respect to the use of the proceeds from the exercise of the Warrants and investors will be relying on the judgment of management
regarding the application of these proceeds. Management could spend most of the proceeds from the exercise of the Warrants in ways
that the Corporation&rsquo;s shareholders may not desire or that do not yield a favorable return. You will not have the opportunity,
as part of your investment in the Common Shares, to influence the manner in which the proceeds from the exercise of the Warrants
are used. At the date of this Prospectus Supplement, the Corporation intend to use the proceeds from the exercise of the Warrants
as described under the heading &ldquo;<I>Use of Proceeds</I>&rdquo;. However, the Corporation&rsquo;s needs may change as the business
and the industry the Corporation addresses evolve. As a result, the proceeds to be received from the exercise of the Warrants may
be used in a manner significantly different from the Corporation&rsquo;s current expectations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Positive return on an investment in
the Common Shares is not guaranteed</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no guarantee that an investment
in the Common Shares will earn any positive return in the short term or long term. A purchase under the Offering involves a high
degree of risk and should be undertaken only by purchasers whose financial resources are sufficient to enable them to assume such
risks and who have no need for immediate liquidity in their investment. An investment in the Common Shares is appropriate only
for purchasers who have the capacity to absorb a loss of some or all of their investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Corporation does not currently intend
to pay any cash dividends on the Common Shares in the foreseeable future; therefore, the Corporation&rsquo;s shareholders may not
be able to receive a return on their Common Shares until they sell them</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation has never paid or declared
any cash dividends on its Common Shares. The Corporation does not anticipate paying any cash dividends on its Common Shares in
the foreseeable future because, among other reasons, the Corporation currently intends to retain any future earnings to finance
its business. The future payment of dividends will be dependent on factors such as cash on hand and achieving profitability, the
financial requirements to fund growth, the Corporation&rsquo;s general financial condition and other factors the board of directors
of the Corporation may consider appropriate in the circumstances. Until the Corporation pays dividends, which it may never do,
its shareholders will not be able to receive a return on their Common Shares unless they sell them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>You may be unable to enforce actions
against us, certain of our directors and officers, or the experts named in this Prospectus Supplement under U.S. federal securities
laws.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a company continued under the laws
of the Province of Alberta, Canada. Most of our directors and officers as well as the certain of the experts named in this Prospectus
Supplement and the accompanying Prospectus, reside principally in Canada. Because all or a substantial portion of our assets and
the assets of these persons are located outside of the United States, it may not be possible for you to effect service of process
within the United States upon us or those persons. Furthermore, it may not be possible for you to enforce against us or those persons
in the United States, judgments obtained in U.S. courts based upon the civil liability provisions of the U.S. federal securities
laws or other laws of the United States. There is doubt as to the enforceability, in original actions in Canadian courts, of liabilities
based upon U.S. federal securities laws and as to the enforceability in Canadian courts of judgments of U.S. courts obtained in
actions based upon the civil liability provisions of the U.S. federal securities laws. Therefore, it may not be possible to enforce
those actions against us, certain of our directors and officers or certain of the experts named in this Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Corporation is likely a &ldquo;passive
foreign investment company&rdquo; which may have adverse U.S. federal income tax consequences for U.S. shareholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">U.S. holders of Warrant Shares should be
aware that the Corporation believes it was classified as a passive foreign investment company (&ldquo;<B>PFIC</B>&rdquo;) during
the tax year ended December 31, 2018 and based on current business plans and financial expectations, the Corporation expects that
it will be a PFIC for the current tax year and may be a PFIC in future tax years. If the Corporation is a PFIC for any year during
a U.S. shareholder&rsquo;s holding period of the Warrant Shares (as determined under the PFIC rules), then such U.S. shareholder
generally will be required to treat any gain realized upon a disposition of Warrant Shares, or any &ldquo;excess distribution&rdquo;
received on its Warrant Shares, as ordinary income, and to pay an interest charge on a portion of such gain or distribution, unless
the shareholder makes certain elections, to the extent available, in a timely and effective manner. This paragraph is qualified
in its entirety by the discussion below under the heading &ldquo;Certain United States Federal Income Tax Considerations.&rdquo;
Each U.S. shareholder should consult its own tax advisors regarding the PFIC rules and the U.S. federal income tax consequences
of the acquisition, ownership, and disposition of Common Shares.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="main_007"></A>THE CORPORATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Oncolytics Biotech Inc. was incorporated
pursuant to the ABCA on April&nbsp;2, 1998 as 779738 Alberta Ltd. On April&nbsp;8, 1998, we amended our articles of incorporation
(the &ldquo;<B>Articles</B>&rdquo;) and changed our name to Oncolytics Biotech Inc. On July&nbsp;29, 1999, we amended our Articles
by removing the private company restrictions included therein and subdivided the 2,222,222 Common Shares issued and outstanding
into 6,750,000 Common Shares. On February&nbsp;9, 2007, we amended our Articles to permit shareholder meetings to be held at any
place in Alberta or at any other location as determined by our board of directors (the &ldquo;<B>Board</B>&rdquo;). On May 22,
2018, we amended our Articles of Incorporation to effect a consolidation (the &ldquo;<B>Consolidation</B>&rdquo;) of the Common
Shares on the basis of 9.5 pre-Consolidation Common Shares for each one post-Consolidation Common Share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have two material operating subsidiaries:
Oncolytics Biotech (Barbados) Inc. and Oncolytics Biotech (US) Inc., a Delaware corporation. Oncolytics Biotech (Barbados) Inc.
is incorporated pursuant to the laws of Barbados and is a wholly-owned direct subsidiary of the Corporation. Oncolytics Biotech
(U.S.) Inc. is incorporated pursuant to the laws of Delaware and is a wholly-owned direct subsidiary of Oncolytics Biotech (Barbados)
Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our head office and principal place of
business is located at 210, 1167 Kensington Crescent N.W., Calgary, Alberta, T2N&nbsp;1X7. Our registered office is located at
4000, 421&nbsp;-&nbsp;7<SUP>th</SUP>&nbsp;Avenue S.W., Calgary, Alberta, T2P&nbsp;4K9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="main_008"></A>RECENT DEVELOPMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 5, 2019, the Corporation announced
that it has entered into an agreement with Merck KGaA, Darmstadt, Germany, a leading science and technology company, which operates
in the United States and Canada as EMD Serono, and Pfizer Inc. (NYSE:PFE). The agreement is to conduct a clinical study of pelareorep
in combination with paclitaxel and avelumab*, a human anti-PD-L1 antibody, for the treatment of hormone-receptor positive, human
epidermal growth factor 2-negative (HR+ / HER2-) metastatic breast cancer (&ldquo;<B>mBC</B>&rdquo;). The Corporation and Pfizer
will equally share costs associated with the phase 2 clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The study known as BRACELET-1 (<B>BR</B>east
c<B>A</B>n<B>CE</B>r with the Oncolytic Reovirus Pe<B>L</B>areor<B>E</B>p in Combina<B>T</B>ion with anti-PD-L 1 and paclitaxel)
is an open label study that will enroll 45 patients into three cohorts with 15 patients per cohort: paclitaxel alone, paclitaxel
in combination with pelareorep and paclitaxel in combination with both pelareorep and avelumab. The study will examine the expression
of immune-related biomarkers to identify changes in T cell clonality between pre-treatment and on-therapy biopsies to confirm our
previously identified biomarker and is designed to assess efficacy in terms of overall response rate at week 16 per RECIST 1.1
and iRECIST. The safety of the combination will also be evaluated. During the period of the study and for 90 days after a pre-determined
interim analysis, the Corporation may exclusively develop pelareorep in HR+ / HER2- mBC with Merck KGaA, Darmstadt, Germany, and
Pfizer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">*Avelumab is under clinical investigation
for treatment of hormone receptor-positive, human epidermal growth factor 2-negative (HR+ / HER2-) metastatic breast cancer and
has not been demonstrated to be safe and effective for this use. There is no guarantee that avelumab will be approved for HR+ /
HER2- metastatic breast cancer by any health authority worldwide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 14, 2019, we filed a prospectus
supplement to the Prospectus in respect of the Unit Offering.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="main_009"></A>BUSINESS OF THE CORPORATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since our inception in April of 1998, Oncolytics
Biotech Inc. has been a development stage company and we have focused our research and development efforts on the development of
pelareorep, a systemically administered immuno-oncology (&ldquo;<B>I-O</B>&rdquo;) viral agent with the potential to treat a variety
of cancers. We have not been profitable since our inception and expect to continue to incur substantial losses as we continue research
and development efforts. We do not expect to generate significant revenues until, if and when, pelareorep becomes commercially
viable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our potential product for human use, pelareorep,
an unmodified reovirus, is a first in class systemically administered I-O viral agent for the treatment of solid tumors and hematological
malignancies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Scientific Background </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pelareorep&rsquo;s anti-tumor activity
is based on three modes of action which are complementary but not interdependent (see Figure 1, below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Selective viral replication in permissive cancer cells which leads to tumor cell lysis.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Activation of innate immunity in response to the infection which results in a cascade of chemokines/cytokines
causing natural killer (&ldquo;<B>NK</B>&rdquo;) cells to be activated and attack cancer cells.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">A specific adaptive immune response triggered by tumor- and viral-associated antigens displayed
by antigen-presenting cells (including infected tumor cells and/or dendritic cells, &ldquo;<B>APCs</B>&rdquo;) to T cells.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Summary of Research and Development
highlights </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Preclinical and Translational Research
data to date indicates the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Pelareorep has anticancer effects in models of metastatic cancers that can prolong survival in
these models when using immuno-competent rodents.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The survival benefit in animal models can be enhanced when pelareorep is given in combination with
chemotherapy, immunotherapy or radiotherapy.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">A toxic dose of pelareorep has not been reached/established in animal models and infection presents
with minimal side-effects.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical data to date indicate the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">More than 1,400 patients have been enrolled in clinical studies conducted in the United States,
Canada and the European Union. Of these, more than 1,000 patients received pelareorep, with over 930 via intravenous (&ldquo;<B>IV</B>&rdquo;)
administration and over 90 by intratumoral injections (&ldquo;<B>ITu</B>&rdquo;). The remaining patients were randomized to control
arms on other therapies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Pelareorep has been administered as single or multiple doses (intratumoral or intravenous), either
as a mono-therapy or in combination with chemotherapy, immunotherapy (e.g., checkpoint inhibitors), and radiotherapy.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">No Maximum Tolerated Dose (&ldquo;<B>MTD</B>&rdquo;) for intravenous pelareorep as mono-therapy
was defined in the two Phase 1 trials (REO 004 and 005). Dose-limiting toxicities (&ldquo;<B>DLTs</B>&rdquo;) were seen in some
of the combination trials with pelareorep and chemotherapy, which generally enrolled heavily pre-treated patients.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">When combined with chemotherapeutic agents, pelareorep does not appear to enhance either the frequency
or severity of the adverse effects of the chemotherapeutic agents.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There is emerging evidence that pelareorep may impact overall survival (&ldquo;<B>OS</B>&rdquo;)
in mBC and metastatic adenocarcinoma of the pancreas (&ldquo;<B>MAP</B>&rdquo;):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In a randomized, controlled Phase 2 study of paclitaxel with pelareorep versus paclitaxel alone
in mBC (Canadian Cancer Trials Group IND. 213) median survival time was greater for subjects treated with paclitaxel and pelareorep
(median 17.4 months) than subjects treated with paclitaxel alone (10.4 months, hazard ratio (&ldquo;<B>HR</B>&rdquo;) 0.65).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In a single arm study with gemcitabine plus pelareorep in first line MAP (REO 017) the median overall
survival (mOS) was 10 months with a 1-year and 2-year survival of 46% and 24%, respectively.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In a two-arm Phase 2 randomized study (NCI 8601), patients with MAP were randomized to receive
either carboplatin, paclitaxel and pelareorep (test arm) or carboplatin and paclitaxel alone (control arm). The median OS was similar
for both arms, but the probability of survival at Year 2 was 20% in the test arm versus 9% in the control arm.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Mechanism of Action </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Figure 1. Proposed mechanism of action for pelareorep.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tv527785_img02.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Direct cell lysis - Reovirus Replication in Permissive
Cancer Cells</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Selective viral replication and lysis in
cancer cells and not normal cells is mediated by the host cellular protein dsRNA-activated protein kinase (&ldquo;<B>PKR</B>&rdquo;).
In non-cancer cells that are infected with reovirus, PKR activates in the presence of the virus which in turn inhibits viral gene
translation. However, in permissive cancer cells, PKR activation is inhibited, allowing for viral gene translation and eventual
cell lysis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It was originally established that selective
lysis with reovirus was mediated by tumor cells with an activated rat sarcoma virus oncogene (&ldquo;<B>RAS</B>&rdquo;) pathway,
since active RAS inhibits PKR activation. However, more recent investigations have revealed that reovirus replication is not just
restricted to cells with an active RAS pathway, oncogenic mutations and amplifications in upstream and downstream mediators of
the RAS-pathway also allow for viral replication and oncolysis. Moreover, active RAS is known to stimulate over 18 downstream effector
proteins, many of which have been shown to facilitate viral replication, such as. Cells bearing dysfunctional or deleted tumor
suppressor genes and or chemo- or radiation-induced cell stress also show increased sensitivity to reovirus replication and lysis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Induction of Innate Immunity</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Preclinical and clinical studies provide
compelling lines of evidence that pelareorep functions as an immunogenic agent. Indeed, preclinical studies by Steele and colleagues
demonstrated that melanoma cells infected with pelareorep can produce an innate immune response triggering the release of inflammatory
cytokines. This inflammatory environment promotes a chemotactic response in NK cells, dendritic cells, and cytotoxic T-cells, altering
the tumour microenvironment to support bystander immune-mediated cancer cell death. Intriguingly, preclinical studies have also
demonstrated that the beneficial immunogenic functions of pelareorep can occur independent of viral replication. Pelareorep performs
this immunogenic function, in part, by activating dendritic cells, key regulators of both adaptive and innate immunity. Dendritic
cells activated by reovirus in turn stimulate the innate antitumor activity of natural killer (&ldquo;<B>NK</B>&rdquo;) cells and
aid in the priming of specific antitumor cytotoxic lyphocyte, demonstrating that dendritic cells&rsquo; recognition of reovirus
may trigger a beneficial innate immune response.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A clinical trial with pelareorep (REO 013)
provided an opportunity to study human NK cell activation in a controlled manner. Ten colorectal cancer patients with liver metastases
received between one and five doses of pelareorep prior to surgical resection of their tumor. NK cell activation peaked 24 to 48
hours post-infection, coincident with a peak of pro-inflammatory cytokines. NK cells within reovirus-treated blood mononuclear
cells were stimulated to kill tumor targets, but not normal hepatocytes. Moreover, peripheral blood mononuclear cells were able
to hand-off virus to tumors for direct oncolytic killing. Similarly, NK cells within liver mononuclear cells became selectively
cytotoxic towards tumor cells when activated by reovirus. These results showed that reovirus modulates human NK cell activity in
vivo and suggest that this may contribute to the therapeutic effect of pelareorep.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Induction of Adaptive Immunity</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Adaptive anti-tumor immunity allows for
elimination of existing cancer cells and performs constant surveillance, preventing relapse, and increasing patient overall survival.
An adaptive immune response requires two signals: a signal from an APC, as well as a co-stimulation signal in the form of cytokines.
In the absence of both signals, the adaptive immune response fails. Therapy with pelareorep has the potential to activate both
signals. Following its therapeutic administration, pelareorep enhances the expression of &lsquo;foreign&rsquo; antigens/markers
on tumor cells. Oncolysis of tumor cells exposes tumor-associated antigens (&ldquo;<B>TAAs</B>&rdquo;) and viral-associated antigens
(&ldquo;<B>VAAs</B>&rdquo;) for processing and presentation by APCs, such as dendritic cells. Through the combined actions of these
immunological events, pelareorep facilitates the display of novel &lsquo;foreign&rsquo; antigens on the surface of infected tumor
cells and APCs. Simultaneously, pelareorep induces an inflammatory response promoting the expression of co-stimulatory molecules
and inflammatory cytokines. Together, pelareorep mediated immunological events over-rule tumor antigen presentation impairments
and initiate adaptive anti-tumor immunity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">By promoting the expression of novel antigens
and the release of inflammatory cytokines, pelareorep, promotes an inflamed tumor phenotype. An inflamed tumor phenotype is characterized
by NK and T-cell infiltration, increased expression of chemokines/ cytokines, and increased expression of checkpoint ligands. This
phenotype correlates with an increase in overall survival and has a positive prognostic value for early stage cancers. In patients
with metastatic cancer, an inflamed tumor phenotype is associated with better clinical outcomes when treated with immunotherapies,
including immune checkpoint blockade inhibitors, cancer vaccines, and adoptive T-cell therapies. By promoting an inflamed tumor
phenotype, pelareorep primes an anti-cancer immune response (see Figure 2, below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Figure 2. Pelareorep primes an anti-cancer immune response</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tv527785_img03.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Clinical Development Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The primary objective of our clinical development
plan is to obtain regulatory approval for pelareorep as quickly as possible and is based on the compelling mBC survival data that
was presented at the 2017 American Association for Cancer Research Annual Meeting, in Washington, D.C. The second objective is
to expand pelareorep into commercially valuable new treatment areas. Our clinical development program focuses on the three components
of pelareorep&rsquo;s mechanism of action and includes the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Immunotherapy Combinations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This program focuses on the potential for
pelareorep to cause a specific adaptive immune response in combination with checkpoint inhibitors. In 2017, we announced our first
data set combining a checkpoint inhibitor with pelareorep and pembrolizumab (Keytruda&reg;) in pancreatic cancer, which demonstrated
safety and tolerability and in five efficacy evaluable patients, one had a partial response (six-month duration) and two had stable
disease (lasting 126 and 221 days). In the first half of 2019 we announced the regulatory approval and the start of enrollment
in our AWARE-1 study which examines the use of pelareorep and atezolizumab (Tecentriq&reg;) in a breast cancer window-of -opportunity
study. Additional studies are now being planned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Chemotherapy Combinations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This program focuses on the investigation
of chemotherapy combination clinical trials investigating the use of different chemotherapy agents in various tumor types. In 2017,
we reported additional clinical data from our randomized clinical program which includes clinical trial collaborations with the
Canadian Cancer Trials Group (formerly known as the National Cancer Institute of Canada). Specifically, subgroup analysis in the
IND 213 trial in mBC revealed a significant improvement in the overall survival of patients that are hormone receptor positive
(HR+) / human epidermal growth factor receptor 2 negative (HER2-). In HR+/HER2- patients, pelareorep therapy in combination with
paclitaxel doubled the overall survival from 10.8 month with paclitaxel therapy alone to 21.8 months with pelareorep plus paclitaxel.
This increase in overall survival is consistent with previous survival data reported from our U.S. NCI pancreatic trial which suggests
a long-term survival benefit when comparing test and control arms at 24 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Business Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business strategy is to develop and
market pelareorep in an effective and timely manner, and access additional technologies at a time and in a manner that we believe
is best for our development. We intend to achieve our business strategy by focusing on these key areas:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Develop pelareorep through our clinical development plan assessing the safety and efficacy in human
subjects;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Establish collaborations with experts to assist us with scientific and clinical developments of
this new potential pharmaceutical product;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Implement strategic alliances with select biopharmaceutical companies and laboratories, at a time
and in a manner whereby such alliances may complement and expand our own research and development efforts, and which may eventually
expand to include providing additive sales and marketing capabilities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Utilize our broadening patent base and collaborator network as a mechanism to meet our strategic
objectives; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Develop relationships with companies that could be instrumental in assisting us to access other
innovative therapeutics.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business strategy is based on attaining
a number of commercial objectives, which, in turn, are supported by a number of product development goals. In this Prospectus Supplement,
statements of our &ldquo;belief&rdquo; are based primarily upon our results derived to date from our research and development program
with animals, early stage human trials and our most recent data in HR+/HER2- mBC patients, upon which we believe that we have a
reasonable scientific basis to expect the particular results to occur. It is not possible to predict, based upon studies in animals,
or early stage human trials, whether a new therapeutic will ultimately prove to be safe and effective in humans. There are no assurances
that the particular result expected by us will occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date hereof, we do not intend
to become a fully integrated pharmaceutical company with substantial in-house research and development, marketing and distribution
or manufacturing capabilities. We are pursuing a strategy of establishing relationships with larger companies as strategic partners.
It is anticipated that future clinical development into large international or pivotal trials would generally occur in conjunction
with a strategic partner or partners, who would contribute expertise and financial assistance. In exchange for certain product
rights and commitments to market our products, the strategic partners would be expected to share in proceeds from the sale of our
product or products.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="main_010"></A>USE OF PROCEEDS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, when the Warrants are
exercised, we may receive proceeds equal to the aggregate exercise price of such Warrants. Assuming that all of the Warrants are
exercised prior to their expiry time and that no adjustment based on the anti-dilution provisions contained in the Warrant certificate
has taken place, the gross proceeds to us from the exercise of all of the Warrants sold in the Unit Offering (including those Warrants
issuable pursuant to the exercise of the Over-Allotment Option) will be approximately US$4.16 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The net proceeds from the exercise of the
Warrants are currently intended to be used to advance our clinical development program, our manufacturing activities in support
of the program and general corporate and administrative purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amounts actually expended for the purposes
described above may vary significantly depending upon a number of factors, including those listed under the heading &ldquo;<I>Risk
Factors</I>&rdquo; in this Prospectus Supplement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="main_011"></A>COMMON SHARES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are authorized to issue an unlimited
number of Common Shares. Each Common Share entitles the holder to one vote per share held at meetings of shareholders, to receive
such dividends as declared by us and to receive our remaining property and assets upon dissolution or winding up. Our Common Shares
are not subject to any future call or assessment and there are no pre-emptive, conversion or redemption rights attached to such
shares. See &ldquo;Consolidated Capitalization&rdquo; in this Prospectus Supplement for additional information on our outstanding
Common Shares.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="main_012"></A>TERMS OF WARRANTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants issued under the Unit Offering
will be governed by a Warrant Agency Agreement (the &ldquo;<B>Warrant Agency Agreement</B>&rdquo;) to be entered into between
the Corporation and American Stock Transfer &amp; Trust Company, LLC, as agent for the holders of the Warrants (the &ldquo;<B>Warrant
Agent</B>&rdquo;). The following description is subject to the detailed provisions of the Warrant Agency Agreement. Reference
should be made to the Warrant Agency Agreement for the full text of attributes of the Warrants, which we will file on SEDAR under
our profile at <U>www.sedar.com</U> following the closing of the Unit Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Exercisability</I></B><I>.</I> The
Warrants are exercisable immediately upon issuance and at any time up to the date that is five years from the date of issuance.
The Warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise
notice accompanied by payment in full for the number of Warrant Shares purchased upon such exercise (except in the case of a cashless
exercise as discussed below). Unless otherwise specified in the Warrant, the holder will not have the right to exercise any portion
of the Warrant if the holder (together with its affiliates) would beneficially own in excess of 4.99% (or, upon election by a holder
prior to the issuance of any Warrants, 9.99%) of the number of Common Shares outstanding immediately after giving effect to the
exercise, as such percentage ownership is determined in accordance with the terms of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For greater certainty, all Warrants, including
the Warrants issued pursuant to, or in connection with, the Over-Allotment Option, will expire on the same expiry date five years
from the Closing Date, subject to acceleration in certain events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Cashless Exercise</I></B><I>.</I>
In the event that a registration statement covering Common Shares underlying the Warrants, or an exemption from registration, is
not available for the resale of such Common Shares underlying the Warrants, the holder may, in its sole discretion, exercise the
Warrant in whole or in part and, in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise
in payment of the aggregate exercise price, elect instead to receive upon such exercise the net number of Common Shares determined
according to the formula set forth in the Warrant. In no event shall we be required to make any cash payments or net cash settlement
to the registered holder in lieu of issuance of Warrant Shares underlying the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Exercise Price</I></B><I>.</I> The
initial exercise price per share of Warrants Shares purchasable upon exercise of the Warrants is US$0.90. The exercise price is
subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations,
reclassifications or similar events affecting our Common Shares and also upon any distributions of assets, including cash, shares
or other property to our shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Certain Adjustments</I></B><I>.</I>
The exercise price and the number of Common Shares purchasable upon the exercise of the Warrants are subject to adjustment upon
the occurrence of specific events, including stock dividends, stock splits, combinations and reclassifications of our Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Transferability</I></B><I>.</I> Subject
to applicable laws, the Warrants may be transferred at the option of the holders upon surrender of the Warrants to us together
with the appropriate instruments of transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Warrant Agent and Exchange Listing</I></B><I>.</I>
The Warrants will be issued in registered form under the Warrant Agency Agreement between the Warrant Agent, as warrant agent,
and the Corporation. There will be no market through which the Warrants may be sold and purchasers may not be able to resell the
Warrants. This may affect the pricing of the Warrants in the secondary market, the transparency and availability of trading prices
and the liquidity of the Warrants. See &ldquo;<I>Risk Factors</I>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Fundamental Transaction</I></B>.
If, at any time while the Warrants are outstanding, (1) we consolidate or merge with or into another corporation and we are not
the surviving corporation, (2) we sell, lease, license, assign, transfer, convey or otherwise dispose of all or substantially all
of our assets, (3) any purchase offer, tender offer or exchange offer (whether by us or another individual or entity) is completed
pursuant to which holders of our Common Shares are permitted to sell, tender or exchange their Common Shares for other securities,
cash or property and has been accepted by the holders of 50% or more of our outstanding Common Shares, (4) we effect any reclassification
or recapitalization of our Common Shares or any compulsory share exchange pursuant to which our Common Shares are converted into
or exchanged for other securities, cash or property, or (5) we consummate a stock or share purchase agreement or other business
combination with another person or entity whereby such other person or entity acquires more than 50% of our outstanding Common
Shares, each, a &ldquo;<B>Fundamental Transaction</B>,&rdquo; then upon any subsequent exercise of the Warrants, the holders thereof
will have the right to receive the same amount and kind of securities, cash or property as it would have been entitled to receive
upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder
of the number of Warrant Shares then issuable upon exercise of the Warrant, and any additional consideration payable as part of
the Fundamental Transaction. Notwithstanding the foregoing, in the event of a fundamental transaction (other than certain fundamental
transactions where the Company remains the surviving company) as described above, the holder may, subject to certain conditions,
require the Company or a successor entity to purchase the warrant from the holder by paying to the holder an amount in cash equal
to the Black-Scholes value of the remaining unexercised portion of the warrant on the effective date of such change of control;
provided, however, that, if the change of control is not within the Company&rsquo;s control, including not approved by the Company&rsquo;s
board of directors, the holder will only be entitled to receive from the Company or any successor entity, as of the date of consummation
of such change of control, the same type or form of consideration (and in the same proportion), at the Black-Scholes value of the
unexercised portion of the warrant, that is being offered and paid to the holders of our common stock in connection with the change
of control, whether that consideration is in the form of cash, stock or any combination thereof, or whether the holders of common
stock are given the choice to receive from among alternative forms of consideration in connection with the change of control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Rights as a Shareholder</I></B><I>.</I>
Except as otherwise provided in the Warrants or by virtue of such holder&rsquo;s ownership of Common Shares, the holder of a Warrant
does not have the rights or privileges of a holder of our Common Shares, including any voting rights, until the holder exercises
the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>No fractional Warrant Shares will be
issuable upon the exercise of any Warrants, and no cash or other consideration will be paid in lieu of fractional shares. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="main_013"></A>CONSOLIDATED CAPITALIZATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the consolidated
capitalization of the Corporation as at June 30, 2019 before and after giving effect to the Unit Offering. There has not been any
material change in the share and loan capital of the Corporation, on a consolidated basis, since the Corporation&rsquo;s most recently
filed financial statements for the three and six months ended June 30, 2019. The table below should be read in conjunction with
our interim consolidated financial statements for the three and six months ended June 30, 2019 and the related management&rsquo;s
discussion and analysis thereof, incorporated in each case by reference in this Prospectus Supplement and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">As at June 30, 2019</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap"><FONT STYLE="font-size: 10pt"><B>As at June 30, 2019 after</B></FONT><BR> <FONT STYLE="font-size: 10pt"><B>giving effect to the Unit</B></FONT><BR> <FONT STYLE="font-size: 10pt"><B>Offering<SUP>(1)(3)</SUP></B></FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap"><FONT STYLE="font-size: 10pt"><B>As at June 30, 2019 after</B></FONT><BR> <FONT STYLE="font-size: 10pt"><B>giving effect to the Unit</B></FONT><BR> <FONT STYLE="font-size: 10pt"><B>Offering, including the</B></FONT><BR> <FONT STYLE="font-size: 10pt"><B>Over-Allotment Option<SUP>(2)(3)</SUP></B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 49%; font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top; white-space: nowrap">Share capital</TD><TD STYLE="width: 2%; font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="width: 15%; font-size: 10pt; text-align: center; white-space: nowrap">C$292,611,439<BR> (20,359,295 Common<BR> Shares)</TD><TD STYLE="width: 2%; font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="width: 15%; font-size: 10pt; text-align: center; white-space: nowrap">C$296,768,621<BR> (24,979,068 Common<BR> Shares)</TD><TD STYLE="width: 2%; font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="width: 15%; font-size: 10pt; text-align: center; white-space: nowrap">C$297,451,025<BR> (25,672,033 Common<BR> Shares)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top">Warrants</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">C$<FONT STYLE="font-size: 10pt">3,617,570</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">C$<FONT STYLE="font-size: 10pt">3,669,535</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">C$<FONT STYLE="font-size: 10pt">3,730,030</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top">Contributed surplus</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">C$<FONT STYLE="font-size: 10pt">28,752,377</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">C$<FONT STYLE="font-size: 10pt">28,752,377</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">C$<FONT STYLE="font-size: 10pt">28,752,377</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top">Accumulated other comprehensive income</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">C$<FONT STYLE="font-size: 10pt">482,549</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">C$<FONT STYLE="font-size: 10pt">482,549</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">C$<FONT STYLE="font-size: 10pt">482,549</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top">Accumulated deficit</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">C$<FONT STYLE="font-size: 10pt">(321,675,987)</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">C$<FONT STYLE="font-size: 10pt">(321,675,987)</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">C$<FONT STYLE="font-size: 10pt">(321,675,987)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top">Total shareholders&rsquo; equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">C$<FONT STYLE="font-size: 10pt">3,787,948</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">C$<FONT STYLE="font-size: 10pt">7,997,095</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">C$<FONT STYLE="font-size: 10pt">8,688,028</FONT></TD></TR>
</TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Notes:</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Based on the issuance of 4,619,773 Common Shares underlying Units pursuant to the Unit Offering
for aggregate gross proceeds of US$3,742,016.13, less the Underwriter Fee of US$261,941.13 and the expenses of the Unit Offering,
estimated at US$300,000.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">Based on the issuance of 5,312,738 Common Shares underlying Units pursuant to the Unit Offering,
assuming the exercise in full of the Over-Allotment Option, for aggregate gross proceeds of US$4,303,317.78, less the Underwriter
Fee of US$301,232.24 and the expenses of the Unit Offering, estimated at US$300,000.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">Assumes no exercise of Warrants underlying Units pursuant to the Unit Offering.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="main_014"></A>TRADING PRICE AND
VOLUME</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Common Shares are listed and posted
for trading on the TSX under the trading symbol &ldquo;ONC&rdquo; and on the NASDAQ under the trading symbol &ldquo;ONCY&rdquo;.
On August 14, 2019, the closing price of our Common Shares on Nasdaq was US$0.58 per Common Share and on the TSX was C$0.76 per
Common Share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the market
price ranges and the aggregate volume of trading of the Common Shares on the TSX and NASDAQ for the periods indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">TSX</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">NASDAQ</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Low</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Close</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Volume</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Low</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Close</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Volume</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Period</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(C$)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(C$)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(C$)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Shares)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(US$)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(US$)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(US$)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Shares)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><B><U>2018</U></B></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 20%">August</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">6.76</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">5.23</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">5.46</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">447,865</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">5.31</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">4.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">4.18</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">1,362,577</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>September</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.52</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.94</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.96</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">747,789</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.12</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.77</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.86</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,412,087</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>October</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.47</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.41</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.05</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,006,423</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.33</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.60</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.07</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,943,334</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>November</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.12</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.82</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">503,826</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.13</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.61</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">858,710</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>December</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.44</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.26</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.51</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">526,966</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.61</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.6382</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.81</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,158,436</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><B><U>2019</U></B></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>January</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.25</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.43</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.72</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">704,629</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.76</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.09</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,008,478</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>February</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.13</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.55</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.70</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">605,259</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.37</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.95</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.035</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,490,764</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>March</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.87</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.35</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.48</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">711,198</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.14</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.7501</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.86</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,935,669</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>April</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.68</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.41</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.59</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">639,246</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.01</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.91</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,962,881</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>May</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.32</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">578,061</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.96</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.5993</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.72</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">935,942</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>June</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.61</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.18</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.26</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">546,095</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.94</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.61</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.70</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,205,291</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>July</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.26</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.79</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">349,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.78</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.311</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.34</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">644,978</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>August 1 to 14</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.74</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.76</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,271,178</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.33</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.53</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.58</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,972,888</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="main_015"></A>PRIOR SALES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as disclosed under this heading,
no other Common Shares or securities exchangeable or convertible into Common Shares have been issued during the twelve month period
preceding the date of this Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the twelve month period prior to
the date of this Prospectus Supplement, the Corporation has issued:</P>

<P STYLE="color: #010000; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(a)</FONT></TD><TD STYLE="text-align: justify">an aggregate of 1,590,747 Common Shares pursuant to the Equity Distribution Agreement and a prospectus
supplement dated October 24, 2018 to the Prospectus, at prices ranging from US$1.6014 to US$3.1167 per Common Share, with the weighted
average price being US$1.9368 per Common Share;</TD></TR></TABLE>

<P STYLE="color: #010000; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(b)</FONT></TD><TD STYLE="text-align: justify">an aggregate of 2,188,063 Common Shares pursuant to a purchase agreement dated September 28, 2018
between the Corporation and Lincoln Park Capital Fund and a prospectus supplement dated September 28, 2018 to the Prospectus, at
prices ranging from US$1.7358 to US$4.1082 per Common Share, with the weighted average price being US$2.3878 per Common Share;
and</TD></TR></TABLE>

<P STYLE="color: #010000; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(c)</FONT></TD><TD STYLE="text-align: justify">an aggregate of 79,550 Common Shares issued on the exercise of stock options granted pursuant to
its amended and restated stock option plan or on the vesting of restricted share awards granted pursuant to its amended and restated
incentive share award plan, particulars of which are set forth in the following table:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Date of Issue</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Common Shares Issued</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Price per Common Share (US$)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 50%">September 12, 2018</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; text-align: right">6,473</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; text-align: right">2.82</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>September 17, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.04</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>September 18, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,700</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.39</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>September 27, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,420</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.39</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>October 2, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,210</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.20</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>November 30, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,263</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.38</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>November 30, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,052</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.35</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>January 4, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,982</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.78</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>February 22, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,105</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.03</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>April 3, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,575</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.85</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>April 16, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,354</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.90</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>July 4, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,311</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.72</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>July 5, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,105</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.71</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stock Options</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the twelve month period preceding
the date of this Prospectus Supplement, the Corporation granted stock options pursuant to its amended and restated stock option
plan exercisable for an aggregate of 444,500 Common Shares. The particulars of such grants are set forth in the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Date of Grant</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Options Granted</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Exercise Price (C$)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 50%">September 20, 2018</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; text-align: right">1,500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; text-align: right">5.67</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>November 19, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">203,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.44</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>November 29, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.23</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>December 14, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">195,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.73</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>July 16, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.12</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Share Awards</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the twelve month period preceding
the date of this Prospectus Supplement, the Corporation granted restricted share awards pursuant to its amended and restated incentive
share award plan which, upon vesting, will entitle the holders thereof to receive up to an aggregate of 113,225 Shares. The particulars
of such grants are set forth in the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; width: 70%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Date of Grant</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Share Awards Granted</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 81%">November 27, 2018</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">75,698</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>December 31, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,266</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>March 31, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,113</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>June 30, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,148</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="main_016"></A>PLAN OF DISTRIBUTION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus supplement relates to the
qualification for distribution of: (i) up to 4,619,773 Warrant Shares issuable from time to time, on exercise of up to 4,619,773
Warrants (expected to be issued by us on or about August 16, 2019 pursuant to the Unit Offering (as defined herein)), (ii) up to
692,965 Warrant Shares issuable from time to time, on exercise of 692,965 Common Share purchase warrants that may be issued on
the exercise of the Over-Allotment Option granted to the underwriter pursuant to the Unit Offering; and (iii) such indeterminate
number of additional Warrant Shares that may be issuable by reason of the anti-dilution provisions contained in the Warrant Agency
Agreement (as defined herein). See &quot;Terms of Warrants&quot; for additional information on the terms of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 14, 2019, we filed a prospectus
supplement to the Prospectus with the Alberta Securities Commission and a registration statement on Form F-10 (File No. 333224432),
principally filed on April 25, 2018, as amended May 4, 2018, with the SEC relating to the Unit Offering of up 4,619,773 Units,
each Unit consisting of one Common Share and one Warrant at a price of US$0.80 per Unit. Each Warrant will entitle the holder to
purchase one Warrant Share upon payment of US$0.90, subject to adjustment, at any time until 5:00 p.m. (New York City time) on
the date that is five years from the date of the closing of the Unit Offering. The exercise price of the Warrants was determined
by negotiation between us and the underwriter for the Unit Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Prospectus Supplement registers the
offering of the securities to which it relates under the U.S. Securities Act in accordance with MJDS. This Prospectus Supplement
does not qualify the distribution of the Warrant Shares in any province or territory of Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holders of Warrants resident in the United
States who acquire Warrant Shares pursuant to the exercise of Warrants in accordance with their terms and under the Prospectus
and this Prospectus Supplement may have a right of action against us for any misrepresentation in the Prospectus and this Prospectus
Supplement. However, the existence and enforceability of such a right of action is not without doubt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares to which this Prospectus
Supplement relates will be sold directly by us to holders of Warrants, as the case may be, on the exercise of such Warrants. No
underwriters, dealers or agents will be involved in these sales. No underwriter has been involved in the preparation of, or has
performed any review of, this Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is a condition of closing of the Unit
Offering that the shelf registration statement remain effective with the SEC and that we file with the SEC a prospectus supplement
registering the offering of the Warrant Shares issuable from time to time on the exercise of the Warrants. No U.S. Person, person
within the United States or person holding Warrants for the account or benefit of a U.S. Person or person within the United States
may exercise the Warrants during any period of time when a registration statement covering such Warrant Shares is not effective
or an exemption from such registration is not otherwise available. If a registration statement under the U.S. Securities Act is
not effective, the Warrants may be exercised on a net cashless basis. See &ldquo;<I>Terms of Warrants</I>&rdquo; for additional
information of the terms of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="main_017"></A>CERTAIN UNITED STATES
FEDERAL INCOME TAX CONSIDERATIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a general summary of certain
U.S. federal income tax considerations applicable to a U.S. Holder (as defined below) arising from and relating to the acquisition,
ownership, and disposition of Warrant Shares received upon exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This summary is for general information
purposes only and does not purport to be a complete analysis or listing of all potential U.S. federal income tax considerations
that may apply to a U.S. Holder as a result of the acquisition of Warrant Shares pursuant to this Prospectus Supplement. In addition,
this summary does not take into account the individual facts and circumstances of any particular U.S. Holder that may affect the
U.S. federal income tax consequences to such U.S. Holder, including specific tax consequences to a U.S. Holder under an applicable
tax treaty. Accordingly, this summary is not intended to be, and should not be construed as, legal or U.S. federal income tax advice
with respect to any particular U.S. Holder. This summary does not address the U.S. federal net investment income, U.S. federal
alternative minimum, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences to U.S. Holders of the acquisition,
ownership, and disposition of Warrant Shares. In addition, except as specifically set forth below, this summary does not discuss
applicable tax reporting requirements. Each U.S. Holder should consult its own tax advisor regarding the U.S. federal, U.S. federal
net investment income, U.S. federal alternative minimum, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences
relating to the acquisition, ownership and disposition of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No opinion from legal counsel or ruling
from the Internal Revenue Service (the &ldquo;<B>IRS</B>&rdquo;) has been requested, or will be obtained, regarding the U.S. federal
income tax considerations applicable to U.S. Holders as discussed in this summary. This summary is not binding on the IRS, and
the IRS is not precluded from taking a position that is different from, and contrary to, the positions taken in this summary. In
addition, because the authorities on which this summary is based are subject to various interpretations, the IRS and the U.S. courts
could disagree with one or more of the positions taken in this summary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Scope of this Summary</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Authorities</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This summary is based on the Internal Revenue
Code of 1986, as amended (the &ldquo;<B>Code</B>&rdquo;), Treasury Regulations (whether final, temporary, or proposed) promulgated
under the Code, published rulings of the IRS, published administrative positions of the IRS and U.S. court decisions, that are
in effect and available, as of the date of this document. Any of the authorities on which this summary is based could be changed
in a material and adverse manner at any time, and any such change could be applied retroactively. This summary does not discuss
the potential effects, whether adverse or beneficial, of any proposed legislation that, if enacted, could be applied on a retroactive
or prospective basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>U.S. Holders</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of this summary, the term
&ldquo;<B>U.S. Holder</B>&rdquo; means a beneficial owner of Warrant Shares acquired pursuant to this Prospectus Supplement that
is for U.S. federal income tax purposes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a citizen or individual resident of the United States;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) organized
under the laws of the United States, any state thereof or the District of Columbia;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">an estate whose income is subject to U.S. federal income taxation regardless of its source; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a trust that (1) is subject to the primary supervision of a court within the United States and
the control of one or more U.S. persons for all substantial decisions or (2) has a valid election in effect under applicable Treasury
Regulations to be treated as a U.S. person.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>U.S. Holders Subject to Special U.S.
Federal Income Tax Rules Not Addressed</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This summary does not address the U.S.
federal income tax considerations applicable to U.S. Holders that are subject to special provisions under the Code, including U.S.
Holders that: (a) are tax-exempt organizations, qualified retirement plans, individual retirement accounts, or other tax-deferred
accounts; (b) are financial institutions, underwriters, insurance companies, real estate investment trusts, or regulated investment
companies; (c) are brokers or dealers in securities or currencies or U.S. Holders that are traders in securities that elect to
apply a mark-to-market accounting method; (d) have a &ldquo;functional currency&rdquo; other than the U.S. dollar; (e) own Warrants
or Warrant Shares as part of a straddle, hedging transaction, conversion transaction, constructive sale, or other integrated transaction;
(f) acquired Warrants or Warrant Shares in connection with the exercise of employee stock options or otherwise as compensation
for services; (g) hold Warrants or Warrant Shares other than as a capital asset within the meaning of Section 1221 of the Code
(generally, property held for investment purposes); (h) are partnerships and other pass-through entities (and investors in such
partnerships and entities); (i) are required to accelerate the recognition of any item of gross income with respect to Warrants
or Warrant Shares as a result of such income being recognized on an applicable financial statement; or (i) own, have owned or will
own (directly, indirectly, or by attribution) 10% or more of the total combined voting power or value of the Corporation&rsquo;s
outstanding shares. This summary also does not address the U.S. federal income tax considerations applicable to U.S. Holders who
are (a) U.S. expatriates or former long-term residents of the U.S., or (b) subject to taxing jurisdictions other than, or in addition
to, the United States. U.S. Holders that are subject to special provisions under the Code, including U.S. Holders described immediately
above, should consult their own tax advisors regarding the U.S. federal, U.S. federal net investment income, U.S. federal alternative
minimum, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences relating to the acquisition, ownership
and disposition of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an entity or arrangement that is classified
as a partnership for U.S. federal income tax purposes holds Warrants or Warrant Shares, the U.S. federal income tax consequences
to such entity or arrangement and the owners of such entity or arrangement generally will depend on the activities of such entity
or arrangement and the status of such owners. This summary does not address the tax consequences to any such entity or arrangement
or owner. Owners of entities or arrangements that are classified as partnerships for U.S. federal income tax purposes should consult
their own tax advisor regarding the U.S. federal income tax consequences arising from and relating to the acquisition, ownership,
and disposition of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Passive Foreign Investment Company Rules</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Corporation is considered a &ldquo;passive
foreign investment company&rdquo; within the meaning of Section 1297 of the Code (a &ldquo;<B>PFIC</B>&rdquo;) at any time during
a U.S. Holder&rsquo;s holding period for Warrant Shares, the following sections will generally describe the potentially adverse
U.S. federal income tax consequences to U.S. Holders of the acquisition, ownership, and disposition of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation believes that it was classified
as a PFIC for the tax year ended December 31, 2018, and based on current business plans and financial expectations, the Corporation
expects that it may be a PFIC for its current tax year ending December 31, 2019 and may be a PFIC in future tax years. No opinion
of legal counsel or ruling from the IRS concerning the status of the Corporation as a PFIC has been obtained or is currently planned
to be requested. The determination of whether any corporation was, or will be, a PFIC for a tax year depends, in part, on the application
of complex U.S. federal income tax rules, which are subject to differing interpretations. In addition, whether any corporation
will be a PFIC for any tax year depends on the assets and income of such corporation over the course of each such tax year and,
as a result, the Corporation&rsquo;s PFIC status for the current year and future years cannot be predicted with certainty as of
the date of this document. Accordingly, there can be no assurance that the IRS will not challenge any PFIC determination made by
the Corporation (or by one of the Corporation&rsquo;s subsidiaries). Each U.S. Holder should consult its own tax advisor regarding
the Corporation&rsquo;s status as a PFIC and the PFIC status of each non-U.S. subsidiary of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In any year in which the Corporation is
classified as a PFIC, a U.S. Holder will be required to file an annual report with the IRS containing such information as Treasury
Regulations and/or other IRS guidance may require. In addition to penalties, a failure to satisfy such reporting requirements may
result in an extension of the time period during which the IRS can assess a tax. U.S. Holders should consult their own tax advisors
regarding the requirements of filing such information returns under these rules, including the requirement to file an IRS Form
8621.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation generally will be a PFIC
for any tax year in which (a) 75% or more of the gross income of the Corporation for such tax year is passive income (the &ldquo;<B>PFIC
income test</B>&rdquo;) or (b) 50% or more of the value of the assets of the Corporation either produce passive income or are held
for the production of passive income, based on the quarterly average of the fair market value of such assets (the &ldquo;<B>PFIC
asset test</B>&rdquo;). &ldquo;Gross income&rdquo; generally includes sales revenues less the cost of goods sold, plus income from
investments and from incidental or outside operations or sources, and &ldquo;passive income&rdquo; generally includes, for example,
dividends, interest, certain rents and royalties, certain gains from the sale of stock and securities, and certain gains from commodities
transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of the PFIC income test and
PFIC asset test described above, if the Corporation owns, directly or indirectly, 25% or more of the total value of the outstanding
shares of another corporation, the Corporation will be treated as if it (a) held a proportionate share of the assets of such other
corporation and (b) received directly a proportionate share of the income of such other corporation. In addition, for purposes
of the PFIC income test and PFIC asset test described above, &ldquo;passive income&rdquo; does not include any interest, dividends,
rents, or royalties that are received or accrued by the Corporation from a &ldquo;related person&rdquo; (as defined in Section
954(d)(3) of the Code), to the extent such items are properly allocable to the income of such related person that is not passive
income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under certain attribution rules, if the
Corporation is a PFIC, U.S. Holders will be deemed to own their proportionate share of any of the Corporation&rsquo;s subsidiaries
which is also a PFIC (a &ldquo;<B>Subsidiary PFIC</B>&rdquo;), and will generally be subject to U.S. federal income tax under the
&ldquo;Default PFIC Rules Under Section 1291 of the Code&rdquo; discussed below on their proportionate share of any (i) distribution
on the shares of a Subsidiary PFIC and (ii) disposition or deemed disposition of shares of a Subsidiary PFIC, both as if such U.S.
Holders directly held the shares of such Subsidiary PFIC. Accordingly, U.S. Holders should be aware that they could be subject
to tax under the PFIC rules even if no distributions are received and no redemptions or other dispositions of Warrant Shares are
made. In addition, U.S. Holders may be subject to U.S. federal income tax on any indirect gain realized on the stock of a Subsidiary
PFIC on the sale or disposition of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Default PFIC Rules Under Section 1291
of the Code</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Corporation is a PFIC, the U.S.
federal income tax consequences to a U.S. Holder of the acquisition, ownership, and disposition of Warrant Shares will depend on
whether such U.S. Holder makes a &ldquo;qualified electing fund&rdquo; or &ldquo;QEF&rdquo; election (a &ldquo;<B>QEF Election</B>&rdquo;)
or makes a mark-to-market election under Section 1296 of the Code (a &ldquo;<B>Mark-to-Market Election</B>&rdquo;) with respect
to Common Shares. A U.S. Holder that does not make either a QEF Election or a Mark-to-Market Election (a &ldquo;<B>Non-Electing
U.S. Holder</B>&rdquo;) will be taxable as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Non-Electing U.S. Holder will be subject
to the rules of Section 1291 of the Code with respect to (a) any gain recognized on the sale or other taxable disposition of Warrant
Shares and (b) any excess distribution received on the Warrant Shares. A distribution generally will be an &ldquo;excess distribution&rdquo;
to the extent that such distribution (together with all other distributions received in the current tax year) exceeds 125% of the
average distributions received during the three preceding tax years (or during a U.S. Holder&rsquo;s holding period for the Warrant
Shares, if shorter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under Section 1291 of the Code, any gain
recognized on the sale or other taxable disposition of Warrant Shares of a PFIC (including an indirect disposition of shares of
a Subsidiary PFIC), and any excess distribution received on such Warrant Shares (or a distribution by a Subsidiary PFIC to its
shareholder that is deemed to be received by a U.S. Holder) must be ratably allocated to each day in a Non-Electing U.S. Holder&rsquo;s
holding period for the Warrant Shares. The amount of any such gain or excess distribution allocated to the tax year of disposition
or distribution of the excess distribution and to years before the entity became a PFIC, if any, would be taxed as ordinary income
(and not eligible for certain preferential tax rates, as discussed below). The amounts allocated to any other tax year would be
subject to U.S. federal income tax at the highest tax rate applicable to ordinary income in each such year, and an interest charge
would be imposed on the tax liability for each such year, calculated as if such tax liability had been due in each such year. A
Non-Electing U.S. Holder that is not a corporation must treat any such interest paid as &ldquo;personal interest,&rdquo; which
is not deductible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Corporation is a PFIC for any tax
year during which a Non-Electing U.S. Holder holds Warrant Shares or Warrants, it will continue to be treated as a PFIC with respect
to such Non-Electing U.S. Holder, regardless of whether it ceases to be a PFIC in one or more subsequent tax years. If the Corporation
ceases to be a PFIC, a Non-Electing U.S. Holder may terminate this deemed PFIC status with respect to Warrant Shares by electing
to recognize gain (which will be taxed under the rules of Section 1291 of the Code as discussed above) as if such Warrant Shares
were sold on the last day of the last tax year for which the Corporation was a PFIC. No such election, however, may be made with
respect to the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under proposed Treasury Regulations, if
a U.S. holder has an option, warrant, or other right to acquire stock of a PFIC (such as the Warrants), such option, warrant or
right is considered to be PFIC stock subject to the default rules of Section 1291 of the Code. Under rules described below, the
holding period for the Warrant Shares will begin on the date a U.S. Holder acquires the Warrants. This will impact the availability
of the QEF Election and Mark-to-Market Election with respect to the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>QEF Election</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As discussed above, under proposed Treasury
Regulations, if a U.S. holder has an option, warrant or other right to acquire stock of a PFIC (such as the Warrants), such option,
warrant or right is considered to be PFIC stock subject to the default rules of Section 1291 of the Code. However, a U.S. Holder
of an option, warrant or other right to acquire stock of a PFIC may not make a QEF Election that will apply to the option, warrant
or other right to acquire PFIC stock. In addition, under proposed Treasury Regulations, if a U.S. Holder holds an option, warrant
or other right to acquire stock of a PFIC, the holding period with respect to shares of stock of the PFIC acquired upon exercise
of such option, warrant or other right will include the period that the option, warrant or other right was held.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Consequently, under the proposed Treasury
Regulations, if a U.S. Holder of Common Shares makes a QEF Election, such election generally will not be treated as a timely QEF
Election with respect to Warrant Shares and the rules of Section 1291 of the Code discussed above will continue to apply with respect
to such U.S. Holder&rsquo;s Warrant Shares. However, a U.S. Holder of Warrant Shares should be eligible to make a timely QEF Election
if such U.S. Holder elects in the tax year in which such Warrant Shares are received to recognize gain (which will be taxed under
the rules of Section 1291 of the Code discussed above) as if such Warrant Shares were sold for fair market value on the date such
U.S. Holder acquired them by exercising the corresponding Warrant. In addition, gain recognized on the sale or other taxable disposition
(other than by exercise) of the Warrants by a U.S. Holder will be subject to the rules of Section 1291 of the Code discussed above.
Each U.S. Holder should consult its own tax advisor regarding the application of the PFIC rules to the Warrants and Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A U.S. Holder that makes a timely QEF Election
under the rules set forth in the preceding paragraph generally will not be subject to the rules of Section 1291 of the Code discussed
above with respect to its Warrant Shares. However, a U.S. Holder that makes a QEF Election will be subject to U.S. federal income
tax on such U.S. Holder&rsquo;s pro rata share of (a) the Corporation&rsquo;s net capital gain, which will be taxed as long-term
capital gain to such U.S. Holder, and (b) the Corporation&rsquo;s ordinary earnings, which will be taxed as ordinary income to
such U.S. Holder. Generally, &ldquo;net capital gain&rdquo; is the excess of (a) net long-term capital gain over (b) net short-term
capital loss, and &ldquo;ordinary earnings&rdquo; are the excess of (a) &ldquo;earnings and profits&rdquo; over (b) net capital
gain. A U.S. Holder that makes a QEF Election will be subject to U.S. federal income tax on such amounts for each tax year in which
the Corporation is a PFIC, regardless of whether such amounts are actually distributed to such U.S. Holder by the Corporation.
However, for any tax year in which the Corporation is a PFIC and has no net income or gain, U.S. Holders that have made a QEF Election
would not have any income inclusions as a result of the QEF Election. If a U.S. Holder that made a QEF Election has an income inclusion,
such a U.S. Holder may, subject to certain limitations, elect to defer payment of current U.S. federal income tax on such amounts,
subject to an interest charge. If such U.S. Holder is not a corporation, any such interest paid will be treated as &ldquo;personal
interest,&rdquo; which is not deductible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A U.S. Holder that makes a timely QEF Election
as described above generally (a) may receive a tax-free distribution from the Corporation to the extent that such distribution
represents &ldquo;earnings and profits&rdquo; that were previously included in income by the U.S. Holder because of such QEF Election
and (b) will adjust such U.S. Holder&rsquo;s tax basis in the Warrant Shares to reflect the amount included in income or allowed
as a tax-free distribution because of such QEF Election. In addition, a U.S. Holder that makes a QEF Election generally will recognize
capital gain or loss on the sale or other taxable disposition of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A QEF Election will apply to the tax year
for which such QEF Election is made and to all subsequent tax years, unless such QEF Election is invalidated or terminated or the
IRS consents to revocation of such QEF Election. If a U.S. Holder makes a QEF Election and, in a subsequent tax year, the Corporation
ceases to be a PFIC, the QEF Election will remain in effect (although it will not be applicable) during those tax years in which
the Corporation is not a PFIC. Accordingly, if the Corporation becomes a PFIC in another subsequent tax year, the QEF Election
will be effective and the U.S. Holder will be subject to the QEF rules described above during any subsequent tax year in which
the Corporation qualifies as a PFIC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation: (a) will make available
to U.S. Holders, upon their written request, information as to its status as a PFIC and the PFIC status of any subsidiary in which
the Corporation owns more than 50% of such subsidiary&rsquo;s total aggregate voting power and (b) for each year in which the Corporation
is a PFIC, provide to a U.S. Holder, upon written request, such information and documentation that a U.S. Holder making a QEF Election
with respect to the Corporation and such more than 50% owned subsidiary which constitutes a PFIC is reasonably required to obtain
for U.S. federal income tax purposes. The Corporation may elect to provide such information on its website. With respect to any
Subsidiary PFIC in which the Corporation owns 50% or less of the aggregate voting power, upon the written request of a U.S. Holder
acquiring Warrant Shares, the Corporation will request that such Subsidiary PFIC provide such U.S. Holder with the information
that such U.S. Holder requires to report under the QEF rules; provided, however, the Corporation can provide no assurances that
such Subsidiary PFIC will provide such information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A U.S. Holder makes a QEF Election by attaching
a completed IRS Form 8621, including a PFIC Annual Information Statement, to a timely filed U.S. federal income tax return. However,
if the Corporation does not provide the required information with regard to the Corporation or any of its Subsidiary PFICs, U.S.
Holders will not be able to make a QEF Election for such entity and will continue to be subject to the rules of Section 1291 of
the Code discussed above that apply to Non-Electing U.S. Holders with respect to the taxation of gains and excess distributions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Mark-to-Market Election</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A U.S. Holder may make a Mark-to-Market
Election with respect to Warrant Shares only if the Warrant Shares are marketable stock. The Warrant Shares generally will be &ldquo;marketable
stock&rdquo; if the Warrant Shares are regularly traded on (a) a national securities exchange that is registered with the SEC,
(b) the national market system established pursuant to Section 11A of the U.S. Exchange Act or (c) a foreign securities exchange
that is regulated or supervised by a governmental authority of the country in which the market is located, provided that (i) such
foreign exchange has trading volume, listing, financial disclosure, and other requirements and the laws of the country in which
such foreign exchange is located, together with the rules of such foreign exchange, ensure that such requirements are actually
enforced and (ii) the rules of such foreign exchange ensure active trading of listed stocks. If such stock is traded on such a
qualified exchange or other market, such stock generally will be considered &ldquo;regularly traded&rdquo; for any calendar year
during which such stock is traded, other than in de minimis quantities, on at least 15 days during each calendar quarter. Provided
that the Warrant Shares are &ldquo;regularly traded&rdquo; as described in the preceding sentence, the Warrant Shares are expected
to be marketable stock. The Corporation believes that its Common Shares were &ldquo;regularly traded&rdquo; in the second calendar
quarter of 2019 and expects that the Common Shares should be &ldquo;regularly traded&rdquo; in the third calendar quarter of 2019.
However, there can be no assurance that the Common Shares will be &ldquo;regularly traded&rdquo; in subsequent calendar quarters.
U.S. Holders should consult their own tax advisors regarding the marketable stock rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A U.S. Holder that makes a Mark-to-Market
Election with respect to its Warrant Shares generally will not be subject to the rules of Section 1291 of the Code discussed above
with respect to such Warrant Shares. However, if a U.S. Holder does not make a Mark-to-Market Election beginning in the first tax
year of such U.S. Holder&rsquo;s holding period for the Warrant Shares and such U.S. Holder has not made a timely QEF Election,
the rules of Section 1291 of the Code discussed above will apply to certain dispositions of, and distributions on, the Warrant
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any Mark-to-Market Election made by a U.S.
Holder for its Common Shares will also apply to such U.S. Holder&rsquo;s Warrant Shares. As a result, if a Mark-to-Market Election
has been made by a U.S. Holder with respect to its Common Shares, any Warrant Shares received will automatically be marked-to-market
in the year of exercise. Because, under the proposed Treasury Regulations, a U.S. Holder&rsquo;s holding period for Warrant Shares
includes the period during which such U.S. Holder held the Warrants, a U.S. Holder will be treated as making a Mark-to-Market Election
with respect to its Warrant Shares after the beginning of such U.S. Holder&rsquo;s holding period for the Warrant Shares unless
the Warrant Shares are acquired in the same tax year as the year in which the U.S. Holder acquired its Warrants. Consequently,
the default rules under Section 1291 described above generally will apply to the mark-to-market gain realized in the tax year in
which Warrant Shares are received. However, the general mark-to-market rules will apply to subsequent tax years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A U.S. Holder that makes a Mark-to-Market
Election will include in ordinary income, for each tax year in which the Corporation is a PFIC, an amount equal to the excess,
if any, of (a) the fair market value of the Warrant Shares, as of the close of such tax year over (b) such U.S. Holder&rsquo;s
tax basis in the Warrant Shares. A U.S. Holder that makes a Mark-to-Market Election will be allowed a deduction in an amount equal
to the excess, if any, of (i) such U.S. Holder&rsquo;s adjusted tax basis in the Warrant Shares, over (ii) the fair market value
of such Warrant Shares (but only to the extent of the net amount of previously included income as a result of the Mark-to-Market
Election for prior tax years).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A U.S. Holder that makes a Mark-to-Market
Election generally also will adjust such U.S. Holder&rsquo;s tax basis in the Warrant Shares to reflect the amount included in
gross income or allowed as a deduction because of such Mark-to-Market Election. In addition, upon a sale or other taxable disposition
of Warrant Shares, a U.S. Holder that makes a Mark-to-Market Election will recognize ordinary income or ordinary loss (not to exceed
the excess, if any, of (a) the amount included in ordinary income because of such Mark-to-Market Election for prior tax years over
(b) the amount allowed as a deduction because of such Mark-to-Market Election for prior tax years).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A U.S. Holder makes a Mark-to-Market Election
by attaching a completed IRS Form 8621 to a timely filed U.S. federal income tax return. A timely Mark-to-Market Election applies
to the tax year in which such Mark-to-Market Election is made and to each subsequent tax year, unless the Warrant Shares cease
to be &ldquo;marketable stock&rdquo; or the IRS consents to revocation of such election. Each U.S. Holder should consult its own
tax advisor regarding the availability of, and procedure for making, a Mark-to-Market Election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although a U.S. Holder may be eligible
to make a Mark-to-Market Election with respect to the Warrant Shares, no such election may be made with respect to the stock of
any Subsidiary PFIC that a U.S. Holder is treated as owning because such stock is not marketable. Hence, the Mark-to-Market Election
will not be effective to eliminate the interest charge and other income inclusion rules described above with respect to deemed
dispositions of Subsidiary PFIC stock or distributions from a Subsidiary PFIC to its shareholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Other PFIC Rules</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under Section 1291(f) of the Code, the
IRS has issued proposed Treasury Regulations that, subject to certain exceptions, would cause a U.S. Holder that had not made a
timely QEF Election to recognize gain (but not loss) upon certain transfers of Warrant Shares that would otherwise be tax-deferred
(e.g., gifts and exchanges pursuant to corporate reorganizations). However, the specific U.S. federal income tax consequences to
a U.S. Holder may vary based on the manner in which Warrants or Warrant Shares are transferred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If finalized in their current form, the
proposed Treasury Regulations applicable to PFICs would be effective for transactions occurring on or after April 1, 1992. Because
the proposed Treasury Regulations have not yet been adopted in final form, they are not currently effective, and there is no assurance
that they will be adopted in the form and with the effective date proposed. Nevertheless, the IRS has announced that, in the absence
of final Treasury Regulations, taxpayers may apply reasonable interpretations of the Code provisions applicable to PFICs and that
it considers the rules set forth in the proposed Treasury Regulations to be reasonable interpretations of those Code provisions.
The PFIC rules are complex, and the implementation of certain aspects of the PFIC rules requires the issuance of Treasury Regulations
which in many instances have not been promulgated and which, when promulgated, may have retroactive effect. U.S. Holders should
consult their own tax advisors about the potential applicability of the proposed Treasury Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain additional adverse rules will apply
with respect to a U.S. Holder if the Corporation is a PFIC, regardless of whether such U.S. Holder makes a QEF Election. For example
under Section 1298(b)(6) of the Code, a U.S. Holder that uses Warrants or Warrant Shares as security for a loan will, except as
may be provided in Treasury Regulations, be treated as having made a taxable disposition of such Warrants or Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, a U.S. Holder who acquires
Warrants or Warrant Shares from a decedent will not receive a &ldquo;step up&rdquo; in tax basis of such Warrants or Warrant Shares
to fair market value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Special rules also apply to the amount
of foreign tax credit that a U.S. Holder may claim on a distribution from a PFIC. Subject to such special rules, foreign taxes
paid with respect to any distribution in respect of stock in a PFIC are generally eligible for the foreign tax credit. The rules
relating to distributions by a PFIC and their eligibility for the foreign tax credit are complicated, and a U.S. Holder should
consult with their own tax advisor regarding the availability of the foreign tax credit with respect to distributions by a PFIC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The PFIC rules are complex, and each U.S.
Holder should consult its own tax advisor regarding the PFIC rules (including the applicability and advisability of a QEF Election
and Mark-to-Market Election) and how the PFIC rules may affect the U.S. federal income tax consequences of the acquisition, ownership,
and disposition of Warrants and Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>U.S. Federal Income Tax Consequences
of the Ownership, Exercise and Disposition of Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following discussion describes the
general rules applicable to the ownership, exercise and disposition of the Warrants but is subject in its entirety to the special
rules described above under the heading &ldquo;Passive Foreign Investment Company Rules.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Exercise of Warrants</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A U.S. Holder should not recognize gain
or loss on the exercise of a Warrant and related receipt of a Warrant Share (unless cash is received in lieu of the issuance of
a fractional Warrant Share). A U.S. Holder&rsquo;s initial tax basis in the Warrant Share received on the exercise of a Warrant
should be equal to the sum of (a) such U.S. Holder&rsquo;s tax basis in such Warrant plus (b) the exercise price paid by such U.S.
Holder on the exercise of such Warrant. It is unclear whether a U.S. Holder&rsquo;s holding period for the Warrant Share received
on the exercise of a Warrant would commence on the date of exercise of the Warrant or the day following the date of exercise of
the Warrant. If, as anticipated, the Corporation is a PFIC, a U.S. Holder&rsquo;s holding period for the Warrant Share for PFIC
purposes only will begin on the date on which such U.S. Holder acquired its Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Disposition of Warrants</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A U.S. Holder will recognize gain or loss
on the sale or other taxable disposition of a Warrant in an amount equal to the difference, if any, between (a) the amount of cash
plus the fair market value of any property received and (b) such U.S. Holder&rsquo;s tax basis in the Warrant sold or otherwise
disposed of. Subject to the PFIC rules discussed above, any such gain or loss generally will be a capital gain or loss, which will
be long-term capital gain or loss if the Warrant is held for more than one year. Deductions for capital losses are subject to complex
limitations under the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Expiration of Warrants Without Exercise</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the lapse or expiration of a Warrant,
a U.S. Holder will recognize a loss in an amount equal to such U.S. Holder&rsquo;s tax basis in the Warrant. Any such loss generally
will be a capital loss and will be long-term capital loss if the Warrants are held for more than one year. Deductions for capital
losses are subject to complex limitations under the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Certain Adjustments to the Warrants</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under Section 305 of the Code, an adjustment
to the number of Warrant Shares that will be issued on the exercise of the Warrants, or an adjustment to the exercise price of
the Warrants, may be treated as a constructive distribution to a U.S. Holder of the Warrants if, and to the extent that, such adjustment
has the effect of increasing such U.S. Holder&rsquo;s proportionate interest in the &ldquo;earnings and profits&rdquo; or the Corporation&rsquo;s
assets, depending on the circumstances of such adjustment (for example, if such adjustment is to compensate for a distribution
of cash or other property to the shareholders). Adjustments to the exercise price of Warrants made pursuant to a bona fide reasonable
adjustment formula that has the effect of preventing dilution of the interest of the holders of the Warrants should generally not
be considered to result in a constructive distribution. Any such constructive distribution would be taxable whether or not there
is an actual distribution of cash or other property. (See more detailed discussion of the rules applicable to distributions made
by the Corporation at &ldquo;Distributions on Warrant Shares&rdquo; below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General Rules Applicable to U.S. Federal
Income Tax Consequences of the Acquisition, Ownership, and Disposition of Warrant Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following discussion describes the
general rules applicable to the acquisition, ownership and disposition of the Warrant Shares but is subject in its entirety to
the special rules described above under the heading &ldquo;Passive Foreign Investment Company Rules.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Distributions on Warrant Shares</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A U.S. Holder that receives a distribution,
including a constructive distribution, with respect to a Warrant Share (as well as any constructive distribution on a Warrant as
described above) will be required to include the amount of such distribution in gross income as a dividend (without reduction for
any Canadian income tax withheld from such distribution) to the extent of the Corporation&rsquo;s current and accumulated &ldquo;earnings
and profits&rdquo;, as computed under U.S. federal income tax principles. A dividend generally will be taxed to a U.S. Holder at
ordinary income tax rates if the Corporation is a PFIC for the tax year of such distribution or the preceding tax year. To the
extent that a distribution exceeds the current and accumulated &ldquo;earnings and profits&rdquo; of the Corporation, such distribution
will be treated first as a tax-free return of capital to the extent of a U.S. Holder&rsquo;s tax basis in the Warrant Shares and
thereafter as gain from the sale or exchange of such Warrant Shares (see &ldquo;<I>Sale or Other Taxable Disposition of Warrant
Shares</I>&rdquo; below). However, the Corporation may not maintain the calculations of earnings and profits in accordance with
U.S. federal income tax principles, and each U.S. Holder may be required to assume that any distribution by the Corporation with
respect to the Warrant Shares will constitute ordinary dividend income. Dividends received on Warrant Shares generally will not
be eligible for the &ldquo;dividends received deduction&rdquo; generally applicable to corporations. Subject to applicable limitations
and provided the Corporation is eligible for the benefits of the Convention Between Canada and the United States of America with
Respect to Taxes on Income and on Capital, signed September 26, 1980, as amended, or the Common Shares are readily tradable on
a United States securities market, dividends paid by the Corporation to non-corporate U.S. Holders, including individuals, generally
will be eligible for the preferential tax rates applicable to long-term capital gains for dividends, provided certain holding period
and other conditions are satisfied, including that the Corporation not be classified as a PFIC in the tax year of distribution
or in the preceding tax year. The dividend rules are complex, and each U.S. Holder should consult its own tax advisor regarding
the application of such rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Sale or Other Taxable Disposition of
Warrant Shares</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the sale or other taxable disposition
of Warrant Shares, a U.S. Holder generally will recognize capital gain or loss in an amount equal to the difference between (a)
the amount of cash plus the fair market value of any property received and (b) such U.S. Holder&rsquo;s tax basis in such Warrant
Shares sold or otherwise disposed of. Gain or loss recognized on such sale or other taxable disposition generally will be long-term
capital gain or loss if, at the time of the sale or other taxable disposition, the Warrant Shares have been held for more than
one year. Preferential tax rates may apply to long-term capital gain of a U.S. Holder that is an individual, estate, or trust.
There are no preferential tax rates for long-term capital gain of a U.S. Holder that is a corporation. Deductions for capital losses
are subject to significant limitations under the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Additional Tax Considerations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Receipt of Foreign Currency</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amount of any distribution paid to
a U.S. Holder in foreign currency or on the sale, exchange or other taxable disposition of Warrants or Warrant Shares generally
will be equal to the U.S. dollar value of such foreign currency based on the exchange rate applicable on the date of receipt (regardless
of whether such foreign currency is converted into U.S. dollars at that time). If the foreign currency received is not converted
into U.S. dollars on the date of receipt, a U.S. Holder will have a tax basis in the foreign currency equal to its U.S. dollar
value on the date of receipt. Any U.S. Holder who receives payment in foreign currency and engages in a subsequent conversion or
other disposition of the foreign currency may have a foreign currency exchange gain or loss that would be treated as ordinary income
or loss, and generally will be U.S. source income or loss for foreign tax credit purposes. Different rules apply to U.S. Holders
who use the accrual method of tax accounting. Each U.S. Holder should consult its own U.S. tax advisor regarding the U.S. federal
income tax consequences of receiving, owning, and disposing of foreign currency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Foreign Tax Credit</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the PFIC rules discussed above,
a U.S. Holder that pays (whether directly or through withholding) Canadian income tax with respect to dividends paid on the Warrant
Shares (or with respect to any constructive dividend on the Warrants) generally will be entitled, at the election of such U.S.
Holder, to receive either a deduction or a credit for such Canadian income tax paid. Generally, a credit will reduce a U.S. Holder&rsquo;s
U.S. federal income tax liability on a dollar-for-dollar basis, whereas a deduction will reduce a U.S. Holder&rsquo;s income subject
to U.S. federal income tax. This election is made on a year-by-year basis and applies to all foreign taxes paid or accrued (whether
directly or through withholding) by a U.S. Holder during a year. The foreign tax credit rules are complex and involve the application
of rules that depend on a U.S. Holder&rsquo;s particular circumstances. Accordingly, each U.S. Holder should consult its own tax
advisor regarding the foreign tax credit rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Information Reporting; Backup Withholding
Tax</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under U.S. federal income tax laws certain
categories of U.S. Holders must file information returns with respect to their investment in, or involvement in, a foreign corporation.
For example, U.S. return disclosure obligations (and related penalties) are imposed on U.S. Holders that hold certain specified
foreign financial assets in excess of certain threshold amounts. The definition of specified foreign financial assets includes
not only financial accounts maintained in foreign financial institutions, but also, unless held in accounts maintained by a financial
institution, any stock or security issued by a non-U.S. person. U. S. Holders may be subject to these reporting requirements unless
their Warrants and Warrant Shares are held in an account at certain financial institutions. Penalties for failure to file certain
of these information returns are substantial. U.S. Holders should consult their own tax advisors regarding the requirements of
filing information returns, including the requirement to file IRS Form 8938.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Payments made within the U.S., or by a
U.S. payor or U.S. middleman, of dividends on, and proceeds arising from the sale or other taxable disposition of the Warrants
and Warrant Shares generally may be subject to information reporting and backup withholding tax, currently at the rate of 24%,
if a U.S. Holder (a) fails to furnish its correct U.S. taxpayer identification number (generally on Form W-9), (b) furnishes an
incorrect U.S. taxpayer identification number, (c) is notified by the IRS that such U.S. Holder has previously failed to properly
report items subject to backup withholding tax, or (d) fails to certify, under penalty of perjury, that it has furnished its correct
U.S. taxpayer identification number and that the IRS has not notified such U.S. Holder that it is subject to backup withholding
tax. However, certain exempt persons, such as U.S. Holders that are corporations, generally are excluded from these information
reporting and backup withholding tax rules. Any amounts withheld under the U.S. backup withholding tax rules will be allowed as
a credit against a U.S. Holder&rsquo;s U.S. federal income tax liability, if any, or will be refunded, if such U.S. Holder furnishes
required information to the IRS in a timely manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The discussion of reporting requirements
set forth above is not intended to constitute a complete description of all reporting requirements that may apply to a U.S. Holder.
A failure to satisfy certain reporting requirements may result in an extension of the time period during which the IRS can assess
a tax and, under certain circumstances, such an extension may apply to assessments of amounts unrelated to any unsatisfied reporting
requirement. Each U.S. Holder should consult its own tax advisors regarding the information reporting and backup withholding rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE ABOVE SUMMARY IS NOT INTENDED TO
CONSTITUTE A COMPLETE ANALYSIS OF ALL TAX CONSIDERATIONS APPLICABLE TO U.S. HOLDERS WITH RESPECT TO THE ACQUISITION, OWNERSHIP,
AND DISPOSITION OF WARRANTS AND WARRANT SHARES. U.S. HOLDERS SHOULD CONSULT THEIR OWN TAX ADVISORS AS TO THE TAX CONSIDERATIONS
APPLICABLE TO THEM IN THEIR OWN PARTICULAR CIRCUMSTANCES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="main_018"></A>CERTAIN CANADIAN
FEDERAL INCOME TAX CONSIDERATIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is, as of the date hereof,
a general summary of the principal Canadian federal income tax considerations under the Tax Act and the regulations thereunder
(the &ldquo;<B>Regulations</B>&rdquo;) generally applicable to a holder who acquires Warrant Shares issuable from time to time
on the exercise of Warrants as beneficial owner and who, for purposes of the Tax Act and at all relevant times: (a) deals at arm&rsquo;s
length with the Corporation and the Underwriter; (b) is not affiliated with the Corporation or the Underwriter; (c) acquires and
holds the Warrant Shares acquired on the exercise of Warrants as capital property; and (d) is neither resident nor deemed to be
resident in Canada and does not use or hold, and will not be deemed to use or hold, Common Shares in carrying on a business in
Canada (each, a &ldquo;<B>Non-Resident Holder</B>&rdquo;). The Warrant Shares will generally be considered to be capital property
to a Non-Resident Holder unless the Non-Resident Holder holds or uses the Common Shares, or is deemed to hold or use the Common
Shares, in the course of carrying on a business of trading or dealing in securities or has acquired them, or is deemed to have
acquired them, in a transaction or transactions considered to be an adventure in the nature of trade. The term &ldquo;<B>U.S. Holder</B>,&rdquo;
for the purposes of this summary, means a Non-Resident Holder who, for purposes of Canada-United States Income Tax Convention (1980)
(the &ldquo;<B>Canada-U.S. Tax Convention</B>&rdquo;), is at all relevant times a resident of the United States and is a &ldquo;qualifying
person&rdquo; within the meaning of the Canada-U.S. Tax Convention. In some circumstances, persons deriving amounts through fiscally
transparent entities (including limited liability companies) may be entitled to benefits under the Canada-U.S. Tax Convention.
U.S. Holders are urged to consult their own tax advisors to determine their entitlement to benefits under the Canada-U.S. Tax Convention
based on their particular circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Special considerations, which are not discussed
in this summary, may apply to a Non-Resident Holder that is an insurer that carries on an insurance business in Canada and elsewhere
or an authorized foreign bank (as defined in the Tax Act). Such Non-Resident Holders should consult their own tax advisors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This summary is based upon the current
provisions of the Tax Act and the Regulations in force as of the date hereof, specific proposals to amend the Tax Act and the Regulations
(the &ldquo;<B>Tax Proposals</B>&rdquo;) which have been publically announced by or on behalf the Minister of Finance (Canada)
prior to the date hereof, the current provisions of the Canada-U.S. Tax Convention and counsel&rsquo;s understanding of the current
published administrative policies and assessing practices of the Canada Revenue Agency (the &ldquo;<B>CRA</B>&rdquo;). This summary
assumes that the Tax Proposals will be enacted in the form proposed and does not take into account or anticipate any other changes
in law, whether by way of judicial, legislative or governmental decision or action, or changes in the CRA&rsquo;s administrative
policies and assessing practices, nor does it take into account provincial, territorial or foreign income tax legislation or considerations,
which may differ from the Canadian federal income tax considerations discussed herein. No assurances can be given that the Tax
Proposals will be enacted as proposed or at all, or that legislative, judicial or administrative changes will not modify or change
the statements expressed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>This summary is not exhaustive of all
possible Canadian federal income tax considerations applicable to an investment in Common Shares. This summary is of a general
nature only and is not intended to be, nor should it be construed to be, legal or income tax advice to any particular Non-Resident
Holder. Non-Resident Holders should consult their own income tax advisors with respect to the tax consequences applicable to them
based on their own particular circumstances.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Exercise of Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No gain or loss will be realized by a Non-Resident
Holder upon the exercise of a Warrant to acquire a Warrant Share. When a Warrant is exercised, the Non-Resident Holder&rsquo;s
cost of the Warrant Share acquired thereby will be the aggregate of the Non-Resident Holder&rsquo;s adjusted cost base of such
Warrant and the exercise price paid for the Warrant Share. The Non-Resident Holder&rsquo;s adjusted cost base of the Warrant Share
so acquired will be determined by averaging such cost with the adjusted cost base to the Non-Resident Holder of all Common Shares
of the Corporation owned by the Non-Resident Holder as capital property immediately prior to such acquisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Taxation of Dividends</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dividends paid or credited, or deemed to
be paid or credited, to a Non-Resident Holder on the Shares will be subject to Canadian withholding tax under the Tax Act at the
rate of 25% of the gross amount of the dividend. Such rate is generally reduced under the Canada-U.S. Tax Convention to 15% if
the beneficial owner of such dividend is a U.S. Holder. The rate of withholding tax is further reduced to 5% if the beneficial
owner of such dividend is a U.S. Holder that is a company that owns, directly or indirectly, at least 10% of the voting stock of
the Corporation. In addition, under the Canada-U.S. Tax Convention, dividends may be exempt from such Canadian withholding tax
if paid to certain U.S. Holders that are qualifying religious, scientific, literary, educational or charitable tax-exempt organizations
or qualifying trusts, companies, organizations or arrangements operated exclusively to administer or provide pension, retirement
or employee benefits or benefits for the self-employed under one or more funds or plans established to provide pension or retirement
benefits or other employee benefits that are exempt from tax in the United States and that have complied with specific administrative
procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Disposition of Warrant Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Non-Resident Holder will not be subject
to tax under the Tax Act in respect of any capital gain realized by such Non-Resident Holder on a disposition of Warrant Shares,
unless the Warrant Shares constitute &ldquo;taxable Canadian property&rdquo; (as defined in the Tax Act) of the Non-Resident Holder
at the time of the disposition and are not &ldquo;treaty-protected property&rdquo; (as defined in the Tax Act) of the Non-Resident
Holder at the time of the disposition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Generally, as long as the Common Shares
are then listed on a designated stock exchange (which currently includes the TSX), the Warrant Shares will not constitute taxable
Canadian property of a Non-Resident Holder, unless at any time during the 60-month period immediately preceding the disposition
the following two conditions are met concurrently: (a) the Non-Resident Holder, persons with which the Non-Resident Holder does
not deal at arm&rsquo;s length, partnerships whose members include, either directly or indirectly through one or more partnerships,
the Non-Resident Holder or persons which do not deal at arm&rsquo;s length with the Non-Resident Holder, or any combination of
them, owned 25% or more of the issued shares of any class or series of shares of the capital stock of the Corporation, and (b)
more than 50% of the fair market value of the Common Shares was derived directly or indirectly, from one or any combination of
real or immovable property situated in Canada, &ldquo;Canadian resource properties&rdquo;, &ldquo;timber resource properties&rdquo;
(each as defined in the Tax Act) and options in respect of or interests in, or for civil law rights in, any such property (whether
or not such property exists).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the case of a US Holder, the Common
Shares of such US Holder will generally constitute &ldquo;treaty-protected property&rdquo; for purposes of the Tax Act unless the
value of the Common Shares is derived principally from real property situated in Canada. For this purpose, &ldquo;real property&rdquo;
has the meaning that term has under the laws of Canada and includes any option or similar right in respect thereof and usufruct
of real property, rights to explore for or to exploit mineral deposits, sources and other natural resources and rights to amounts
computed by reference to the amount or value of production from such resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Non-Resident Holders whose Warrant Shares
may be taxable Canadian property should consult their own tax advisors.</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="main_019"></A>LEGAL MATTERS AND
INTEREST OF EXPERTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The auditors of the Corporation are Ernst
&amp; Young LLP, Chartered Accountants, 1000, 440 &ndash; 2<SUP>nd</SUP> Avenue S.W., Calgary, Alberta, T2P 5E9. Ernst &amp; Young
LLP is independent of the Corporation in accordance with the Rules of Professional Conduct as outlined by the Institute of Chartered
Accountants of Alberta. Ernst &amp; Young LLP is registered with the U.S. Public Corporation Accounting Oversight Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain legal matters relating to the Offering
will be passed upon on our behalf by McCarthy T&eacute;trault LLP with respect to certain Canadian legal matters and by Dorsey
&amp; Whitney LLP with respect to certain U.S. legal matters and on behalf of the Underwriter by Osler, Hoskin &amp; Harcourt LLP
with respect to certain Canadian legal matters and by Ellenoff Grossman &amp; Schole LLP with respect to certain U.S. legal matters.
As at the date hereof, the partners and associates of each of McCarthy T&eacute;trault LLP and Osler, Hoskin &amp; Harcourt LLP
beneficially own, directly or indirectly, less than 1% of the Common Shares.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="main_020"></A>AGENT FOR SERVICE
OF PROCESS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Messrs. Wayne Pisano, William G. Rice and
Bernd R. Seizinger are directors of the Corporation who reside outside of Canada. Messrs. Pisano, Rice and Seizinger have appointed
the Corporation, at its principal place of business, as agent for service of process. Purchasers are advised that it may not be
possible for investors to enforce judgments obtained in Canada against any person that resides outside of Canada, even if the party
has appointed an agent for service of process.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="main_021"></A>WHERE YOU CAN FIND
ADDITIONAL INFORMATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation has filed with the SEC
a registration statement on Form F-10 relating to, among other securities, the Common Shares. This Prospectus Supplement and the
Prospectus, both of which constitute a part of the registration statement, do not contain all of the information contained in
the registration statement, certain items of which are contained in the exhibits to the registration statement as permitted by
the rules and regulations of the SEC. See &ldquo;Documents Filed as Part of the Registration Statement&rdquo; in this Prospectus
Supplement and the Prospectus. Statements contained in this Prospectus Supplement, the Prospectus or a document incorporated by
reference in the Prospectus about the contents of any contract, agreement or other documents referred to are not necessarily complete,
and in each instance you should refer to the exhibits to the registration statement for a more complete description of the matter
involved. The registration statement, and the items of information omitted from this Prospectus Supplement and the Prospectus
but contained in the registration statement, will be available on EDGAR (<U>www.sec.gov/edgar.shtml</U>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation is subject to the information
requirements of the U.S. Exchange Act and applicable Canadian securities legislation and, in accordance therewith, files and furnishes
annual and quarterly financial information and material change reports, business acquisition reports and other material with the
securities commission or similar regulatory authority in each of the provinces of Canada and with the SEC. Under MJDS adopted by
the United States and Canada, documents and other information that the Corporation files with the SEC may be prepared in accordance
with the disclosure requirements of Canada, which are different from those of the United States. As a foreign private issuer within
the meaning of rules made under the U.S. Exchange Act, the Corporation is exempt from the rules under the U.S. Exchange Act prescribing
the furnishing and content of proxy statements, and the Corporation&rsquo;s officers, directors and principal shareholders are
exempt from the reporting and shortswing profit recovery provisions contained in Section 16 of the U.S. Exchange Act. In addition,
the Corporation is not required to publish financial statements as promptly as United States companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You may read any document that the Corporation
has filed with the SEC on EDGAR at <U>www.sec.gov/edgar.shtml</U> and such information can also be inspected and copies ordered
at the SEC&rsquo;s public reference room in Washington, D.C. You may also obtain copies of those documents from the public reference
room of the SEC at 100 F Street, N.E., Washington, D.C. 20549 by paying a fee. You should call the SEC at 1-800-SEC-0330 or access
its website at www.sec.gov for further information about the public reference rooms. You may read and download any public document
that the Corporation has filed with the Canadian securities regulatory authorities under the Corporation&rsquo;s profile on SEDAR
(<U>www.sedar.com</U>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>BASE SHELF PROSPECTUS</B><B> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>May 4, 2018</B><B> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tv527785_img01.jpg" ALT="" STYLE="height: 105px; width: 240px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Cdn.$150,000,000</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Shares</B><BR>
<B>Subscription Receipts</B><BR>
<B>Warrants</B><BR>
<B>Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">______________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Oncolytics Biotech Inc. (the &ldquo;<B>Corporation</B>&rdquo;,
 &ldquo;<B>Oncolytics</B>&rdquo;, &ldquo;<B>we</B>&rdquo;, &ldquo;<B>our</B>&rdquo; or &ldquo;<B>us</B>&rdquo;) may from time to
time offer and issue the following securities: (i) common shares in the capital of the Corporation (&ldquo;<B>Common Shares</B>&rdquo;);
(ii) subscription receipts of the Corporation exchangeable for Common Shares and/or other securities of the Corporation (&ldquo;<B>Subscription
Receipts</B>&rdquo;); (iii) warrants exercisable to acquire Common Shares and/or other securities of the Corporation (&ldquo;<B>Warrants</B>&rdquo;);
and (iv) securities comprised of more than one of Common Shares, Subscription Receipts and/or Warrants offered together as a unit
(&ldquo;<B>Units</B>&rdquo;), or any combination thereof, up to an aggregate offering price of $150,000,000 (or the equivalent
thereof, at the date of issue, in any other currency or currencies, as the case may be) at any time during the 25-month period
that this short form base shelf prospectus (including any amendments hereto, the &ldquo;<B>Prospectus</B>&rdquo;) remains valid.
The Common Shares, Subscription Receipts, Warrants and Units (collectively, the &ldquo;<B>Securities</B>&rdquo;) offered hereby
may be offered separately or together, in separate series, in amounts, at prices and on terms to be set forth in one or more prospectus
supplements (collectively or individually, as the case may be, &ldquo;<B>Prospectus Supplements</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The specific terms of any offering of Securities
will be set forth in the applicable Prospectus Supplement and may include, without limitation, where applicable: (i) in the case
of Common Shares, the number of Common Shares being offered, the offering price (in the event the offering is a fixed price distribution),
the manner of determining the offering price(s) (in the event the offering is not a fixed price distribution) and any other specific
terms; (ii) in the case of Subscription Receipts, the number of Subscription Receipts being offered, the offering price, the terms,
conditions and procedures for the exchange of the Subscription Receipts into or for Common Shares and/or other securities of the
Corporation and any other specific terms; (iii) in the case of Warrants, the number of such Warrants offered, the offering price,
the terms, conditions and procedures for the exercise of such Warrants into or for Common Shares and/or other securities of the
Corporation and any other specific terms; and (iv) in the case of Units, the number of Units being offered, the offering price,
the terms of the Common Shares, Subscription Receipts and/or Warrants, as the case may be, underlying the Units, and any other
specific terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This offering is made by a Canadian issuer
that is permitted, under a multijurisdictional disclosure system adopted by the United States and Canada (&ldquo;<B>MJDS</B>&rdquo;),
to prepare this Prospectus in accordance with Canadian disclosure requirements. Prospective investors in the United States should
be aware that such requirements are different from those of the United States. Financial statements included or incorporated by
reference herein have been prepared in accordance with International Financial Reporting Standards (&ldquo;<B>IFRS</B>&rdquo;)
as issued by the International Accounting Standards Board (&ldquo;<B>IASB</B>&rdquo;) and may not be comparable to financial statements
of United States companies. Such financial statements are subject to Canadian generally accepted auditing standards and auditor
independence standards, in addition to the standards of the Public Company Accounting Oversight Board (United States) and the United
States Securities and Exchange Commission (&ldquo;<B>SEC</B>&rdquo;) independence standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prospective investors should be aware that
the acquisition of the securities described herein may have tax consequences both in the United States and in Canada. Such consequences
for investors who are resident in, or citizens of, the United States may not be described fully herein. Prospective investors should
read the tax discussion contained in the applicable Prospectus Supplement with respect to a particular offering of Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The enforcement by investors of civil
liabilities under the United States federal securities laws may be affected adversely by the fact that the Corporation is incorporated
under the laws of Alberta, Canada, that the majority of its officers and directors are residents of Canada, that many of the experts
named in the registration statement are not residents of the United States, and that a substantial portion of the assets of the
Corporation and said persons are located outside the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NEITHER THE SEC NOR ANY STATE OR CANADIAN
SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED THE SECURITIES OFFERED HEREBY OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR
COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENCE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Any investment in Securities involves
significant risks that should be carefully considered by prospective investors before purchasing Securities. The risks outlined
in this Prospectus and in the documents incorporated by reference herein, including the applicable Prospectus Supplement, should
be carefully reviewed and considered by prospective investors in connection with any investment in Securities. See &ldquo;<I>Risk
Factors</I>&rdquo;.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 32; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All shelf information permitted under applicable
securities legislation to be omitted from this Prospectus including, without limitation, the information disclosed in the specific
terms of any offering of Securities, as discussed above, will be contained in one or more Prospectus Supplements that will be delivered
to purchasers together with this Prospectus, except in cases where an exemption from such delivery requirements has been obtained.
Each Prospectus Supplement will be incorporated by reference into this Prospectus for the purposes of securities legislation as
of the date of such Prospectus Supplement and only for the purposes of the distribution of the Securities to which that Prospectus
Supplement pertains.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may sell the Securities to or through
one or more underwriters or dealers purchasing as principals and may also sell the Securities to one or more purchasers directly,
through applicable statutory exemptions, or through one or more agents designated by us from time to time. The Securities may be
sold from time to time in one or more transactions at fixed prices or not at fixed prices, such as market prices prevailing at
the time of sale, prices related to such prevailing market prices or prices to be negotiated with purchasers, which prices may
vary as between purchasers and during the period of distribution of the Securities. The Prospectus Supplement relating to a particular
offering of Securities will identify each underwriter, dealer or agent engaged in connection with the offering and sale of such
Securities, as well as the method of distribution and the terms of the offering of such Securities, including the initial offering
price (in the event the offering is a fixed price distribution), the manner of determining the offering price(s) (in the event
the offering is not a fixed price distribution), the net proceeds to us and, to the extent applicable, any fees, discounts or any
other compensation payable to underwriters, dealers or agents and any other material terms. See &ldquo;<I>Plan of Distribution</I>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with any offering of the
Securities other than an &ldquo;at-the-market distribution&rdquo; (as defined under applicable Canadian legislation) (unless otherwise
specified in the relevant Prospectus Supplement), the underwriters or agents may over-allot or effect transactions that stabilize
or maintain the market price of the offered Securities at a level above that which might otherwise prevail on the open market.
Such transactions, if commenced, may be interrupted or discontinued at any time. See &ldquo;<I>Plan of Distribution</I>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No underwriter or dealer involved in an
 &ldquo;at-the-market distribution&rdquo; under this Prospectus, no affiliate of such an underwriter or dealer and no person or
company acting jointly or in concert with such underwriter or dealer will over-allot securities in connection with such distribution
or effect any other transactions that are intended to stabilize or maintain the market price of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Owning the Securities may subject you to
tax consequences. This Prospectus and any applicable Prospectus Supplement may not describe the tax consequences fully. You should
read the tax discussion in any applicable Prospectus Supplement and consult with your own tax advisor with respect to your own
particular circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Unless otherwise specified in the applicable
Prospectus Supplement, the Subscription Receipts, Warrants and Units will not be listed on any securities exchange. There is no
market through which these securities may be sold and purchasers may not be able to resell such securities purchased under this
Prospectus. This may affect the pricing of such securities in the secondary market, the transparency and availability of trading
prices, the liquidity of such securities, and the extent of issuer regulation. See &ldquo;<I>Forward-Looking Statements</I>&rdquo;
and &ldquo;<I>Risk Factors</I>&rdquo;.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our outstanding securities are listed
for trading on the Toronto Stock Exchange (&ldquo;<B>TSX</B>&rdquo;) under the trading symbol &ldquo;<B>ONC</B>&rdquo; and are
quoted for trading on the OTCQX Best Market (&ldquo;<B>OTCQX</B>&rdquo;) under the trading symbol &ldquo;<B>ONCYF</B>&rdquo;.
On May 3, 2018, the closing price of our Common Shares on the TSX was $0.63 per Common Share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Messrs. Wayne Pisano, William G. Rice and
Bernd R. Seizinger are directors of the Corporation who reside outside of Canada. Messrs. Pisano, Rice and Seizinger have appointed
the Corporation, at its principal place of business, as agent for service of process. Purchasers are advised that it may not be
possible for investors to enforce judgments obtained in Canada against any person that resides outside of Canada, even if the party
has appointed an agent for service of process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>No underwriter, agent or dealer has
been involved in the preparation of this Prospectus or performed any review of the contents of this Prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our head office and principal place of
business is located at 210, 1167 Kensington Crescent N.W., Calgary, Alberta, T2N&nbsp;1X7. Our registered office is located at
4000, 421&nbsp;-&nbsp;7<SUP>th</SUP>&nbsp;Avenue S.W., Calgary, Alberta, T2P&nbsp;4K9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><U>TABLE
OF CONTENTS</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Page</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_001">ABOUT
    THIS PROSPECTUS AND OTHER MATTERS</A></FONT></TD>
    <TD STYLE="width: 10%; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_001">4</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_002">FORWARD-LOOKING
    STATEMENTS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_002">4</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_003">RISK
    FACTORS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_003">6</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_004">DOCUMENTS
    INCORPORATED BY REFERENCE</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_004">6</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_005">DOCUMENTS
    FILED AS PART OF THE REGISTRATION STATEMENT</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_005">7</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_006">ADDITIONAL
    INFORMATION</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_006">8</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_007">THE
    CORPORATION</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_007">8</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_008">BUSINESS
    OF THE CORPORATION</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_008">8</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_009">CONSOLIDATED
    CAPITALIZATION</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_009">9</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_010">USE
    OF PROCEEDS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_010">9</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_011">DESCRIPTION
    OF SHARE CAPITAL</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_011">9</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_012">DESCRIPTION
    OF SUBSCRIPTION RECEIPTS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_012">10</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_013">DESCRIPTION
    OF WARRANTS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_013">11</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_014">DESCRIPTION
    OF UNITS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_014">12</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_015">PLAN
    OF DISTRIBUTION</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_015">12</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_016">PRIOR
    SALES</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_016">13</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_017">TRADING
    PRICE AND VOLUME</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_017">13</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_018">CERTAIN
    INCOME TAX CONSIDERATIONS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_018">14</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_019">LEGAL
    MATTERS AND INTEREST OF EXPERTS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_019">14</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_020">AUDITORS,
    TRANSFER AGENT AND REGISTRAR</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_020">14</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_021">AGENT
    FOR SERVICE OF PROCESS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_021">14</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_022">ENFORCEABILITY
    OF CIVIL LIABILITIES AGAINST NON-U.S. PERSONS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_022">14</A></FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_001"></A>ABOUT THIS PROSPECTUS
AND OTHER MATTERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this Prospectus and any Prospectus Supplement,
unless otherwise indicated, references to &ldquo;<B>we</B>&rdquo;, &ldquo;<B>us</B>&rdquo;, &ldquo;<B>our</B>&rdquo;, &ldquo;<B>issuer</B>&rdquo;
 &ldquo;<B>Oncolytics</B>&rdquo; or the &ldquo;<B>Corporation</B>&rdquo; are to Oncolytics Biotech Inc., including, where the context
requires, its subsidiaries and affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this Prospectus and in any Prospectus
Supplement, unless otherwise specified or the context otherwise requires, all references to &ldquo;<B>dollars</B>&rdquo; or &ldquo;<B>$</B>&rdquo;
are to Canadian dollars and all references to &ldquo;<B>US$</B>&rdquo; are to United States dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise indicated, all financial
information included and incorporated by reference in this Prospectus and any Prospectus Supplement is determined using IFRS as
issued by IASB and adopted by the Accounting Standards Board of Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Prospectus provides you with a general
description of the Securities that the Corporation may offer. Each time the Corporation sells Securities under this Prospectus,
the Corporation will file and deliver, except in cases where an exemption from such delivery requirement has been obtained, a Prospectus
Supplement that will contain specific information about the terms of that offering of Securities. The Prospectus Supplement also
may add, update or change information contained in this Prospectus. Before investing, investors should read both this Prospectus
and any applicable Prospectus Supplement together with additional information described under the heading &ldquo;<I>Documents Incorporated
by Reference</I>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>You should rely only on the information
contained in or incorporated by reference in this Prospectus or any applicable Prospectus Supplement. The Corporation has not authorized
anyone to provide you with different or additional information. The Corporation is not making an offer of these Securities in any
jurisdiction where the offer is not permitted by law. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_002"></A>FORWARD-LOOKING STATEMENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Prospectus and the documents incorporated
by reference herein contain certain statements relating to future events or the Corporation&rsquo;s future performance which constitute
forward-looking statements within the meaning of applicable Canadian securities laws and within the meaning of the United States
Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties
and other factors which may cause the actual results, performance or achievements of the Corporation, or industry results, to be
materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.
Forward-looking statements are statements that are not historical facts, and include, but are not limited to, estimates and their
underlying assumptions; statements regarding plans, objectives and expectations with respect to the efficacy of our technologies;
the timing and results of clinical studies related to our technologies; future operations, products and services; the impact of
regulatory initiatives on our operations; the size of and opportunities related to the markets for our technologies; general industry
and macroeconomic growth rates; expectations related to possible joint and/or strategic ventures and statements regarding future
performance. Forward-looking statements generally, but not always, are identified by the words &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo;
 &ldquo;believes,&rdquo; &ldquo;intends,&rdquo; &ldquo;estimates,&rdquo; &ldquo;projects&rdquo;, &ldquo;potential&rdquo;, &ldquo;possible&rdquo;
and similar expressions, or that events or conditions &ldquo;will,&rdquo; &ldquo;may,&rdquo; &ldquo;could&rdquo; or &ldquo;should&rdquo;
occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The forward-looking statements in this
Prospectus are subject to various risks and uncertainties, most of which are difficult to predict and generally beyond our control,
including without limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to all of our products, including REOLYSIN&reg;, being in the research and development
stage and requiring further development and testing before they can be marketed commercially;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks inherent in pharmaceutical research and development;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to timing and possible delays in our clinical trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to some of our clinical trials being conducted in, and subject to the laws of foreign
countries;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our pharmaceutical products being subject to intense regulatory approval processes
in the United States and other foreign jurisdictions;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to being subject to government manufacturing and testing regulations;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the extremely competitive biotechnology industry and our competition with larger
companies with greater resources;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our reliance on patents and proprietary rights to protect our technology;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to potential product liability claims;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our limited manufacturing experience and reliance on third parties to commercially
manufacture our products, if and when developed;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our new products not being accepted by the medical community or consumers;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our technologies becoming obsolete;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our dependence on third party relationships for research and clinical trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our license, development, supply and distribution agreement with Adlai Nortye
Biopharma Co. Ltd.;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our lack of operating revenues and history of losses;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">uncertainty regarding our ability to obtain third-party reimbursement for the costs of our product;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to other third-party arrangements;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our ability to obtain additional financing to fund future research and development
of our products and to meet ongoing capital requirements;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to potential increases in the cost of director and officer liability insurance;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our dependence on key employees and collaborators;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to Barbados law, including those relating to the enforcement of judgments obtained
in Canada or the United States;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the effect of changes in the law on our corporate structure;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to expenses in foreign currencies and our exposure to foreign currency exchange rate
fluctuations;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to fluctuations in interest rates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to information technology systems; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our Common Shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This list is not exhaustive of the factors
that may affect any of the Corporation&rsquo;s forward-looking statements. Some of the important risks and uncertainties that could
affect forward-looking statements are described further under the heading &ldquo;<I>Risk Factors</I>&rdquo; in our Annual Report.
If one or more of these risks or uncertainties materializes, or if underlying assumptions prove incorrect, our actual results may
vary materially from those expected, estimated or projected. Forward-looking statements in this document are not a prediction of
future events or circumstances, and those future events or circumstances may not occur. Given these uncertainties, users of the
information included herein, including investors and prospective investors, are cautioned not to place undue reliance on such forward-looking
statements. Investors should consult our quarterly and annual filings with the Canadian and U.S. securities commissions for additional
information on risks and uncertainties relating to forward-looking statements. The Corporation does not undertake any obligation
to publicly update or revise any forward-looking statements other than as required under applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Prospective investors should carefully
consider the information contained under the heading &ldquo;<I>Risk Factors</I>&rdquo; in our Annual Report and all other information
included in or incorporated by reference in this Prospectus before making investment decisions with regard to the Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_003"></A>RISK FACTORS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>An investment in the Securities involves
a high degree of risk. Prospective investors should note that there is no market through which the Subscription Receipts, Warrants
or Units may be sold and purchasers may not be able to resell the Subscription Receipts, Warrants or Units purchased under this
Prospectus. This may affect the pricing of these securities in the secondary market, the transparency and availability of trading
prices, the liquidity of the securities, and the extent of issuer regulation.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prospective investors should consider carefully
the risks described in the documents incorporated by reference in this Prospectus (including in subsequently filed documents incorporated
by reference) and those described in any Prospectus Supplement before purchasing the Securities offered hereby. Discussions of
certain risks affecting the Corporation in connection with its business are provided under the heading &ldquo;<I>Risk Factors</I>&rdquo;
in our Annual Report filed with the various securities regulatory authorities, which is incorporated by reference in this Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_004"></A>DOCUMENTS INCORPORATED
BY REFERENCE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Information has been incorporated
by reference in this Prospectus from documents filed with securities commissions or similar authorities in Canada. </B>Copies
of the documents incorporated herein by reference may be obtained on request without charge from our Corporate Secretary at 210,
1167 Kensington Crescent N.W., Calgary, Alberta, T2N&nbsp;1X7 telephone (403)&nbsp;670-7377, and are available electronically
under the Corporation&rsquo;s profile on SEDAR (www.sedar.com) and on EDGAR (www.sec.gov/edgar.shtml).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have filed the following documents with
the securities commissions or similar regulatory authorities in certain of the provinces of Canada and such documents are specifically
incorporated by reference in, and form an integral part of, this Prospectus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(a)</FONT></TD><TD STYLE="text-align: justify">our annual report on Form 20-F (&ldquo;<B>Annual Report</B>&rdquo;) dated March 19, 2018, for the
year ended December 31, 2017 (filed in Canada with the Canadian securities regulatory authorities in lieu of an annual information
form);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(b)</FONT></TD><TD STYLE="text-align: justify">our management information circular dated March 27, 2018 relating to the annual general meeting
of shareholders to be held on May 3, 2018;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(c)</FONT></TD><TD STYLE="text-align: justify">our audited consolidated financial statements, together with the notes thereto, as at December&nbsp;31,
2017 and 2016, which comprise the consolidated statements of financial position as at December&nbsp;31, 2017 and 2016, and the
consolidated statements of loss and comprehensive loss, changes in equity, and cash flows for the years ended December&nbsp;31,
2017 and 2016, together with the independent auditors&rsquo; report thereon; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(d)</FONT></TD><TD STYLE="text-align: justify">our management&rsquo;s discussion and analysis of financial condition and results of operations
dated March&nbsp;8, 2018, for the year ended December&nbsp;31, 2017.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any documents of the type required by National
Instrument 44-101 - <I>Short Form Prospectus Distributions</I> to be incorporated by reference in a short form prospectus, including
any annual information form, annual report on Form 20-F, comparative annual consolidated financial statements and the auditors&rsquo;
report thereon, comparative interim consolidated financial statements, management&rsquo;s discussion and analysis of financial
condition and results of operations, material change report (except a confidential material change report), business acquisition
report and information circular, if filed by us with the securities commissions or similar authorities in Canada after the date
of this Prospectus and prior to the date which is 25 months from the date of this Prospectus, shall be deemed to be incorporated
by reference in this Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, to the extent that any document
or information incorporated by reference into this Prospectus is included in any report filed with or furnished to the SEC pursuant
to the United States Securities Exchange Act of 1934, as amended (the &ldquo;<B>U.S. Exchange Act</B>&rdquo;), after the date of
this Prospectus, such document or information shall be deemed to be incorporated by reference as an exhibit to the registration
statement of which this Prospectus forms a part (in the case of documents or information deemed furnished on Form 6-K or Form 8-K,
only to the extent specifically stated therein)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Any statement contained in this Prospectus
or in a document incorporated or deemed to be incorporated by reference herein will be deemed to be modified or superseded for
the purposes of this Prospectus to the extent that a statement contained in this Prospectus or in any other subsequently filed
document which also is, or is deemed to be, incorporated by reference into this Prospectus modifies or supersedes that statement.
The modifying or superseding statement need not state that it has modified or superseded a prior statement or include any other
information set forth in the document that it modifies or supersedes. The making of a modifying or superseding statement shall
not be deemed an admission for any purposes that the modified or superseded statement, when made, constituted a misrepresentation,
an untrue statement of a material fact or an omission to state a material fact that is required to be stated or that is necessary
to make a statement not misleading in light of the circumstances in which it was made. Any statement so modified or superseded
shall not be deemed, except as so modified or superseded, to constitute part of this Prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon a new annual information form and
the related audited annual financial statements and management&rsquo;s discussion and analysis being filed by us with the applicable
securities regulatory authorities during the term of this Prospectus, the previous annual information form, the previous audited
annual financial statements and related management&rsquo;s discussion and analysis, all unaudited interim financial statements
and related management&rsquo;s discussion and analysis, material change reports and business acquisition reports filed prior to
the commencement of our financial year in which the new annual information form and the related audited annual financial statements
and management&rsquo;s discussion and analysis are filed shall be deemed no longer to be incorporated into this Prospectus for
purposes of future offers and sales of Securities hereunder. Upon new interim financial statements and related management&rsquo;s
discussion and analysis being filed by us with the applicable securities regulatory authorities during the term of this Prospectus,
all interim financial statements and related management&rsquo;s discussion and analysis filed prior to the new interim consolidated
financial statements and related management&rsquo;s discussion and analysis shall be deemed no longer to be incorporated into this
Prospectus for purposes of future offers and sales of Securities hereunder. Upon a new information circular relating to an annual
general meeting of holders of Common Shares being filed by us with the applicable securities regulatory authorities during the
term of this Prospectus, the information circular for the preceding annual general meeting of holders of Common Shares shall be
deemed no longer to be incorporated into this Prospectus for purposes of future offers and sales of Securities hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any &ldquo;template version&rdquo;
of any &ldquo;marketing materials&rdquo; (as such terms are defined in National Instrument 41-101) pertaining to a distribution
of Securities will be filed under the Corporation&rsquo;s profile on SEDAR (www.sedar.com). In the event that such marketing materials
are filed subsequent to the date of filing of the applicable prospectus supplement pertaining to the distribution of the Securities
to which such marketing materials relates and prior to the termination of such distribution, such filed versions of the marketing
materials will be deemed to be incorporated by reference into the Prospectus for purposes of future offers and sales of Securities
hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">One or more Prospectus Supplements containing
the specific variable terms for an issue of the Securities and other information in relation to such Securities will be delivered
to purchasers of such Securities together with this Prospectus, except in cases where an exemption from such delivery requirement
has been obtained, and will be deemed to be incorporated by reference into this Prospectus as of the date of the Prospectus Supplement
solely for the purposes of the offering of the Securities covered by any such Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_005"></A>DOCUMENTS FILED AS
PART OF THE REGISTRATION STATEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following documents have been or
will be filed with the SEC as part of the registration statement of which this Prospectus forms a part: (i)&nbsp;the documents
set out under the heading &ldquo;<I>Documents Incorporated by Reference</I>&rdquo;; (ii)&nbsp;the consents of the Corporation&rsquo;s
auditor and legal counsel; and (iii)&nbsp;the powers of attorney from the directors and certain officers of the Corporation. A
copy of the form of warrant indenture, unit indenture or subscription receipt agreement, as applicable, will be filed by post-effective
amendment or by incorporation by reference to documents filed or furnished with the SEC under the U.S.&nbsp;Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_006"></A>ADDITIONAL INFORMATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation has filed with the
SEC a registration statement on Form F-10 relating to the Securities. This Prospectus, which constitutes a part of the registration
statement, does not contain all of the information contained in the registration statement, certain items of which are contained
in the exhibits to the registration statement as permitted by the rules and regulations of the SEC. See &ldquo;<I>Documents Filed
as Part of the Registration Statement</I>&rdquo;. Statements included or incorporated by reference in this Prospectus about the
contents of any contract, agreement or other documents referred to are not necessarily complete, and in each instance you should
refer to the exhibits to the registration statement for a more complete description of the matter involved. The registration statement,
and the items of information omitted from this Prospectus but contained in the registration statement, will be available on EDGAR
(www.sec.gov/edgar.shtml). Each time we sell Securities under the registration statement, we will provide a Prospectus Supplement
that will contain specific information about the terms of that offering. The Prospectus Supplement may also add to, update or
change information contained in this Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation is subject to the information
requirements of the U.S.&nbsp;Exchange Act and applicable Canadian securities legislation and, in accordance therewith, files
and furnishes annual and quarterly financial information and material change reports, business acquisition reports and other material
with the securities commission or similar regulatory authority in each of the provinces of Canada and with the SEC. Under MJDS
adopted by the United States and Canada, documents and other information that the Corporation files with the SEC may be prepared
in accordance with the disclosure requirements of Canada, which are different from those of the United States. As a foreign private
issuer within the meaning of rules made under the U.S.&nbsp;Exchange Act, the Corporation is exempt from the rules under the U.S.&nbsp;Exchange
Act prescribing the furnishing and content of proxy statements, and the Corporation&rsquo;s officers, directors and principal
shareholders are exempt from the reporting and shortswing profit recovery provisions contained in Section&nbsp;16 of the U.S.&nbsp;Exchange
Act. In addition, the Corporation is not required to publish financial statements as promptly as United States companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">You may read any
document that the Corporation has filed with the SEC on EDGAR at www.sec.gov/edgar.shtml and such information can also be inspected
and copies ordered at the SEC&rsquo;s public reference room in Washington, D.C. You may also obtain copies of those documents
from the public reference room of the SEC at 100&nbsp;F&nbsp;Street,&nbsp;N.E., Washington, D.C.&nbsp;20549 by paying a fee. You
should call the SEC at 1-800-SEC-0330 or access its website at www.sec.gov for further information about the public reference
rooms. You may read and download any public document that the Corporation has filed with the Canadian securities regulatory authorities
under the Corporation&rsquo;s profile on SEDAR (www.sedar.com).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_007"></A>THE CORPORATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Oncolytics Biotech Inc. was incorporated
pursuant to the ABCA on April&nbsp;2, 1998 as 779738 Alberta Ltd. On April&nbsp;8, 1998, we amended our articles of incorporation
(the &ldquo;<B>Articles</B>&rdquo;) and changed our name to Oncolytics Biotech Inc. On July&nbsp;29, 1999, we further amended our
Articles by removing the private company restrictions included therein and subdivided the 2,222,222 Common Shares issued and outstanding
into 6,750,000 Common Shares. On February&nbsp;9, 2007, we further amended our Articles to permit shareholder meetings to be held
at any place in Alberta or at any other location as determined by our board of directors (the &ldquo;<B>Board</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have two material operating subsidiaries:
Oncolytics Biotech (Barbados) Inc. and Oncolytics Biotech (US) Inc., a Delaware corporation. Oncolytics Biotech (Barbados) Inc.
is incorporated pursuant to the laws of Barbados and is a wholly-owned direct subsidiary of the Corporation. Oncolytics Biotech
(U.S.) Inc. is incorporated pursuant to the laws of Delaware and is a wholly-owned direct subsidiary or Oncolytics Biotech (Barbados)
Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our head office and principal place of
business is located at 210, 1167 Kensington Crescent N.W., Calgary, Alberta, T2N&nbsp;1X7. Our registered office is located at
4000, 421&nbsp;-&nbsp;7<SUP>th</SUP>&nbsp;Avenue S.W., Calgary, Alberta, T2P&nbsp;4K9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_008"></A>BUSINESS OF THE CORPORATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">General</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since our inception in April of 1998, Oncolytics
Biotech Inc. has been a development stage company and we have focused our research and development efforts on the development of
REOLYSIN (pelareorep), a systemically administered immuno-oncology (&ldquo;<B>I-O</B>&rdquo;) viral agent with the potential to
treat a variety of cancers. We have not been profitable since our inception and expect to continue to incur substantial losses
as we continue research and development efforts. We do not expect to generate significant revenues until, if and when, pelareorep
becomes commercially viable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our potential product for human use, pelareorep,
an unmodified reovirus, is a first in class systemically administered I-O viral agent for the treatment of solid tumors and hematological
malignancies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further information regarding the business
of the Corporation is contained in the Annual Report under the heading &ldquo;<I>Item 4 &ndash; Information on the Company</I>&rdquo;,
which document is incorporated by reference in this Prospectus. See &ldquo;Documents Incorporated by Reference.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Recent Developments</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 23, 2018, the Corporation received
approval from the holders of Common Shares to amend the Articles to effect the consolidation of the issued and outstanding Common
Shares on the basis of a consolidation ratio to be selected by the Board, in its sole discretion, provided that the ratio may be
not less than two (2), and not more than fifteen (15), pre-consolidation Common Shares for each one post-consolidation Common Share,
such amendment to become effective at a date in the future to be determined by the Board when the Board considers it to be in the
best interests of the Corporation, but in any event no later than February 22, 2019, subject to approval of the Toronto Stock Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_009"></A>CONSOLIDATED CAPITALIZATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There has been no material change in the
share and loan capital of the Corporation on a consolidated basis since December 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_010"></A>USE OF PROCEEDS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The use of proceeds from the issue and
sale of specific Securities pursuant to this Prospectus will be described in the Prospectus Supplement relating to the issuance
and sale of such Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_011"></A>DESCRIPTION OF SHARE
CAPITAL</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Authorized Capital</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our authorized capital consists of an unlimited
number of Common Shares. The following is a summary of the provisions attached to our Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Common Shares</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The holders of our Common Shares are entitled
to one vote per share at meetings of shareholders, to receive such dividends as declared by the Board and to receive our remaining
property and assets upon dissolution or wind up. Our Common Shares are not subject to any future call or assessment and there are
no pre-emptive, conversion or redemption rights attached to such shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As at the date hereof, we have 142,325,222
Common Shares issued and outstanding. After giving effect to the exercise of all outstanding options to acquire Common Shares and
all outstanding share awards granted under the Corporation&rsquo;s Incentive Share Award Plan, we would have 154,164,330 Common
Shares issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Common Share Purchase
Warrants</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date hereof, we have 16,445,000
Common Share purchase warrants (the &ldquo;<B>2017 Warrants</B>&rdquo;) issued and outstanding. Each 2017 Warrant entitles the
holder to purchase one Common Share until June 1, 2022, at an exercise price of $0.95. The 2017 Warrants are subject to acceleration
if the volume weighted average price of the Common Shares equals or exceeds $2.50 for a period of 15 consecutive trading dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, as of the date hereof, the
Corporation has outstanding Common Share purchase warrants as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a Common Share purchase warrant (the &ldquo;<B>First Adlai Warrant</B>&rdquo;) exercisable by the
holder thereof until May 14, 2018 to purchase such number of Common Shares as is calculated by dividing US$2,000,000 by the Exercise
Price (as defined below); and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a Common Share purchase warrant (the &ldquo;<B>Second Adlai Warrant</B>&rdquo;) exercisable by
the holder thereof until November 14, 2020 to purchase such number of Common Shares as is calculated by dividing US$6,000,000 by
the Exercise Price.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of the First Adlai Warrant
and the Second Adlai Warrant, the term &ldquo;<B>Exercise Price</B>&rdquo; means an amount equal to 120% of the volume weighted
average trading price of the Common Shares on the TSX (or, if the Common Shares begin trading on The NASDAQ Capital Market, on
The NASDAQ Capital Market as of the date such trading commences) for the five trading days immediately preceding the exercise date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The First Adlai Warrant is subject to a
right to call by the Corporation upon the later of: (i) May 14, 2018; and (ii) the date of the enrollment of the first patient
in a Phase III Study related to pelareorep. The Second Adlai Warrant is subject to a right to call by the Corporation upon the
date of the enrollment of the fiftieth (50<SUP>th</SUP>) patient in a Phase III Study related to pelareorep.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_012"></A>DESCRIPTION OF SUBSCRIPTION
RECEIPTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following description of the terms
of Subscription Receipts sets forth certain general terms and provisions of Subscription Receipts in respect of which a Prospectus
Supplement may be filed. The particular terms and provisions of Subscription Receipts offered by any Prospectus Supplement, and
the extent to which the general terms and provisions described below may apply thereto, will be described in the Prospectus Supplement
filed in respect of such Subscription Receipts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subscription Receipts may be offered
separately or in combination with one or more other Securities. The Subscription Receipts will be issued under a subscription
receipt agreement (the&nbsp;&rdquo;<B>Subscription Receipt Agreement</B>&rdquo;). A copy of the Subscription Receipt Agreement
will be filed by us with the applicable securities regulatory authorities after it has been entered into by us and will be available
electronically under the Corporation&rsquo;s profile on SEDAR (www.sedar.com) and, if applicable, we will file with the SEC via
EDGAR (www.sec.gov/edgar.shtml) as exhibits to the registration statement of which this Prospectus is a part, or will incorporate
by reference from a Report of Foreign Private Issuer on Form 6-K that we file with the SEC, any Subscription Agreement describing
the terms and conditions of such Subscription Receipts that we are offering before the issuance of such Subscription Receipts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Subscription Receipt Agreement,
original purchasers of Subscription Receipts will have a contractual right of rescission against the Corporation, following the
issuance of the underlying Common Share or other securities to such purchasers upon the surrender or deemed surrender of the Subscription
Receipts, to receive the amount paid for the Subscription Receipts in the event that this Prospectus or a Prospectus Supplement,
and any amendment thereto, contains a misrepresentation or is not delivered to such purchaser, provided such remedy for rescission
is exercised within 180&nbsp;days from the closing date of the offering of Subscription Receipts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The description of general terms and provisions
of Subscription Receipts described in any Prospectus Supplement will include, where applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the number of Subscription Receipts offered;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the price at which the Subscription Receipts will be offered;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">if other than Canadian dollars, the currency or currency unit in which the Subscription Receipts
are denominated;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the procedures for the exchange of the Subscription Receipts into Common Shares or other securities;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the number of Common Shares or other securities that may be obtained upon exercise of each Subscription
Receipt;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the designation and terms of any other Securities with which the Subscription Receipts will be
offered, if any, and the number of Subscription Receipts that will be offered with each Security;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the terms applicable to the gross proceeds from the sale of the Subscription Receipts plus any
interest earned thereon;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the material Canadian tax consequences of owning such Subscription Receipts; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any other material terms, conditions and rights (or limitations on such rights) of the Subscription
Receipts.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We reserve the right to set forth in a
Prospectus Supplement specific terms of the Subscription Receipts that are not within the options and parameters set forth in this
Prospectus. In addition, to the extent that any particular terms of the Subscription Receipts described in a Prospectus Supplement
differ from any of the terms described in this Prospectus, the description of such terms set forth in this Prospectus shall be
deemed to have been superseded by the description of such differing terms set forth in such Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_013"></A>DESCRIPTION OF WARRANTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following description of the terms
of Warrants sets forth certain general terms and provisions of Warrants in respect of which a Prospectus Supplement may be filed.
The particular terms and provisions of Warrants offered by any Prospectus Supplement, and the extent to which the general terms
and provisions described below may apply thereto, will be described in the Prospectus Supplement filed in respect of such Warrants.
Warrants may be offered separately or in combination with one or more other Securities. If applicable, we will file with the SEC
as exhibits to the registration statement of which this Prospectus is a part, or will incorporate by reference from a current report
on Form 6-K that we file with the SEC, any warrant indenture or form of warrant describing the terms and conditions of such Warrants
that we are offering before the issuance of such Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The description of general terms and provisions
of Warrants described in any Prospectus Supplement will include, where applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the designation and aggregate number of Warrants offered;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the price at which the Warrants will be offered;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">if other than Canadian dollars, the currency or currency unit in which the Warrants are denominated;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the designation and terms of the Common Shares that may be acquired upon exercise of the Warrants;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the date on which the right to exercise the Warrants will commence and the date on which the right
will expire;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the number of Common Shares that may be purchased upon exercise of each Warrant and the price at
which and currency or currencies in which that amount of securities may be purchased upon exercise of each Warrant;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the designation and terms of any Securities with which the Warrants will be offered, if any, and
the number of the Warrants that will be offered with each Security;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the date or dates, if any, on or after which the Warrants and the related Securities will be transferable
separately;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the minimum or maximum amount, if any, of Warrants that may be exercised at any one time;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">whether the Warrants will be subject to redemption or call, and, if so, the terms of such redemption
or call provisions; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any other material terms, conditions and rights (or limitations on such rights) of the Warrants.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We reserve the right to set forth in a
Prospectus Supplement specific terms of the Warrants that are not within the options and parameters set forth in this Prospectus.
In addition, to the extent that any particular terms of the Warrants described in a Prospectus Supplement differ from any of the
terms described in this Prospectus, the description of such terms set forth in this Prospectus shall be deemed to have been superseded
by the description of such differing terms set forth in such Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 42; Options: NewSection; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_014"></A>DESCRIPTION OF UNITS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may issue Units comprised of one or
more of the other Securities described in this Prospectus in any combination. Each Unit will be issued so that the holder of the
Unit is also the holder of each Security included in the Unit. Thus, the holder of a Unit will have the rights and obligations
of a holder of each included Security. The unit agreement, if any, under which a Unit is issued may provide that the Securities
comprising the Unit may not be held or transferred separately, at any time or at any time before a specified date. If applicable,
we will file with the SEC as exhibits to the registration statement of which this Prospectus is a part, or will incorporate by
reference from a current report on Form 6-K that we file with the SEC, any unit agreement describing the terms and conditions of
such Units that we are offering before the issuance of such Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The particular terms and provisions of
Units offered by any Prospectus Supplement, and the extent to which the general terms and provisions described below may apply
to them, will be described in the Prospectus Supplement filed in respect of such Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The particular terms of each issue of Units
will be described in the related Prospectus Supplement. This description will include, where applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the designation and aggregate number of Units offered;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the price at which the Units will be offered;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">if other than Canadian dollars, the currency or currency unit in which the Units are denominated;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the terms of the Units and of the Securities comprising the Units, including whether and under
what circumstances those securities may be held or transferred separately;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any provisions for the issuance, payment, settlement, transfer or exchange of the Units or of the
Securities comprising the Units; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any other material terms, conditions and rights (or limitations on such rights) of the Units.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We reserve the right to set forth in a
Prospectus Supplement specific terms of the Units that are not within the options and parameters set forth in this Prospectus.
In addition, to the extent that any particular terms of the Units described in a Prospectus Supplement differ from any of the terms
described in this Prospectus, the description of such terms set forth in this Prospectus shall be deemed to have been superseded
by the description of such differing terms set forth in such Prospectus Supplement with respect to such Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_015"></A>PLAN OF DISTRIBUTION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may sell the Securities to or through
one or more underwriters or dealers purchasing as principals and we may also sell the Securities to one or more purchasers directly,
through applicable statutory exemptions, or through one or more agents designated from time to time. The Securities may be sold
from time to time in one or more transactions at fixed prices or not at fixed prices, such as market prices prevailing at the time
of sale, prices related to such prevailing market prices or prices to be negotiated with purchasers, which prices may vary as between
purchasers and during the period of distribution of the Securities. The Prospectus Supplement relating to a particular offering
and sale of Securities will identify each underwriter, dealer or agent engaged in connection with the offering and sale of such
Securities, as well as the method of distribution and the terms of the offering and sale of such Securities, including the initial
offering price (in the event the offering is a fixed price distribution), the manner of determining the offering price(s) (in the
event the offering is not a fixed price distribution), the net proceeds to us and, to the extent applicable, any fees, discounts
or any other compensation payable to underwriters, dealers or agents and any other material terms. Only underwriters so named in
the Prospectus Supplement are deemed to be underwriters in connection with the Securities offered and sold thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 43; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the underwriters purchase Securities
from us as principal, the Securities will be acquired by the underwriters for their own account and may be resold from time to
time in one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined
at the time of sale, at market prices prevailing at the time of sale or at prices related to such prevailing market prices. The
obligations of the underwriters to purchase such Securities as principal will be subject to certain conditions precedent, and the
underwriters will be obligated to purchase all the Securities offered and sold by the Prospectus Supplement if any of such Securities
are purchased. Any public offering price and any discounts or concessions allowed or re-allowed or paid to underwriters, dealers
or agents may be changed from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Securities may be sold from time to
time in one or more transactions at a fixed price or prices which may be changed or at market prices prevailing at the time of
sale, at prices related to such prevailing market prices or at negotiated prices, including sales in transactions that are deemed
to be &ldquo;at-the-market distributions&rdquo; as defined in National Instrument 44-102 &ndash; <I>Shelf Distributions</I>, including
sales made directly on the TSX or other existing trading markets for the Common Shares. In the event that we elect to pursue an
 &ldquo;at-the-market distribution&rdquo; in Canada, we will apply for the required exemptive relief from the applicable securities
commissions or similar regulatory authorities in Canada. The prices at which the Securities may be offered may vary as between
purchasers and during the period of distribution. If, in connection with the offering of Securities at a fixed price or prices,
the underwriters have made a bona fide effort to sell all of the Securities at the initial offering price fixed in the applicable
Prospectus Supplement, the public offering price may be decreased and thereafter further changed, from time to time, to an amount
not greater than the initial public offering price fixed in such Prospectus Supplement, in which case the compensation realized
by the underwriters will be decreased by the amount that the aggregate price paid by purchasers for the Securities is less than
the gross proceeds paid to us by the underwriters. Any such reduction to the public offering price will not affect the net proceeds
received by the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Securities may also be sold directly
by us, pursuant to applicable statutory exemptions, at such prices and upon such terms as agreed to by us and the purchaser or
through one or more agents designated by us from time to time. Any agent involved in the offering and sale of the Securities in
respect of which this Prospectus is delivered will be named, and any commissions payable by us to such agent will be set forth,
in the Prospectus Supplement. Unless otherwise indicated in the Prospectus Supplement, any agent would be acting on a best efforts
basis for the period of its appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may agree to pay the underwriters a
commission for various services relating to the issue and sale of any Securities offered hereby. Any such commission will be paid
out of our general funds. Underwriters, dealers and agents who participate in the distribution of the Securities may be entitled
under agreements to be entered into with us to indemnification by us against certain liabilities under securities legislation,
or to contribution with respect to payments which such underwriters, dealers or agents may be required to make in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any offering of Subscription Receipts,
Warrants or Units will be a new issue of securities with no established trading market. Unless otherwise specified in the applicable
Prospectus Supplement, the Subscription Receipts, Warrants or Units will not be listed on any securities exchange. Certain dealers
may make a market in these Securities, but will not be obligated to do so and may discontinue any market making at any time without
notice. No assurance can be given that any dealer will make a market in these Securities or as to the liquidity of the trading
market, if any, for these Securities. See &ldquo;<I>Risk Factors</I>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise specified in a Prospectus
Supplement, in connection with any offering of the Securities, the underwriters or agents may over-allot or effect transactions
which stabilize or maintain the market price of the Securities offered at a higher level than that which might exist in the open
market. Such transactions, if commenced, may be interrupted or discontinued at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_016"></A>PRIOR SALES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Information regarding prior sales of Securities
will be provided as required in a Prospectus Supplement with respect to the issuance of Securities pursuant to such Prospectus
Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_017"></A>TRADING PRICE AND
VOLUME</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Information regarding trading price and
volume of the Securities will be provided as required for all of the Corporation&rsquo;s issued and outstanding Securities that
are listed on any securities exchange, as applicable, in each Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 44; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_018"></A>CERTAIN INCOME TAX
CONSIDERATIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The applicable Prospectus Supplement may
describe certain Canadian federal income tax consequences which may be applicable to a purchaser of Securities offered thereunder,
and may also include a discussion of certain United States federal income tax consequences to the extent applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_019"></A>LEGAL MATTERS AND
INTEREST OF EXPERTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise specified in the Prospectus
Supplement relating to an offering and sale of Securities, certain legal matters relating to such offering and sale of Securities
will be passed upon on behalf of the Corporation by McCarthy T&eacute;trault LLP with respect to matters of Canadian law and Dorsey
 &amp; Whitney LLP, with respect to matters of U.S. law. In addition, certain legal matters in connection with an offering and sale
of Securities will be passed upon for any underwriters, dealers or agents by counsel to be designated at the time of such offering
and sale by such underwriters, dealers or agents with respect to matters of Canadian and, if applicable, United States or other
foreign law. As at the date hereof, the partners and associates of McCarthy T&eacute;trault LLP, as a group, own less than 1% of
the outstanding securities of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_020"></A>AUDITORS, TRANSFER
AGENT AND REGISTRAR</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The auditor of the Corporation is Ernst
 &amp; Young LLP, Chartered Professional Accountants, Calgary, Alberta. Ernst &amp; Young LLP has confirmed that it is independent
of the Corporation within the meaning of the relevant rules and related interpretations prescribed by the relevant professional
bodies in Canada and applicable legislation or regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transfer agent and registrar for the
Common Shares is Computershare Trust Company of Canada at its principal offices located in Calgary, Alberta and Toronto, Ontario.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_021"></A>AGENT FOR SERVICE
OF PROCESS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Messrs. Wayne Pisano, William G. Rice and
Bernd R. Seizinger are directors of the Corporation who reside outside of Canada. Messrs. Pisano, Rice and Seizinger have appointed
the Corporation, at its principal place of business, as agent for service of process. Purchasers are advised that it may not be
possible for investors to enforce judgments obtained in Canada against any person that resides outside of Canada, even if the party
has appointed an agent for service of process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_022"></A>ENFORCEABILITY OF
CIVIL LIABILITIES AGAINST NON-U.S. PERSONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation is a corporation existing
under the <I>Business Corporations Act</I> (Alberta). Most of the Corporation&rsquo;s directors and officers, and some or all
of the experts named in this Prospectus, are residents of Canada or otherwise reside outside the United States, and all or a substantial
portion of their assets, and substantially all of the Corporation&rsquo;s assets, are located outside the United States. The Corporation
has appointed an agent for service of process in the United States, but it may be difficult for holders of Securities who reside
in the United States to effect service within the United States upon those directors, officers and experts who are not residents
of the United States. It may also be difficult for holders of Securities who reside in the United States to realize in the United
States upon judgments of courts of the United States predicated upon the Corporation&rsquo;s civil liability and the civil liability
of its directors, officers and experts under the United States federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation filed with the SEC,
concurrently with its registration statement on Form&nbsp;F-10 of which this Prospectus is a part, an appointment of agent for
service of process on Form&nbsp;F-X. Under the Form&nbsp;F-X, the Corporation appointed DL&nbsp;Services Inc. as its agent for
service of process in the United States in connection with any investigation or administrative proceeding conducted by the SEC,
and any civil suit or action brought against or involving the Corporation in a United States court arising out of or related to
or concerning the offering of the Securities under this Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 45; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tv527785_img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv527785_img01.jpg
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M.<9!^AZ53\0?$#1?#E^+"Y>XN+W;N-O:Q&1U'J>PJ?PWXUTGQ5)/%ISS+<0
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MJMHOBNPUR[GM($NK>[@4.]O=P-#)M/ 8 ]1FK=AK-KJ-_?V=N7,UA(L<P*X
M)7<,'OQ6+??$71+&\N(";R=;5BES/;VKR10$=0S 8X[UJW_B&TLM(AU)$N+R
MVFV^6;.$S%@PR#A>WO5'P_XWT[Q-<"/3[?4-I#$32VK)'P<$;CQGVJ&;X@:9
M'J5U8QVNJ7$MK*896M[)Y%5O3(K5UWQ#I_ARS2YU&4H)'$<:(A=Y'/154<DT
MW0O$-MK\<S6]O>P-"0'2ZMVB;GIC/6HK3Q9IM[X8FU^%I?L$*R.Q*$-A"0W'
MX&M.RNX[^QM[N DQ3QK*A(P=K#(X^AJO>ZQ:Z?J-A93EQ-?NR0@+D$JNXY/;
MBHKCQ%I]KX@M]%N)O+O;F(RPJPP' ., ^O!XI]GKEG>ZEJ-C"[";3B@N-RX4
M;EW#![\5DV7Q TC4M0CMK*._GCEE\I+I+1S S9Q]_&,9[]*Z>BBBBBBBD(S6
M?JNC6>L64EIJ%M'<6\GWD<9'U'H?<5YU/\+=4T*X>?P9X@GL0QR;:<DI^8R#
M^*_C2>7\5X?W6_2YL_\ +7]WQ_+^5-?P+XT\2?)XE\2+#:D_-!:#[P], */S
MS7:^&/!>D^%;8QZ9;;7<8DG<[I)/J?3V&!71*NT5RWQ*LKF_\&S0V<%Q/+Y\
M+;+=<R8$BDE1Z@"LKP99WP\8WM\+?5_L$EFL;3ZRH$_F!LA4[[,$D^];'ABQ
MN;;Q1XIFG@DCBN+J)H79<"0", D'OS6!HMWJ?@S1[G0)O#=_J$ZRRFWGMXP\
M-R'8L"[9^7K@Y["NJ\$Z+/X>\'Z=IMVRM<01GS-IR 68M@?3./PJC\-;"ZTW
MP=%;WUO+;S">9C'(N" 9&(./H:Y.WM;W3?%^MSW%MXLCCFU$S1#38@8)5XY;
M/7./RKJ?&-C?1ZUH6OV-E)J"Z8\HFM(\;RLBA=R ]2,=*V="UQM<CFD.F:C8
M)&0%^VQ"-I/4@9)X]Z\VTSP/JA^&5[YE[KEO=F.XVZ8KA8W.YL+LVYPWUYS7
MIOAZ&2W\-:7#,C1RQVD2NC#!4A "#63XDLKFY\6^%IX())(;>XG:9U7(C!B(
M!)[9-9GB7PK_ ,)'X]A^U03BT&E.J7<8(,$XE!4JW9AUJKX<\/ZY,WC*TUL^
M7=W\<<*7<:[4E_=,@D7WZ$CL:N^%=<OM-L=,T"]\-:I#<VZI;/-%$K6^%&/,
MWYQ@XSCKS756&H->SWD;6=U;BVF\H/,@"S#&=R<\K5VBBBBBBBBFE0:3RQ2A
M *6EJK?7\>GI"TJL1+,D"[1_$[8'X<U67Q)H[I<NNI6I6U_UQ\P8CYQS^/'U
MIQU_2Q;07!O[?R)VVQR;^&(.",^QJ&'Q3I4JWS-=)$ME/]GE,AQ\WMZ]_P C
M4\.MV<]ZULLJYQ&4?<-LN]69=I[\*31>:U:6>C3:IO,]M&I8>3\QD.<!5]23
MP/>H-1\3Z9IFE1W]Q<*(YHO-A3(WRC /RC\1^8JS)K6G0SSP2WD*2V\9DE5F
MP44#))]@",U5?Q5I*FQ\N[CE6]G-O&R'(#A2<'T[#_@0JS;:S9SP>89HT/RY
M4NI(W.47H<<L"![U#/XBLEAN'M)%O'MW5)(H77<I+;>Y Z_UJ+1_%-CK=[+:
M6HE$\*%Y5=0-A#LFTG/7*D_0@]ZVJ*****************I:GI_]HQVZ>9Y?
MDW$<^<9SL8-C\<5C-X.5K:.'[81LC9,^7US.LOK_ +./QS4>J>"WU"WGA34?
M+CG>=W5HB0/-(.0 P^9<$ G(P3Q4U]X4EO//VWVS-[]LA^1AL8H4925=2003
MC!7'O45]X4>+1[J'3)-D[Q0);[1M\AHR<."2?[Q.#].<UI7OAZ&[TZQL$FE@
MM+1T;;$Q5F"#Y!N!R,':?PK*F\$R"R^RVFI&-#!+:$RP^:?)=]P .X?,O3/<
M=1P*;JWA"ZN9=1NX[P32S07"0QNI!S(@ !8MC"XXPHJ]#X=NEGCNY;^-KS[:
MMU(RP81@(C%M"[N/E/7)Y[8XIMOX1B@FTR0W+,+(OO79@3Y8LF>>-K'(I="\
M(V^CM)YCK<KM\N(N&W*F[=@Y8CKCH%Z5LP6%K;2F2"WBCD88+(@!(ZU8HHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
=HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tv527785_img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv527785_img02.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!=@'1 P$1  (1 0,1 ?_$ -8   $$ P$! 0
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M6<(BPI/4=NQ\UC8[C0E!:D\XV-!S91/<0" #N=MO+;KX:*#@F'BA"DJ422/
MD^!W^?GHX(D#.!ZVD**E] >IV &WAX?IT,8(J!&<"GPAU74D[= 4GKXGIO\
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M/?28?&0CY;QTL-)64D*3WD$;?3T'CX?#1B$.<(:#5\IAST^\*W.Q2K;;Q_9
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MN-_#2X8.9@D6 L)/8$_(_/\ #0)E!I3JA*ZPE*MB!NH;[CR_X;:*<'H,-B9
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M$C4@/)*4*2G;SV\O#8_$[Z.&H3BO0I\+[P3U/E^)\!H0(VRHVS87]20 3TV
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MJXV=QV)EC=.R]E>)TN:TWY1?U-ZS^1Y"EUVM$URIDR6ZVR+;.[D9XH?1N.Y
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M0!44(Z?6LHZ@#<D:*4#S+.K3J\4:G22QT/U=N_0^9(.^_GI4%&BN<2%CU"5
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M7T=!4<G9A?\ .E]G.'VN!6=W4<CO<@R7W,"=A3J6.S5158=7NML,B8XR("F
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MFWW,N:IJ^8\3D1++O^V'3(]V?LHS#D'.+&RR9W$Z]SW+>VWW UMA"X>FV?\
M&4? <"@4?(V.HA18\551+L<H;>>=+P2R^A0<;;<WVT)B&_TV\R 25D:2)S/L
M_P <X(1?>S[<HR*+%%S81P&[J?>:UR- <XP8><MI7(N275OPBV_+=J';'[6,
M)R) ]-:6X2TCU!W ;'.#3:KV3@53&GB>&?\ '&(BYV]T_MQSCV<TO$F 5-'
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M\AY8?I,9AY%1N9#7R\H=J:&'E4AR5E%0[;1T*AUT;)I3JG+!E;B!)627 2=
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M\R@):WVV(('GOX#XZ$"$"TK4@I )W\E$@;;]=_T:$"$H80GHD=Q\5=-^T[>
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M/)4T@8CW%Q7XRU;UU)08] GO)98=GN/27W3U(V4@42WW'?&]$/M4M011)6=
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MZR6&_P!&S17):?U94@@X) (Q,QD<(SFO8822Y3MJ33'.9GW8PV?9;RU;\?\
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MC4"7+D*]5+)=>!6!A'1U'N4,6X]M'#6(Y198QDUOG$Y4W,,YJZ*PK;_&:_\
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MI4.UKR*5@K>K'%8$))0>W5$1=BXY4IMCPT,STIEG*<A/E%#[GV,\8<:5=S9
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M[S5^L'&-YRAF-E_!+,IZ5!I\VL<+AN836L7K3EA86:_0=+,EUK[.*MR0XZ
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M04LSVI*G/2;;;4GM"U$>Q?0O<MII'*FCJ*=NHJW&E)2W(!;BE @(2O!25*.
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M)+)=;6V?!0(.J?O'9=/NBF<IWG%-L.H*5*22E20<RE0D0>T&<2-/4II7$K4
M9&>.,XO:OAWV]^Z:OGYSPGE"*S)(4=VQS?&)M9&IL]QEI"5/+N+[#XKBZK.:
MA@$%ZPIR)24'N4V3T&2T5RW?Z;/B@0A=1MI)D7%S6K3WJF<H[E5S%:YH4@(F
M9 @"1[I?7%'\\X'Y1Q2T,=./N9?6O]KU?D&#(>R&JF,;*4%)3%:<L:^0L?4I
ME]I*TCH?#6JVGU+V->F$-O.ED@8D$I,^.,%462M6VEZGD4*RAT\3^U/E7DN<
MIIVF5@F/QDB1:9/G4:10U\-!0I:&XT>6TU.L)3P20AII&RST4I(ZZCMQ^KNQ
M]N,)31O%VJUR1,DS5(X&><=5!MZX590FJ3I:2H&8PGV'LCK/[&L0XXX&DY;?
MUF&S\NR=NAO(TW/2S"=OZU8:6PTFCA.$J3$2ZZEQP,]RR@[GOV(UYHJMWW[U
M+W4:?<&NELP^4MDMSY?(1/M[(E]R[?8\HA+6E+@4F>&8!Q'MA3E.?95B$J59
M39\=M]V4@QYZE,39]@FP*5,QT,]BY':IOZEA*-^[IX:V>R;?*WDL-H 9G\H
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M\T=D]WM]S))&W1:?([?#STJ-9A'7E]S9LE2@=R2>OZ!YZ(PXWE#IAPPV"\M
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MSZ^GM[G(W7K&+CZ9U>]:0%N2W9SZIK#M4W]RA,0O%;!+B=T JT.Z";J$S).
MB"_MP4+<"#X'?J"3T\2.H2?EU.Q'AX:(Q)H7K'=&F.VWW$J;V(200?,I WVV
M!\_ZM%I"_"<C!K07$EL'23A/E#OQO$KW+;)%1C<"1,E+ 6M2$!"&&$H[W)$E
MUWTVHT9E.Y6XM24H2"2=M.T-%45E0*>G$^Z&+I6VRPVXU%?4)  XD18+"Z.N
MQR4^O"G*;*LDHG6E7W)U\XIKBS '@D_NZV0I*7<OO6UGZ4LA37>D%'>-SK3;
M9L^VV@)NE[= )QT$C"79'FC<?J5NK<%U58?2QLU.HRJ%*F6Y2&1P&7:8_9&C
M&Z_*#RFK/+/D2QC8/DCM]EF2R64S[;D&S0_35T6GQQ)+U52UD!QQR/T4G;M[
MB#T,WN'U*H*VSG;]$@)I4'5J&1D)2^,4/;GH=>+1ZEHW56K6:A;7C:']-*BH
M**AVX2SRBU'M"X#%+@\G.LEK(;=WDM"N]DVMU+CPH>*8@^DNIF.27W$I@0G(
M[0D3'3LLEQIM(.Y"OG-ZKWR[[AKE;:VUJ+I7B$X\<<H^BE$ENV)9N[V$D ?"
M46*XGR'C+GF8UPYC7)-'EU[!O+W)5UZ*R12I_+VHB_NEXPJS2EZ^]9]A"PTA
M"/W8*M@#K+[IL#=%B_\ (,H7J3CD>$2)W'1];0L@),L>\_QC")OVPXE:<@S(
MM-'3:4M.IE<FNB3I-8PQ>3FTH>>0TXDL.R#((/8"GIX#IJ1V?OS>#JB5.*1T
MG-'N ^V.7=:+?3!-0\V%*+0,_:<(Z#<%>SJMX9O8>:Q84;(\RCK$R=9694[0
MX[%E,)0BOAUCW>J_NXC"E=\I92TRL;CKL-;;37W>=U*>C5*0O\4\L/KRC(*N
MOMEQ0JF:;"7%8 Y' \/HYQ<S+<PQMIJ/,SG*8T&#ZS#K=47V:Q:S#4'TVC\D
M.^C%A1&T%;KJEM(;0.I U3MS4M_,WVW345T\AB9Q"HM73(92F8TDZCB!CE]@
MCF;[D+?AG,X#_(7!L;&N0IV:SY-/GC53)?G5N90:I3<R?V,HCK;FVB&TEMUQ
M;1==;4I24K0A2@6T[EN7;50BJN06A+OB(,\)Q:K19*:NIU)N@ 2@>#^/HCB[
M[H.0^!. ^+>;;JW]9JHS#!;&+CV)P(&8S,IE71IH#.'X)Q_AM4U=8O#1"G8_
M%,^ZES8D>#&AK4B('I!7KT[M>XTMR>3=&@I52W)7A5I(G],8IZE6:VOT;E+<
M]8;1J\OIRU$>*9D9"4HY<<AX_B6;\:<<9/EZ8N3Q9&$4[V-WN5V;EQ^6JE-M
MRU5N/JDNO^BMR6REK9ICU=DI0O\ =I2E.\/.M[GIVU75#WY,E))<XIQ&$NR/
M#U&_<+=<7Z(^<%.XHI$P98F0),LHZW>U7GJ]:XDQ>ML,ZN:Z/4-UE#&K'H[B
M8:6HY)CH8^T 1NU'2KL20%@I!.FJNT,76F*<YB)BA;OEGJA4LO&8[8MOG?->
M5U;5+9\?W&)W&*W5F*3,YEY1)G6Y=?B[,%4FL>AS94A3Y#1;>#@;)!(Z:HB/
M3BC:K36D#JX?"+S5^J.XUT7D*AQ2T2SCG9$]T=="Y2RFL354[5%!G.MF9(KT
MH>K'H;B7BI^W0DSP_(:26DIW44MKV)"MMKVTV:>C\F/EC(KA6NNU@KA_R N?
MLGC#V]R=#&Y-L8_,&(QT6*54=57\A,T$AF[:JK&LK(SK=S(L:PO-OA^"^AM]
M[KV*:V=(6=4&]VPM++V4X]L^BGJ-;ZVD1:Z]0FD 8F*4V%@B$$=Y 0DD; DC
MP(W&XW()\/QU71'I E),T?(<N[A&,:<)8! _=J.Q\-S^'PT(*"" &@5#?M_:
M \5  >'EN='"V_G'?".?/#C#R0%)V8<&ZAMO])'38C?1PTG_ (M1_I,>C?O7
M\?Z_\NBE&0:8\S$A,AK9*TC??8?AX'X;]-"9C7]">4&ZMM*2"4)0-ANH'?J2
M!TW/B2='GG""=*I#*#LTAM@+:)4@CJ-S]*O]+;SZZ*.B0TSXPWV'%2%$*W7L
M0%=/+;<;[ ;;C10B"Z/MF6]G $DH(  WWZ>!V.XW)TTI1!E!Q^0T6!ZGU%&X
M(2"KZ3MT'3KT&E(42<8(@&"S"7);?:XI00-^NVYV)\"-MAL/EI?"#!([HF'B
M#E7(^$<JCY5B<MA+A"(MW2V *Z3):C?]]46\8D(<8+1)0X/WC"OK001IK6KG
M''6TJJH$,X&.X_#&=<=>X?$7,LX]?"9=8AA&7X38/(7D>&2GNC:Y#7TO6F//
M!.T:<VGM (2X$KW&BU*YQ4ZJF>H%=)_Q+(G/L,3%&PJ.SL V>XG=.XV!V(Z*
M.VY'D='J5E/.(=ZH;<'26,)@^T8CXP1A<?T<"WMLEA8S21,KR&EJ:#(\L8K@
MWDMW14CJG*:KL)J'"EZ'6N*W:V0%@ ;D[#4>W;*%JH\TAL!_G,_;*+!5;QOU
M;;/T:JJBJV_@TH'"4IA(5\8<-1CG)-5<<B7AN\5R/&I6+URN(^,Y%(SB;M-D
M,&J=7,7F&:M&;:38>3WD<I$M2"AJ*\2EI):W,.NFKV7'2W5=1MQPJT23X9DF
M4]/LSB6J+CZ?.V#;]*[25U/=%URFJFM2@J06TJEI TD2;2"0=,SQ)B@7\P7V
M_P";\A<'8%[D[+#\?J^9N*:6J:YHP[&),O(:"7AK<Y3T";!FO=\JUCX5+<2Q
M,)*^^!(.VP1TD:55=6VY^C=26P )<)G&<NZ0]\/5M?M3;/J-4/[9KWJ[;:%I
M""ZA(&4R1X$S),\#.4L@8Y%\E\N)Y47C9<IGZU%*[=2U2K2]<R6SER,A=8F*
MKV9ST:(FNQ6D0RE%=!"%!AOM ^.N/:UJ;LSZUU!/4/RS4<^'&4:#?]S5-XZ=
M9;:/52&0*P,$C\4LA(=D0+E<=U]L+CM)+;:BD]".TD=Q7V^ 4M0W/Q.K>GHH
M=+R  ZK,Q3@RW3O*J600\K,S)^!)'N$-_'HRVW7"KO4DG<[@[;G<GQ&^VFU2
MU'3E!)\8U*^8F#]_"2([CB$A*PCN[MOAU_#21C!J&D3&<-:BDJ^Z:0X=P0.[
MP /7SV Z]-'(0C4J)91$B^B'D[ @=?CU\-NNY\=%#B0$Y1NCW]M60;&HK[":
MS66NQL8C*P&9!""T2=T%;:UM;H44%)6@]IW3TUQ5-*P^ZEUU,W$B0,S$E3W2
MOIJ9RC8<TTSA!4)),R!(8D$C#D8!EI+R@5-I/GLL*2DI'7L66QW!"O [#?8Z
M>!< TM?-PP!^F(AY*6F%E*=6H8CGC%A>6.7\1RK%#0U2<OM+&QNL=LX%1D,*
MGB4/&$/'H4J/*QK"&ZU+:I$*W#P"EK2E2FTE3REN;=M*V]MB^M7MZ[USRUT(
M).E4B )SD,,/9&N;[WO8;SM*@LM)0H%R;"9J&J<Y 3SPRB0.&L\.'Q..&.7L
M0R[(^+J'D"%R'@4F/;9%CT.GRN- <K%V$#L+5+E%?'C]CGVKZ5]CS86TI/U*
MU8:BEMF[;W3OTCA;IZ!8#Z=:I*(QYX8<I10K==ZVPHK;91MFDJ+E1J:<>+2%
MAR:5 26XE4LY320>V+"9)B4#E2_I\/Y;O5WV79!%M+_@;G+'6ZF KGRJ0R_-
M9XMOWK-]BDI.5X<DHA179SR&W2M*5E8]-2]ZW3MREN6VD[@V4$A2/ M"?&1(
M?-XM1S^F/&OIKZD;FV=OY7I'ZLJ326:X5"FJ>Y+"9-)4K7IG(ITRQF4D]N45
MRNX]=PUEEGAUC0/95#QG*,>SJLK[6]F4T^CSJHJ4I_*\E_A]S\KR=K'GYZV)
M<8A453[*G&5(.^O,]QLIW>P:"X*Z-U97,J/A)TF9$AA\(^@]HWXOT\JCMJR+
M;K+%T2$/I;;4*@*&"P2G,SGA*()G7K]E;VEK)+)GV=E/MGUQ&_19$F?*7,?]
M)L'_ &9II][9L D[;'?PU<[<S3N4A0R &)2E&:NI-0OS]2G2\,1(:3\)0VLD
MN[F]F%^PD/2Y'8&PXZKN4&4+_92E("4#U'"5; ;K42>I)+-+1)I-3= 0A)42
M1GXN)QG'&]=7[F\*BI"EEL! )G@$X@3Y8PF9,J-'&W:E1VW))Z D'?S\M.K*
MPL)>,U\XZD!+B.HD91DU(<=^A3OJ;_ =$_+0@0:;_=-I/AVH!)V\@!U_#IIY
M.0A,9,O-SDK2>H&Z"GH04N$,*/:2.Y8#G<GRW&DN<(=;TE*M6(E%HJWGO(:'
M"<0Q>'QA!B0*NUQ2T@WM7+RFB<N[3"X]U#;D0IE6AM1GV,&_>$TMN2%I*4$
M([FBV,Q%?J6:8.F0S/,_;!X\PYW9U_*3U?P\R8;\"J1D,1NOOE5F))F5$7%J
MW([RA,9N$]?OJ")*;$1XCJ9*BK<LCMUT09;3ED8!6G-68.V6<PXO%E194EA/
MR6TYJET$[*+''<KGVV/,X_<V@R1*A'Q6*B,LNL-15;!YSJE;?:WIM2B#(0WY
M=HJQ=T#E_CSA'0\PW]1+@5U;Q# =CU:LAN,?QQZ+ECUE4#*$8M(385\B8U.L
MUI93AS79*]-1>$A_;MV0I!)429'*'7J"G6U\^LS!E]>$ '^?\IK+U[D"'QU
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M-N3FXT8MQUR5JD/.R913Z\U]XK=V#:4B5]:?6W<'JZ:)]I&FC0M)>YZ0)2P
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M:IE^_JXH1Z-(]"=H8[B64>KZJ26UK*-DH,PU^EH))GA.*[YW[E;&_B<EXRK
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M;ANEBWK>W;OM]A#=J<2A!G,'4F0\,Y<<YB&398]&C-1C&<CV#"G[*-Z\=,I
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M$I<[E@=001N?@!U\=.I!3,'/^.4-3$X?+];$>C(<D(W44A0V^D^!(&Y .PT
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M3UT(/Q*PG!>G,0E"9#"UDC8CP5U_: 'B1HX3TE<S[X<T\AN.$1$#9*2M##A
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MB#(>9N0,DQZD./Q<[RNRR!H3('WD"F8L7UR6:BBA-,_:QX5:MSTTE*?K'^B
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MO_I/V0BG<>98E<-Z5A&4)=L' F"C\@LR92B=D)1O%[0I:NGD-NNFU7.E3_\
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M^/$1V[9-2F]>CV7+42VB-0<PBX;31UV(I:^'V-HC2;9;78ZM2D)+9:!6YNE
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M.9 Y 6_7V&33S KU)D>JM;\F[D("'7HKAV#!2TI1.R$D:.MLE2U5(=:U%"5
MF45BZ6&I6VX\TE1;2"< 3A[!%",5<A4<C-V[YHRFI5193(D;[QL.HGK6\Q&B
M5B?J<W7-DL.H<[N\-H.VPU8'K2?(EX_-*<2]UL*E61E['6 .\81+'#TFRQQ$
MK*)UPIMF#B5G76*'TL6$V6[7)K7[%45ET.(,J5(?,9*F^U;S"@DDC69;OIE/
M[=<:9GUM)F1[8K=A_4+7O"WN-J2$K<3*9 .<N.<*U<PR<AKY%KC5W(LSWK;<
M4_:(8LG7&NB6TPF'T)064CM2GY>.^O.5K]-;W<*-;U)4@.!1)&O$#NCZ8E8>
M:9>K4HU*9&&$^'#ZX0X][K\LQ5F-':SZ^C"X2:]UMBYL?OJ-IY?[X*?4\OL6
MVXV-@>J!T!U5:BU;BL%24.NY'F((B@5X5)21W"&5G'OPS+&;^RPZ;RSG%/\
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MJ@9>J9SG,PVK?D.JJGR+"1 L,M]9*\>3Z;J84&.$;%V:]W;//O$_3ZB#V =
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M)A?92;^ZEO+<69;S"%(_=H;:[G%J*!W].ZMN#-RK%5%E!0@DGEG$?7KW8JC
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M%$L%*VCV;?WM+WAOX;=</F"/+ 9\??&3[7_9G<KHCJW2JZ3I5,%1_+ _SH)
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M6H21W*4V\0' X>I&W3Q!UFV[*HW"O>K:1&AA)PEA.<2- SYD*)^Z!\9P0O\
MG9%O<RJVQLXTYZ\=>K5*E,HEPFG62KN4&0ZVE$LN$>F"1N$ZF_3S;;&YW@AX
M!2]0'MG': 6E@<C$/TUQ>Q,V=8;2I^'$FAF68:3Z:0I:2TZEA2GEM([3LK8*
MZ^&D[ZVZG;%QZ+8D08YU5!JJKH$YF45\]X?,;5-DCV%-8;E.3W2JIF]-A'A3
M#4X[C-=ZLB6].D+8^W#4J4DGL"V_4VV62D!.LXO#];7L"GH2>J#C*-FV0NBV
MX!45;*5IQ()$1QP/QW2<TXK'Y$M;?*GL:EU<B9'E,Q'$4<68S*1]R;6Y>[8\
M:)#B%3CJ4]BS]/8 -]3VSMMV:YJ5;MR+Z:RTI043CK$I#VS,0WJ+Z\[NVT6J
MW;#!6V:E#>D"8TJG,^R40#?V7(O'63T?).&TLT551;-65;;Q7&RMPULY*H\E
M<91+K+"E,I(]0 D)"A\38[;Z95E#7FHMZB[13PXB4;':_4^MW'ME%1N>G"%+
M1X@1+ C&'7RIQ[_B/3(]PN&O)GU&<27)&05-)$4]<8SE9?#5Y'D4\?93,6?)
M'^S/?ZM+A*%A*@"JI5#SED<<;8\)*U3 YSQB_P!8Y176\4Z*U@+VXAAN8(P/
MASQP)^,/GCCV'<NY;:8QDDVMHY.&PJYQZ;4WUM?X':N-2S]Q8"3+D5"[&3(6
MA8"UQV/0001WD==<M#>KA0%;BE&;AU8]THXZVX;<%4IBD2E#2%:6DI$YCN';
M%\L6Q/VB\85J*3/8O&\:]LWU_F]3699<Y.BOAA)BMM3K:()4I(>9 />AF,MQ
MS?<;]=1]WO7G\;DH>3^^9X:?9!)MN^[BPX]MIE02E."RB02><UR&7'*$MA$]
MIO#U%^78C@SN3G*YLJ<J\I*VPL;BO,HI7%5C^2Y:PVBN8CI:1TCE+K92%#J=
M5%^^;89/EZ=Y)!Y3F/>([-NV'U(N-8*>\UJ:1292U+3I5/.81/+D<,8&\=>Y
M?A/%,N?*^3'_ &NWMG$4S>2.0,6AY]A.8W4K]RQD3+<:JDSL7O92#WR=VUQ5
MG<A74C4I;Q:[\R*)J2@@<<9GG,8\83ZF;4W3:Z=*MP--[ALR52912.!BH;:G
MJDXK6T'#.8GB9$#A$Y9?5VEU12[&]LO;U[N,5<;BR8&3\=-4R,FAK:>4["5'
M=QX1)\/[-+_[Q#WI+;;!).R3I%;MQ^@DPR$D @F68$N8$9WMU[;E[2VS96KO
M:'4*5.GJTK2@D'3X7%S2I05@-*S,8B8QAX>WZS]L&$7/YQBM!D5?828Y9<;@
MRG7V69BED3V$V-Q,>]&$)84/5:;<4M(^E>QU;[-<+70)2FID5R'?/VPC=VT]
M^/TJDT2"XUJ(U*E(HYC3V<#*+87/-.+.4+]I+$*=5X]1W3MWC]--EP<4EO-J
M1.MY-E#EQIB9,Z)55+CD-QY"G?4W;2H%T*3IGZ?=K?0C<-%J32J&,H\=N/6J
M];[<V!4Z5UB3(:NSL'MC@3SY[5<O]W<7/O>/C/+F5Q<UDX([R?QUQCR9%2_)
MD<3\>M/UN189B]A311:T9PI^&ENM^_9*;9QXE W)=-;4]^IU'74?'IQ[8U"W
M)=V>]^DL(/E0Z299)U 2)'$$C&4Y3RCF/QIFV+2*VFARYDNER6!82)*;^4V'
MZ1Z1?(4U'A7+HW,9N>VM0W*1V[]P)VU WBRJJ4%+?S&7PQC7+/O9II26W<Y$
M?")A;8M9EG85T+%G)&6I6D.JAODLK)3Z@<;F,EMM^(\-BA25%"@? :KC;MYH
MCY>G4H 0ZZJWW)_S! QA%+X>Y"0ANR0[3US$Z,W*GBPM(D*362UK<1-BO!];
MA&W:>T^"CMX[ZGBY=:Q"$5I)0D")JE33T[*DL"1(@7Q5*J\ :Y$H9\BIJ8.3
MR:V6\_.K'+J*_?5<C[63?15//RE"+<X^\(12CL*7D)6D#=9!W2E15,-,TX\0
M)G[92C/;C2U3#SM4)R/U1V.]FG">1\<X4KGR=3SX>5Y=CE]BOMWQO)57&-5D
MRC4W FYMG&7Y'CD6798N+*E2Y$H ZPI,WL>)(;<052EGLKMOIU/SDN1E[LXR
M:OKTW2[M4#R-3'43J,Y>+4))&/;,G(88PR\]]X^3\;YGFF(81P]AE#BD>XF7
MC\ZNQ;&(D"_M[U_UKB;2RHR%S6IKTA(7*#C+?>23_>(U5+T*BH>D><>J-A^F
MEFJ6DO%MPD9_[E./> Y*<1C_ /7S$N8+\#,^%Z+(8SQ9<LXF,NN8O9MPH<G[
MAB>*$Q9^'WCT!T?M28:UE74+1J%J&Z1(#54H)6)3D3]&6,2]^]/W*)Y1H77"
MQF$N*2X!,9:TS( X2/?'SGS@9/O+4KD[ASF^QS7)*C%X'H<<Y!7Q).0X71D!
MY%;7TE+(5:.5<5QQ?W*T,/J>>'=U 2!:;1365#!=;4%K")2Y>SLBMTU,S8W$
M5%>>C3I?!4220I,\<<@% 9&1[(C/A3^53=<B\@X/@F39A'EV[\F3E'(4BK;5
M4XSQEQ_5PV7UWN1.6;*)L6TL+!T-16EJ27BE39 [21WV)FIJ+B46\Z<>X".G
M=/J39=NT%37U-*FHHZA$J5.G45+E@$#G] Q.$3=_,6_F'\><18?B7L;]I58B
MAXFXLCI@VEW7LQ_6RRRCM)$N[L)K9$N4JYE*>=6I/TN*7]7TA('1N)BMO+NB
MQJ(0V9*EQ4,"3WD16O3W;5;L6O'JMO6M8>WS6IEY)PA1IZ=8'3DC(:42R[Y3
M)CBSQCGL&'F4G+VV(,8VEBS+E5S[+J(:W79&[KZ6R]VDI4K< ^?78ZK-ZM=T
M?ID,N.J0M"2#C&NV&MIZE^KNXJ*4TKSJ5)P3Q$R,N!PB]U[DZ53EYC J<<D-
M997I;L3.QVIG5%TJ'Z@8^_C2F3WO1%+"D'?ZRGZNX=!&6)^X6196I]1;!F1/
M.)*Z[8VONRE6BI72+>4D@ )3,GLPSBLG$WM"YJY%Y*1C-#)IEP,FD&V5?2%-
M0E1V[68I2D-5,5"WEI<<!#33(0A'4=!MJW)W$S4G\_&?.//VX-MC9U65M"5$
M.'"4=M*+^7[C7%.*U=5EMW/NY%;80;:8[CTM=#/5953KTMM$F0VK[I$"/(=*
MBP%%*G6TJ()2-<YNE*I\H;EIG%3N^\*6MH_+TQDB6$:I=)GM5,D2^-N1+C+:
MEE'KO8A?V"Y-C&0A)]2/ DJ+:)?HI;Z(6"M7QUVK0W4-?E?,,3&(W-BI2\:E
M,Y*/\X:[?/UBPY-@SI_V4QJ K:*M);?1)#OIN(= *%QG&U>()UL?IAMJBO*^
MF\D$R/T1S-5+;>#V),0O?<\Y!!MVX<N?9)L''VWH*&BZ4RFRH%+P;0M.S!&^
M^_B-0V^MK)V[4A($A...LN#%,^&A+&(CYUNY%9(K\^BR7HL?*7_1D1T ^BBW
M@(9>?6A0&S"78RS^[_O*3J/V]5.*=#:&]>D:_P"/= K'JH+2:-&ILH!/?C#?
MCW7(W*59'A46,9+DDA#+(;,;'_MHS*U?2W(7/]%I(]/M\E#IXZO%7OFIW#;7
MK8XB2&@D3EE(B(]QNZ5R#2E! 7QY2Q^J+K>T7BC-:'/:FYRZ/)QR/BL23D5G
M+<DH]:.NL3]Q&4T^EWL:D+G=H;!.Y4-9ZC_DX\X[44+R6?+OY1:;CSVD<8UC
MT6?$Y$Y?L[6+E]UR/"DM\KW5+ J,[RA4A=W?8U7TB66J>VELRBS(<;)6^SNA
MPJ23OPU-YJ6:A;22=*5$"'V]OVLM@K2G60)X02R'@WBS&KAV\<Y S*3D"\LK
M,RGR;G*+W))DK,ZV.(D3(ERY,AM3]Y$KDEAB6>XQFOI1LD :Y5WRJ40)QULV
M:UM!12D8B,>7O=$Y$;9I$7=WBU?.9L8U1<U=B\\Q.5/?9DVL=<YI:%?=64J*
MAQ\+.ZG!W>/74M1550^XA2B=.H3]^,<;]LMH"I)$Y'Z(J%;>\;E-TR&'^3,V
ML4A4ZL$DW\JP0J'81TLVR92)#JUHCRFV4)?;43ZH *M]M]::[L*[7*C-UIM0
MI ">R41C5LI:8>8D)B&RGW+\BV>/7^,4&:9-C4YAAQY%?2WTZ+CF3,5T13WV
M5Q6-R#%]:3&V#2PC<=H!W'368W)EPJ\I2G\U*I&).VU-#4]5UQ(F$RQ[(J[1
M_P R+*\FL)$&XY#Y"?R%BNFT$*2W>VU@6*"3VQIU(DMNJ<9:FH;"'&T@(7V@
MD;C6Z[*K]OV>R%5V2DUFF6/:(C[?24MR2[2TP'5"M7L3#6M^:\\Y.SUB;:VV
M5Y%=(-<TS)O%V,J>_ A^DQ7-B7+3]TO[**E"&TI)"4C;;;62;EN%EN%T6JC"
M<3"*-#U/4&G1A+A$T<C^S;ECD_EI-AC5S0X5AU;C.)6?*^;7+\F&Y4YO9Q53
MY..T5>E"3<W@IGHRI*T*0AA:B'=M]CSTURJ; CJI)"2)Q9&: /7=M)&)2/?*
M)P:_E^XG>UD)<;W#9\C(([;+K013UTZKD@*V#;L)H[)2XD;]R75';QVU!W/>
M!NBM50J91,#LG_A'76[?<35+>0, <8N)C7#G&?&V&8U >:QRPY+QF)(KD<E7
MU*U(G1H$^R<?LI-.ET//5326TH:44$KV)V.VN)JZ-U%"]3H_J+04CO(@Z=AE
MH>:<2"MGQ>Z&ODW)D#&+UE$?(EY5V,/J<55J>;0IF/V>HZT\_NI+8"@E6VVP
M.I7:.T;IO D-S)IQ]$.JO3SMKJ.@R/E/#LCL=_B)5?\ ,V_^M.:O?]G7W\2H
MP#S-=_V1_'MBAO$^5._PU=,WCT)N(PD,4MK#CE=@])6T5+,5?59:23^\<W[4
MCQ.^L&#"[6K3BH\CC'IMJIZJI. 2BOV5^WWC",]8S,EK\RRFSN'7[,2).4K@
M--,SEE?J08\ ,LMH!)^I2E*^.NE=TK&P'2Q-L8STC")04M,^CQD$\CC#-XR]
MH?&R,O1D&.VF1UC;2VRY57=I'O"E2EE7V\,+#;C86L?M$G?].I-.YJNZ4BJ!
M3SJ6EC3IUJ YY3E'*JSMH\3:I=@P@CRQ4<Q2<H>QWC'C[(V(50EB/37ED&:+
M':](:2)<YZTLGH\5R2]([B4M>IT\?+7&BG;IS,D+5S.)CFK*%*VNFA4EGEG\
M(B.IXC]T-=82H-E"QJ:BWW>FV,#)8-G9.E2O27'C)9=;90E87N5=#OX ZT_:
M_J:W:[2[:EH'Y0*09#D3A[X@T6UYG!949<R3#HS[)A[<T5F,9&E$3))M8W<W
M?[]MM$5"UDPH0)66U,I2"I:1_K'/CK/W4N[A?75MI&*B2>,B><"H(IG65_Y\
M1SPR,0SC7N%J\JM)T>[M9,>"MTOQH;TU+,92%*4DK*$N-((0RD=PZ]3TUL/I
MUL[:CYZMX<!<1XI'$3&,I'@90JGN-%<+L67E!D)2<O#,@=DHM+QSAZ.0F95E
M&4W6UD<L[2BT B#7^HD/6<MCN(<>#)(:;)"2KM)\3K/?4*[4]7N5:+>VAJG_
M  H2$I]R9")"F6S4G2J0G%R+S/,)XYQ2DQ\R'H]6]'<%;71I!1/G+2DQXEA9
M2.KCTR7)7ZI!/8D?0-@G52L-JK-R7W]'3J#:D@X=N<=CR4T@TMJ3*4\\8I!>
M9K>O9.[30Q,C-.!$A##Y"UI05$MS&'>\K;=;2#W;$ >.K1N+TVK=J5*7FD%U
M7OS$N,1JMR&B6%O.CHC C5ACAEE%M:S$&^7^/(-!R1/D6./-[L7%(VTVLY'6
M!??$G7$U 2BI7%2A83(=7_J@3KMVYMN\W%T384$GLBO[RWAL*R6W]1NE>$K(
MF0%GVY&(_P",.,^$G\*@W& \5<6I;3%LF<CQBCL*3-9-0ZW<V->A<ZV5WVKR
MYC$%+O<IM*&PO8$C7?NK8&Y;6I#K5+5(;7(ZE%6B1XC$@)Y8913MB>MNQ[K;
MZE'7HGTI6H-@)07-/W03*>J69G.<2PFC1=8):X]C]338VIB&XEN/#0VU'CUW
M:I7JQX]>PGODLJ (&^^VX\>FN^U;+>K*5#=2^VYJ'B"931_JP&?U1RW?U5\F
MA+EHIEMA6K%0P7++3B<N/?%&LHXPXZP'$)>5\E9W-B4)MXT5MZFJ 56MM8+5
MZ%='FR)I37376D+?5*?;:8890K=9/TG6=K>AU02BJM-2Z@!0)Z:U)P!G]TB,
M&WC^Z"Z[?2YYVG2WI0HC "<A&CB;W#X%7<AWM-?TU?CU1C;GY?BV4(RQK(,C
M76N-0FVI\R'*CMU621'F(HF#[)SUTLN/%#:^P:T[?7[;:7<6VDW U3IK&QJ4
M2M6H\YF<S[8Q38/[QKHWNTOUC>NG<5@%24!W S B^5I P?-XR:_)VXRA*:E1
M$.3*6O8L+&K"%R&YKNXD/M5MM&4F1'0Z$.^@1WMI)*=>41Z=V1N]-6.H15FH
M0L)4M"E *GVA0GA'MI/K'O.X;<=W?1%E-O=;)0VH#PZ)I,@00)D1RWPY'%.4
M<B2.)>/\$Y'PW!,DLY<%J;C4VY;<KKF:Y(AS;G((B2<-9HIU.REU#;3"0"DI
M"_45VGTA??VP;4N&U!<+<[4,72F0*B:EJ&H-@DI)U8ZIC#C'C.T?O'WJ]Z@B
MP79IIVVNN%N02DZ5$C2H>'"6./"<.O.N(:CB["(D7(KK(\[QR^N++#L.:Q+'
M:]Z?E :6E0MOS;N>;*X'<$_:JC^LX^DM*])1W$)Z2[.IM]TKP>JE4RJ16D +
M*9R[ 1./2_J%^[V^>EM-3VD42JMBH1/4I(7IGP!,Y1J]DO!O(W%'/^6TEG8N
MKXX^RJI%EDM_0OTF./65HJ-+B1(-3.3-B3[!5=,?BSV&GBPA;9"@5I01Y+]1
M&E4>Z%HIP.FTXM)P$C)13,\YRCZ%;1WU4^H?I137JT%:G76VR6PHI7/2E1"9
M8B4Y82$,+W"<@<X<D<DYW08O(MF>/<;DW,>GAXRY.DO7U Q,5&@NRG(7<]*:
M?[@KT5$--)4EL=Q!)I5+;;WO"K73VI!(8,C+NGPX2CTX]=/3#TP]-K5NK=55
M2,WJI=;UI>"203F!J!XYRS,5NXQPA_)[B)52H7WE@JQ*I/=ZK#]<E3:?KL8R
M-U-%Y/@ES8[:Q[U&K[Y8EKL]6V4-I$G",#*<;+>=]T:[>-P6BIICMMRB"BEH
M)2"D@9!( GEC#V&;<SHN+G'\>NZ2JH*&=*JTP'P7 E4<K8[XD0PK%/<^E/TN
M*0H@^6M V-Z.6>_TM-?:A\I2H E))ECS$8U4;FHKGMRMK[40NL"24D_,"!/
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MDRI;LBTE2D.(CQY3P?#:XJUMF0II>_4N(.QU4=G5=NZ;;]Z4"XM0FF66//\
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M?I85@(R%O.0Y5E/0-DCN"$=/CJL5"5JH%4C)E3JF2.9[\\XMU==6J3<]LI7
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MMM76L52L492M!DJ:U\,_O?1%U59]R6V;]^W.H!Q,T)9HZ9:9G(:RT3*>$YS
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MJ;*)\6"*=ND_B*"LL+BUENZBN9FJ0H%#[,63)25@@_2D^&I^T5!*PIPR3V_
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&1A>'*/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tv527785_img03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv527785_img03.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!4P(7 P$1  (1 0,1 ?_$ .8   $$ @,! 0
M       %!@<(! D! @,*"P$!  $% 0$!              4! P0&!P(("1
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MS,O_ -Z:>+LI^"L?_?._#]%>P?>GYR(%+^D?$J*B>BS<Q3_3:::]E4_!6/\
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M&))LJ+U1==&1XVTO(L6E_*H:I5_1(T/=:HA6S8*%^6MU[S.SIU^RO6/]Y_R
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MOQTI7LW%)Q'$<#<45$3=-D5%W_'HO32E9[<)L47V6TV5=U_#K^"II2L"=7*
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MH.MJA@J@2+I=/:*DFW$/-^<T06^T:@=WNIG38"OETW4=U^.Q?Y;:L&KE8;#
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MR:I\HF.R#W;ILNZJJ)^.KX(JEC3?_)'TG#8=VS?<CFR_BG[/35:5TRDWGEB
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M)#O0HO1O"ZDD6YZ&W"J!\P<9E@/)5M4"T$6MF,1[N)6*^#S]6U/)[O@O(*;
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M'E:WOKI;G6SY;'LS-K,O,*?3O9@]4\ 'Z0M'5/D+^12NFU^DWO>L6YR^BO\
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M;ZC;I-^>G"K,N>Q'U0FY[JFK#<KS]\AF76-.1*=QA3E#<2(#$P*Q67#MG)<
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MVULO8(F,[B2U/C&X!00L&QMH1<&NA[MW)NKU8VYA<KLIZ9B6(SG5+2XE3?G
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MYG]6-PX7?^ZY.V,SA9^.:VCD6I+&0"EMMY BQ(+ALE2+\@2$C2IUG^*\%J#
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M0 I?U:4@AF3V.?+H;7X@6JE-+C^(4F;Y+0UEDN)892BX&.N1(A1")MJ,(_2
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M9BA">Z)WC'9:/D8I*5MV)O8$:<[>ZOS/A8_(X"^W,T%L9DG0N@H([_%8U,N
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M^$=G7E R#'XA26?^)AS&*]Z60S4<8'V4%&MD[C[E1%37:_2[#8?()S;"2_\
M614%338!ZU7ULE'%7N!KF_J)ZAY[:S^&6VRVUMV<0)LESP.1QH"IA2K:G4Z&
MMFO 7BJS< WDW*M?&MJ/*Z>97W%/<M.*MC3W#21I,/\ (FQ#Z7ZUE%$54D=0
M=E5=T3:,7N'+3H)P;S+:47U!T^(-3.2Q&WV]T/;XB,O'>A;3Y<E,C_"D=(Z2
M6@>DFUB>^OE@\K6Y6$^:W(6$\D0L/D,8+E\:A@X/@N6ADV/X5A-8Y(9X_P
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M*;+IU1 R>FE0IUA=7%$D>3D!6GU, )E#)N7WU%M)# R#C?Q&T5L@UR/#P(6
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M,7C783V,CQ%NKDN.]1#_ )B$FP'4"KDFUB=*L;XX^(+WYW%S6\-:(ZELIAM
M^5?54#D8TG3[!9LUP&&F4>!''W#<[=NI+\->,\,U/RX@9MX/%@^62D]226_
M2#P()%P>RI_:_P"#,)M=K<6UTO18^1;2MQD@I6$N)"O$G0CYN8JWUUAW!N3Y
M3+O>)>5\0S+),G:EU,:LQVZKLL:*^5HG9JO4$$S88BFD%U9$DV@(QV1IS=4$
MMD?WKG<?M)&R<:PV[@2LEUW0OM@G7P_, .5[:5QJ?Z987/\ J9&]7,JB<WN6
M-TAE9?4A@I3HB[)-EFUKVOWUK_RW[?\ S=FXY*T]80'8CU\S#M"BA'_+9;:3
MF6DJXR2#>G),ITD+W-)\C;?JO?\ *F3F\KCY?ID\N*M+>00+)AW!><MH"'.*
M>KC;E70,'N!ECUXQ;NZ<4ZK$08#BX\]EX@+=5<^6^R#8B][!0UK"Y<XLRO@+
M.:;%L2RH+.CJ,$QC#[6ADPWVZIJ\E5<U^>E?:4;U?9QC!FQ/WGW'2>:?3N94
M"3?7'<+GL)!PRX4EH.98)!41XBW<<%$<.G@2;:@UV'<>/=]4E0]ZJST7!Y%+
MR_)C+2EUEU#:NGKZ%<0;7-@0*\,(\A8E')E4W*>+9+94SUO-K$S2KEMVV)?F
MMA)KW&$?::IF;*-95PL^Q%4YC;(-RE%Q#4M];0G>B<_]# ?DN-PRH)#1-E*M
M8>%)U/NKE6>]/9NU]J26)2,9*Q;BUK7,\MTK2%DDD$#PIN;BQL!8#2KQ85:0
MR&7E$(GJMF6S6?D$-Z /Y:$.2U/2+70+F07TTZ\:&O(Y;32)].KK8D6ZJB;/
MC(D_<6;.V(:BRW'/4W?3J/*U^)[ASKF*(:WL1$S[3L1UA:^AQH+25]"?"%*1
M?J (%Q<<ZCC([:FRS/,.EC:7-5<XA:/VXPAZQ;4XU9-;<JI40W/95767"1IP
M"11(EWW1=9ZL%F\;/3AI969+Z_+0;&X6L]*3\2*AWWHJL@D(Z4H"TW3?B.H:
M>PC2E>/?<@.9';PYU/*FN*Z3[!.,2I\&Z@.B*+#%QILQ5)/3M-4[@7;X:D-I
M9^9M:6U(:8:=$_173XN[E>L=S(/MR^I;@">TFPJZ6&X:G%^)N2LUAQ6,CS=@
M8M91R7P,**BDG'FD%C[1=S\IDA!!0M^Q43?KOMI^3RJ6YBID=LH<ZCRMS-3\
M)B',B=1 M?C32SR[9CR7JJIG27XMC#C183=:ET-G-=-)PVQ$8/\ T2PDBJPD
M<8[(N@8NDX9 0:I+8W=A7TR,BR$L+%PI0L#?46)%C5Z4C$+C>4S'*7>SI()]
MU:Z[;$<_FW PCQX\LB<>B-#3Q;47%B/54T&)5&)P@<6P8>6 ZC0N-@:?5MO+
MOU5=0&)GQ]NY/[Z='4\.RI.>ER?C$>0"K'RO"XV-2+:>)/$>\5>?!N&4P*FY
M*Y#RVUC<9<@X#QK8YIA=JF8NVT#$,K/$[9:-\X@311CV%<$!"<TK+KRH  3C
M:+K<]UR,3N%Z%O0R%JRKVCB ;K0 /UD\0/;7,L K[HR$OT_QVWU)VLT06QUG
MI<*B+]'(DDGA7S@<@<L>1M?E.>65;SMR,1TX]\L5YGR2'*> FF_X4;LMS20R
M[.?5ILFP%OO7X)K'Q>+E9*+*R)?2Q)6+(2M02I?L!L3[JZ[NN7B<-D\?CD82
M-(;?Z?-Z4!?E:#5=@>FW:JU(E7Q7*O;;&L\RO*7^1863U#UGE:+:V3661+)6
ME9<AL6-F<AR=+CN.]P/OD@.(&Y B$/=T7;>V<9@<]!RNZ2F9BWR ^V"%= _R
MQ^J/Z5JTW-G=GJ%MF=LO9T8;3W,T@KCR DK#B?VVS^L.9*;@5>3P(\LLY\/,
MNRF_R' ,BE^-?)5_)Q7+:-Y2G1P&JEO-UM_C=BZV,27E^'PG2!Q"%L9K??')
M1) 4-:S.!DM2YN5#+J-I*)LHH(;(N;65;IT%N=>9:(,UN#LM4^*YZK8Y ,K]
MZGSGAT@'J;!Z[*X_*;<>5;U^>^!_%7FK'L-S>-EUB[AO)-7$RRKR+!X]2#5U
M7V,=8K$Y^/;..SH,H#;5EWN17&'6B;+94US:?ELSB<A&B.N*EX.&>I"'-00=
M;"_\U:OB]O#),Y1UN.J'GI0*'%H24K%A;6R?8>51M7S>&>!J_!L$Q[*,)8IJ
MZ8,VYR/+[[&6LQN8<)U'FXS>+8N_=9GD;[<9E$9:,&XX]J&XWTWUYW-E-U^K
M6[V9V.@,,12$A+3 "E*MIX4IN2=.0K&V3BL)Z+[*?<W/D)$IU!45.R"0A%]0
M5+60E('>??3=YLP:E:BSN1L"FM93QMGUE$N,1Y+@N3YU+51IC#;&1T?(%0,&
M9,H<MQBP$5]LVXQ&P:HH*8=9G&;/V=AI<B#O1R6PVD7C] 4%.*YIDCBD Z>*
MVE69>^]YY>)C9NS6HSTJ4YTS [;I9;/RN,7XA0MJGG<5JHFT_)D2ZSJ'"J[W
M(LWDL0XE= HJ:PFI8T#]H49)]5=QFCHR@3YKS0-(CXN.H1;?^&2:ZGL&)A\?
MM!S<TB< RE1LP5@+(!-O 3?\E6,QO9<7>6/V++QI=:D(^J,@();\Y/ZA<MT]
M9/!-[]U2G3\!<R9!CU;2<F<B8;@$*-6R[HZAV4N6S*I&VWD*LF1*;ZH)]K.;
M9!%;[^P4(D[MA)5UW.;\0E4?=N,DLL?0&Z&2M*7%6/ZJ+]1^%9^?C'<^51M.
M=#>7BIVCJ_+44)'^4JW2/>:V1\=^&^%L^/%ADW(340*JMI'\VO\ (I49HH;%
MI"KYCE(W CV$0/:L7I#[3: (K[)_PQ[OF77&Y;.:WED9.X5E3:7=4J5<!9.M
MDD_-[JW"$[A=BIC85E"7)+9L6TZJ2D<RD:@ :ZT_O'SD?*,<XKMCBTL.WLJG
M&[J132ZMDWX%[.K:^7*J&Y,.\,9E6RLQAI'19DC''NV%GJ@:WO<6UG=IRX>W
MG<E]9C(R4K"VUAQ%U#J(ZDDBX)L1?2M6VQD8&_8ZMW1X#\#*O.*0I+K:FE@!
M12"0H @$:@D:\>^OEVR3/<ZYFY+D3^8'K?+LGSJ+:/MY!>W)0G(=N\VZ<-]Y
MY]E]0KZ^4JL,US+8#LJ  CVZF-H1&,SFI$"6@K\T> 6N5>P<_=77MPQ9^"PK
M,J"(\=B/JZM2@E+?>M1("?:;5DXSY >0W#<R+C&,\I\AXW3XX\4FV7&<UR.K
MC4U?T^HFUM*Z25YMMF">ZV\(-F([==8&X,3.VWE!CI?4%']4@@V]AUK/@(PF
M[(J-R0!"D8HV'[M:%I6I/&Q22";WX5N&X>YLY.YCX9<N>9<JY&=Y-Q=G',IK
MG)V-9#"QOD/!+%73X^Y;Q:*S-J:B5WU<?Z.>W#8;23.9!Z01@?<&;M*7A,;/
M$[<T93^*!_L^F_Y*Y/ZN[6SDICZ7TW>C1\J1_:I6DVOK8D'2Q/"^G"I.Y#QK
M%U?E,\5TQ9#F=@S4VF29_P E8[1R*#"<GGL(5H>)XU7*E3=92^""2J^4BNJ@
M3Y_J9"D@:O(@-;GS1RLP?1XL$V;1H;7TT[;6KQ"&0QD!&.GK"LQTBZQK<VUU
M[+WJJ#N!.8K,F,T.4R/YG*2Y9O7T^(RZ;UQ->]R8[-<B Q%G5T]W]]$;1UG?
M=M>U.S6^O8K[H1T24DQ#P41X;6TUX5;R$=,E\2G2 X!SJ4L H.8<UN)%%/I)
M-6XWV,VKS+?LTS@KL226)Z_PGV'F=C;<!.[L)$]=T3+:G9/[L.,9<O%/,&XM
M[>%:K(D3GG/HB3T&M@?&>!U$1S'<0R5RLDVKJS;(XCAO'-@Q&RCP8#0RF7A5
MI+1YQ750TW[0'IMZQ3KRX?&X-9B'H\>)T21U'XUH@\F.2+W/_(_F2XQ\'K"D
MHN4;V@KH+)/&K=)C<D<?A$TB*1OLDU6HB;+O^"==7'&4R_"KB:FH#CD2)<)4
M+]U7%\:^/,GY"GPG9M>E90T;<:7<WTQER*J5+W<)5/9*$$FR1[5[%'J/JJ].
MLON/<TW*X>+ EQT"8@V\TBP &@NHZ#2I6#-0\OIDJ"SV7O6Q*=>T4NNN)M"D
M&OF0H3-;1M2F[.2T05T<8,6==_E,F'83&FVF$)1;>:7JB(6VM*C-;JR\10P;
M238\4B][>RMACQL+%F Y!GS0>P7JA_E'799D5/'S+#G[][Z-V7C4H9,B:U"L
M\1R![Z"4827'5A-G72' )T_F$FN]")-EUJ^78^]XYBY A4@:%/ZU^>G'C4]Z
M?SHN-R75&1Y:5+-KZ7UY5"G#/&MP4*VQ2]:J,58QM*GWK*JR.9C-W;23>C-Q
MH\F3'D1JIQPD>%2>*0ID*IL*GTUNN%W3%SF-E;$RY3#QBT =:3TI-@!QT%]*
MRM]81YAYO?\ C\$K.;GQ#OD-W<+*@TO4J' ](OQX=]-S[B!6G$D7 >/N,.5[
M_'\'J,?QFRL<,HLXM<92HN\LR+(K7)W;=I+ 9:2K.#'B/@[+1P8K?8*"B*B+
MI\%AYMHX>*OIC:B_ 6O8'LU K8?JH\I<G<^1A-"1T 6-B;](ND'GTDD=]KUK
M0MUY&YBRG)\&R;E_+0QRGK'[G#ZG,.1+OD9@GS19$&@FS#(:Z/*9C;"4EL'$
M)PD0!5$54WV!LV5*?EX]<MKRX[8+9*Q99(O9.OB.O*]<].[GH[<25'VHE,J2
MX0X"OI4!?12AQ2"-=>VLF#@>1X\UQI6X!B602^49%TU)>N,8N7Y8NOUC;EQ6
MNX[7D@2(EA <;64\^K@H"14440>Y4W7,X3'97:.%Q>W&5#=++MWU(%U2!<Z(
M U6?9>L*-&SFT-U[@]0M\[@C)]+I+8;8CN(2$,NE(\!ZK *O< <37TN>/'D[
M@?G5Q_DF&<PM1<9\@>.L7.=F\)Z*W7'FL.@;8@RN0\=F. @P+^.^H?FL%156
MY!H^W_")4#E>73E$NJS./4K'9)DD%*/"L6-KD:$'MN*PX>)PR%Q,;(0C)[=G
M$&(I7C0PI6MCQ"1K=)OPTM5:L'X6\>>$[2]Y'BY!5Y':FEB]_+.>W_'T.I D
M<?=9D3VK*:S6LM,JZOM+_$,C3N7;91UJYWUF8VRYFT/IH:XN266W)*BD2 LG
MY3<W"CR'&MTS?I-"SWJ1B]_Y7*3XL6%CE-KB,]98%@0+A(M<Z:'6G2X_B?-F
M*0,0P6VXYN,RDC*S2/CK=JW6UV6_0SF6WL,PG+*XV,?FYDQ&8<=B0H3K@2$:
M1/G(" <>'Z;9E>WD9N0EQN"19#JDE+:K:62L@))TX FMZD^I^PX6X'ML8J05
MO1&D%]M"@MR.@@?O7T))6V@W *W D \=#>M<7D?P3D6$S(\ZGCY!CV'6II-L
MH=U G2)L**_/]JPLY+@,MR;#\O\ 9=8EL-"KL4T!"W1UHRZ1B<;LP;IQ^-VL
MZ4VZ>M3Q"4A5AU:G0"]ZT65OWU(7M+*;@]08,)T0NHL"'9UQ:+GR[!NZB2FQ
M-M;UYJURUE_([42CJ*;#:+%\9@PXV3VCCM(Q>Q&VXOT25]+8J-G(M)+,EM7Q
M1DRA=Q(?<ZB!K?,]G<+MEQ6T(^03*RJB3]2M8+2+ZV+A/2 .'&HO;&X7]Y[%
M_&47'&#&<0J3](V@A];S>@2&@.LK5:]@+DGA5LN,?%NCO^7*AL7IF6U[N/Q;
MMC"Z9V>O?G+YN#518623HS4ZV8:D/24DM.]S+7<IBXJJ8#\^;@W'N[/8IO8"
M%LR<?&65)+:@M))).A3<<ZV3;6Q=D05O>JCF)DX3(R4CS%/NE9X>(E*C=/;8
M\.%64M\'HN(.:&,:QJ+5AD-?7A8YICOU,F/8QK.^=?L5AQI4(2KY+]43^RM2
MP>3VW&Q[4425-OV[LT0L-.SJ<D&<E!;!;0IP!95:]DI)N==+ 5%;P]7,9D\E
MA=HOX%Z?$FO6<R3;*E,MHO8%: DIM;6YM>JI?=1Y@Y:)>,,&I9=W$P&?@]CD
M%W7M&Q%C9+>0;ERN7\U:KB1)\*FKQ8)EIU&P7WO<]I%5"U#QW;I$IY0$DB]C
MH;GG8ZUL^.Q;2Y"FE62E)TY>'D;'AIRK5YC^7WW'^+-\BX)!'&9F04D&LFV4
M.]M5RJDNH4DRFV5?;TWT[-/^:LN X<8G%-I%1%54^4^@;@V9".W(N[\8I\8Y
MHW6$@V!YW(X:UK.VMQQ8V7F;-W(]!>S[E^ALN(+I3?PV03U<+<JM-XM>5ODE
M(RF/CF4YKR[E''D"*MSRYCU&>49I8X+AK\^+$QWEBCL(ILY-7U6.Y#)C'9,H
M^RW)BF\RON"XJ+S\1U2E*,,%*AJ3S'834Q*Q\-C&>3E?+^O5<(*B "/V=>.E
M;%K^M@17\TQ>SD9K:Q*RQ@VN'2,?BPSM;?*I911;MH#M@[,,8]S"%QLD'Z>!
M'9-"<4B#VUD=WIV[E8\#";+C*3*CD&6MT62]PN 2+*UOPKF_I_BMS[;S&0W+
MO?*8R3@$@F$RHNE31UY7T/#6U1!/XLL(<!2R1S'<9H:^6U(Q[!L;KJ^-60C2
M2\XC-Q?2:VSR'(SC+9R7E=/M:*4I*R#/>ACE;?VKD&(QG;=;9<R )LVY;J]@
M!U]E;!F=VN;W>$/.J$?"FUTMD"_?;OK!KVN1JIR2QC?N9-BI36VH[#40W;G'
MWY"DL?\ AINZ==+ %('57W&2^0U+H9;)&><:D"5 'E2P+*Y>+];\M<JG!W'!
M3D-76PDD C46!TU'=5UN+^.,FKWH&8YS(;K(34<["R.<XA.,18C/N-LOP^]M
M$>L31&D%%[U[NFKLYY_*R!)>2KK'<:C(UT RY9ZG.-N?PJIWW*<CQFAJO&[$
MJZOB/RIT3,.39T2$+P1PES'JS'ZU1B/$^G\%F-($-TZ)U^*Z\XU$_)$ACJ<L
M;>&Y^RI/'.,RY(F16R%#NJL>.YGF>54D-Z"W*E)4/,(Y5JA 00U4%5YEOT>%
M"38Q';;?HF^L&2PEY[Z5T@/WMTGYOAQJ:8>7'CJZ1XR2;5?7A_%<FRDZI^\K
M9U500)50DJY2IL7IZ1[6<U!6F9A!&<E6<=GWE>?>05:A1@-YX@; BU*;AWG(
ME;?CXF1$1]Y(-@LC@!H"3RTM4MB _DA=Q7@)MVU=>^O\=F1+I<?&!6R:NK2F
MQT7&)T\-ZU@HL*PN1K94"991(Y"A*TV^SW-_*)INFM,QT?<.>C%&W%*0[?7I
MN=>?#OJ97C\1]2#G(C3Z.VP.G_1VUK:\M+3EFTISN.+<MSIIB=(_D"_J:&_L
M&H\VOMUCRRKYB194EZ')1N:VY],IH:M/@I;[HI1.1R.=5'7$D2 F0C10*K$$
M:7(.M3^P<+M6#G&G9N+;99>NIHK1TA:0=2@D#J YD7%5DX<XCRN"U*P^_A8O
M1446$<I^[J\F<IKA951, 9=!8V5=9,U[=I73W&P?20Z#D=2W4>Y$36S;9WPC
M*HD[)>LSCG4 %:STH)L ?$; Z]];=ZB;5E-1&-]PMO-9O.0%=;'4YY-QJ4!)
MTN+ 6//E77[@M%7\28[B^*\9\BOXE5'C55<93B%#F%KC+89+>Y5:_FMO>1_K
MHDZ8EQ6M-FV[+$D::;%P4V>0EU>)CG8[RH<!0#?41<<-#V\*S'\G]^P_O/=D
M9D_2MI6E*B" H@$H23\W2?#IQM6M.?3W_*N<6&"W7)^0UV&C2?G6,5UYGV0\
MG5\*4;*.UM5)-\&(#"R6T1SZEL7"13$$#?KK>X&ST9%P0WIZ@E5K^*N8N[US
M+&.1G\7M)POR,J@'I?8'@3H%=H3IQ.@[:4FN+KJLQ_!L=Q'#)=SR?:9%%8.Y
MQRZ?()PHDR9 B5E9(1HVK9#V,W_=$&PCB38BJ*J[?)PS&5V-C-J8..TYO)J2
MKKD('47T=2K)24_,;6! N;BL=^+FMM^H><]4MS;@Z?3"1& 9C+;'0TYTCJU/
MA\)"A?G6_/QV\D,8\K<)M^!N?7(^&\SX;CLMF7?R(;\:PR"'0Q&H+U^S]#'?
M ,JJ207)K* OU2*DED_WA3C.9QV9Q&75.;OCIK)(4$ I6"G0DCC?MTK8X"H6
M6B-.XQEK.;=?MTH> 6A74+@)OI;6PUL.%&;>:^*>/&%2<"8Y&QNUJEC0?S5P
M;?)8SS%A!$(DRWQF@;P\I$:7:0VR<>%Z:XS]8Z?S=NR)OF"W@MY:6WUCSB0@
M]1U*SP%N/4KC;B:YGNC^'S>IG>;B,9+Z5@N)2W)9L$<= #HE/#L %C3X\??O
MN8!Q_ J8-EQUR=E? XQ3I\:Y$L*_'XDO^;ADNA)QZO??L*]I6I((2L'([&W"
M$@$^_N'6_2(4QG G<7DN?=_41YO2?+ZN8Z[=-P>(OQKET+T]GY;<J=E)F0AN
MM2>H-%Y!>"1^L47ZB!S5:W.M1_W&.1>3O*+F>3S [.Y!H, NUC/?TZN)#<W'
M\0K[,V5J,BKZZI"*E[!GP(QNOS2"2ZTZ!M>XVJ WK4<EN':,V;AF, _U!]T"
M0ITV0V;@**R=$IO>UR!:OI7T<]/M[>GNV,]N'=41B1.B@NQ4QQUN%A%^IH)3
M=16Y:X2-23P-1Y-E<K9OR!BV'<<UE56T.*8O71XW),J"_143=24-N:S,GQ[6
M2C;UZ2,[)"%PS;,R4NT4+MF<[E<!M7*RL%BLBB:IQ%_-+B5-)N+VZ[E-A[>%
M=-]--Q93U$]/U[_<Q#F/CRTN/NPTLJ2^/(44I*F>GK!/3S3Q-60M?%!N^S;A
MJNM,HA65'E@K?Y_@E!9V%T4YBM<1(UG6Y*Q7R'V;2WG'W) $C1#4.P!)=M?-
MNZ-][A:P4_8;4@3,<C(-O(\I7F)5>Q/1TW! X&W.MH]/MN[*^\#ZOQ-O/XC>
M*L<ZVIV:M1*3J 5)<MTA7$#2R3W5/T;%6.(^??RWBS().#WF$XW7UN;X)DC!
MVT"[>LY3]C'QMV!*:<IW)U17F#TA1;7V94E60-5;,DVSTYV:_$P\[,#(1V)C
M">MI*W$I*UFYZ4)41U$'0@7UTK2_5?U>D2H>V\',P;^2Q69EEI^:PVM2&F^H
M)ZEMM@@)U-E&UP+\Z\?N7\S<LW6&\48YCT(,;QJSK,@?RZIQU5KZ[([6K*O"
M.DV%%D&*5K,!TW&XSB-MONBZ78OM"HU3,7)3]7H9 XVYGF;>VL$[?Q>/<^FD
M/.KAK60V2.5S9(/.PT XCA6J3&KZUQ[$FN2L7IZZKM#J9>/7$HIEM+R&+9M3
M5>;R2HEP%93%[)Z*/RM@X2-@"%N*KUZ#F-D1\OLV-NO"F0T8"NN98']\GFD=
MO96F83<4#![EE[.W-+8=FY%)3!:4XGS&B;A)Z">H:6Y5/_C5Y#>1[F50L<.\
MY?S_ !N5%L,DY+XTQZPRK,I%]PZRC;-YEU"#TD[FKL\8D2F);OTTF.CZ-DTA
M[.DB<]>;&4N8@*-+]X!X7[-*VMR/"APP)JFQ-!LEU1 3=.@\1TT(K9'EU;@%
M;8V6/V5MG69X9DU>MH X7C)#<7.328KCV,7$MV^F.N54B++F 2Q8@MN(0(#S
MC9>XHYN\'L7)VO$P&WH+;&=85U2)'38/)[.KGWBYKF6T<-O?';KS&],[N*,=
MG= <@QUI'[E"!9UL"VJED$I2!=5[U$T'@;(HF.V!YUDC45J+,C7,[%(D5QIR
M=E]K&#)*QW+,IEX[8,6[4@F&'9,:F"170G13N:-X>[5K:.V)#J5#"LM/YN,.
MMI3EOF.MDWXV/(5T#=>\YF:8QTQ:TXO;,Q02ZVV?/4I.GC+8N1U<;6YVH>J\
MSHY=H.-R?S[$4;EJ5'[;DB5630==@19;7Y<%E/"K<GL>Q.90#EPI ]JIMW*$
MX[(F/,*>QG[K<:205#DL?,/<J]<F^Z,?BMS)&Y?/9PJE7"$(*5+03X5=-@?$
MFQ]].JAX?Y >DNYC;?F3#0U>3'70Y;[+>2)5QZ.V<A@U$]P6"M)A>VVRBDIF
M\:(B:DI60S$MYN:\[?(-I'2;ZAQ(T5_G"]:ZS],_D5RW$J$-#IL+>+RPO33C
M?H_+6SO.,IP6O8E5^/4R5KT2OB,QY^/R'8UA]%#4AW=>:D-OO/->XB$>ZDN^
MWPU![8QV[]T*>9Q24)3CQU:<O;;A6UOXV"@]+P#BNP:FHG9:D9CC8V$&QLY=
M_5V$N3,.]F.R)3U;,C@S7*,MY15V,V\ @@K\R$2(NZ[:BWDN3218E5S?V\ZJ
MP1$Q!5^K<U@8H&69S?8[B5-3SC?99FC9V1LSZC\E8F![$J)*L15G:N;#;YD,
M7/@G3IK<<[N)W<.V(N"E@B>DVZSP &@N>58$7(+;'U4CQN#@.=OMJ4N;N&^/
MLYKL5>8RW)J>[8;"GCY#@MP%5<64<+9"?*SD [&256I:R') *I"3;2*H(JIV
MEI&/@Q\ID!!*"I/#A>IN$\^(I"5AE1[3;[:;H^._$. 88[8\^9O?W'$M! <R
M_D"QSYQF;&OK:-8MCA>/R&6;"0Y9E G/J;4,X4AB<X\R+>SZ;+,2L",#/$=\
M$M'NK#.?S#TD08B6?O+DY<?;PKYF_(SB''./9G(5I2<2Y[Q8N?<C!F-;#S+'
MK'%I!<>$D<*!ZHB7+0V#=/+B@3Z,DC8QGG>TP[M5B/K7E8C#X*8Z5:E6@'M)
MT%;_ /2-1]LS7<$^W,W 4\5+"C>VO;3+_K99TD6AS*-B%;E''F1X];XMBL%U
MV95M09[#;4.VO8TD"(YKK-A&[H[SNQFV(D*#OOKLJ/4/:N#R,F/CX_U2%)&K
M@T)MR)XUQ>/M+U#W5MN,_,R*8.7+Q=0XA83TQP;%B]]%&WR\>ZD3A[)LWS^#
M!XQR?*+9N U^<Y54TTJ4CE38V=.,R;,1EQTBD ^Y7E[S3:$/S=ZD*G\VN63-
MS9N;&5BY#A.$42?+OR)O:WY*ZM$VAM;&9E6[7&DG>\U(0'K"YL ./$\*^H?(
MN#,?Q'Q9\=.,\HN/??H>)\>LY<)@6X"U\S,GIF8V '8*:%.0BNP0>_M1M 5!
MZ+OKGV[I!5.^F;N76T"Z1Q3?74<1[Q6N;1FR9STZ<03UK4$D:]73X?#WW!T%
M44Y(\8,5;R*O?P@JNFN8=<S.9M9-G*?ENLO$;;'MQI$M&WG7%;<0C%581>U"
M'95WWST^R:)TO%Y7"-*PDB.O]XIH?4%-C;J4$WZ;\=;<:YCG,(Y*AY7'[H<&
M<Q;Z3TL/?N"K_)2%6ZK<-.RE#@?+^:?"V]RW,,"N@S[',]E@7)?'F:N/7F(W
M;DH@*7/M8FZDQ<1/?4%DQ4%=OE43;V36R;\VFXQE9F4Q<A$CJ3<ETBQ)U)-_
MCW4VMA9.8V?%:R6+;@34JLA+;Z0X -!9)-SH!Q%7%\BN1.-<0XUPCD]_"[;C
M!>3K&F@TG'F*WTJWAS'9,"VL[NT:II!44<Z*GGLB@@#J@936R[ +??B#V/5,
MQQ?AR7$1[ZLB_43SLD:VOW5U/;T=6-RKN.S<9N5(QZ.H/  A/"P41<7UUX52
M/+N9[V@"E>B\?2I2W;+,VC69=1*V*<=T@<49%'BD%YR,ZVZT*JR<[WD1-B38
ME19#*["F893",HE:W9* II)2>IQ-N*!Q4!S*;U3&^K&/SLZ0W$GML_2*Z7[L
M@>2>0=T\&G#JM?B*L+S!Y"YER%XUXGBKU_&XMQ.%;5$6XI8!22'(W4BG*E+8
M6<Z7^91V*>;"./\ 1>S[:M '\4E,M;#M_"1,CD%[7W>^YCA$ 4A)/EJ5?4$!
M5B:U[/Y!_#L)WUM%EO+JEJ(4M(#J4C@1=%P ;:W-.CQPY.CU]>U)S*TK8.!-
M4T65)^O?B/5D=N<Y'*#,O"=;  5XH_0")6QWZHI:Z;^%<WE<?^'(+"9&46;(
M4A/42.5NFYO:M=W0_CMJ/CU W1-^BVNA(+C06$@$BYO<BVO;6NG[B7'CV \I
M3>5JO&:"DP?.TG9AA+^*RIEC'2R29"<[W7G*Z! KK/)H4AZW=KXSCWT)*:$0
M]R)K2F9DS:N9BOH0L95IWH4W8AP+!MT]/S ]@M>NGX1.&]0]NO8IV0XK%9!D
M*+A/@\JUPLJO;I M=1T[ZB+Q_P#'3E/R8J:;D?(,3<J<69M<YIG;W UH+UZR
MQ,8"U\+![[%';FI>J<G<22RZ"OF9/P6G9;:.$TJ%>W=G'-R9O[V<N76^/:/;
MV>^L?8<6'Z;8)_;#B?\ "Q"5-WT"A?BGMTYBMZ&*8.YA/ 7%F%Y?F]_G;7'>
M.58<=,NA72<NX]=ET%BU&.;E,)Z9.?MF<>OQC !*$%MF.VK $T6VJR,>N'!"
MGG L6OQ!XZU 9?)?3S/J8K#C8=-[]) )[M+$U'^5+'@X1AU?C=M$A9,U"GU:
M,7#CZ2+,3G3WH%BY)F2)IQY/O..,D)FH'[2(':(H*6H;\9S1">H]VM1LV).D
M'[S:ZE-@?, 2![^%0+C_ !C7QJ:3(Y+R]*O*),V2]#9=DL#21*47!6?,?<[0
M-2%$50!OO+N5!0>N^IB1+F38WT4I14U\:PA'EOHZG"0GM.@JZO&T7$%Q,[NL
MN<F%NZ;:"M;5R$V+597,! ARSCG'<=]V2U']]1Z[(?7KK$9<G3%"%CFG"CM2
MDD?D%64Q0XW]4D74*9T&H2BRE[+<?M0^JJXDZYG29BE_QT.FB2+-QB8PV?TZ
M*J1$1'!%M!Z=PJFLL1Y"5^5/0KS.P@W^!J DJ2I5@05=E:Q./Z7$,><G6EJU
M"OKZ[-ZRN79#S4AAEVQFG9OL1>U5$7P<<4B<7<D5/AJ&G&1$F@)5979SKH\%
ME+\']X;:#C[*MUA&05CN15;#SU]"H7WF')4!N9(.I*&;:"P\<%77&766S,37
MM[33;5,QB\S@EB/E2I2%B]B#S%Q60U!C+ECR4%L]XM4ODU=8'8'[S3T]KZ:4
M4$8T)^>U+)TE)B)+!E7#99F,/-NCNB'V[*F^RZD-K9V1M3(">BZL;Q+8U/P%
M8DV>I$KQ:)'/@*L9Q;@++V(.ER0RQ7,Y?CMG70,6MI)G_P E& XS827X+YDD
M.(D*4++"(+9(1J1(I(BZU3(OQVYBLBA'C*BKAVDG^>KT)<AUZ*MA72A*M2=
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M,?=68_=3R ?-:TM?6ZK:<.VQKJV(PCVUX$C=>/*GMOD$"&^#U.6Y-)597'D
MH<K53K">:J*;>9TWQ/CUOR"M'*R!5L;:74XXQ)I8$URN6=$R.=(R*WMEL&52
M0RS&C@XH%^YTWU8A;<GROO&;BTN2$1T?O%.I-D <UDCP@\;FVE;IO#UAQFPV
M,8,IY,./F[(C)1'MY"B!<J  U!YFGUXH^3=S:<I.U5?@+6$G4TUUCN+Y/^9Y
M!=VE);3PCP[*QC_F3,&ID6<>L8[FA-H%06E45$^Y2PL&ZJ/$.8QS"RRFX+B4
MDH!YGJ Z>/#6KSCV)W8C[FE36%];?G?2AQ =6TG4K\N_7Y1_64!;E>FM3VU]
M4<P9(^>;'E&4?4V-E96E[(-J0Q&B.MPJ]UV(3;X+(L2>[V01"!4'O)5[M=DP
MN&Q<23"RV&?:FL25#ZAI2@HHOJ2M-[I%^T"N/9I.[MU(R&U]SPCB##1=AUE"
MD!2!\A!L ;IL=*N)SSC<+G'@Z\PO#J_$LGY2QQNOO9D>V<D,91C\B%3VD=U(
M[5353;FX>R]]F+6_1."+ Q7?J$409[DB<UMG<.(<3DIL4(QCRU>6XI)#:]38
M(61TJ[+ FM/VWZ@[:^\GMF8.=Y^YL#T_6>8XGJ45 $)4";@D<C8D<+UH@P")
MG&6\HX[PMAF/8Y.B9'/=8O*K)IT3'?K(BU#KT[&\;N)[9L,Y)(O1;^E83M67
M(B^PJ[$NUQ&[IQVNK9H2KR7B;  ZW/+MK8\OZ<,.;U@^I<='7EB M]*1=338
M_7< U0@#]8V%;HO"_P 0,V\?KZISYOD/*<$RX^-9&,WL6Y8H6JJ72VF0QI%7
MB)0%O+&-DMOCMA("$#TX.YN<#S+<?W?9<U!XJ!(DKD!I1;NBUSH"1I8'G4YN
M?*0LPTPRI*%!#NEC<V[2+#IUX<01K>K7?E>#U&8R7XE79U.+U5+EC,]B0Y,8
MHHAWDL[>RR"%5-OQX<5]^P8<??06# ]U44;+?O\ 27XD&8.NP([:Y]$F9;-=
M6*4P@GJ( MJ0#IIQJJ&48QDN;9;6/GD-?'P6#.FA92:=QIJ9&99>-)S817F7
M'F71:!4]LU79=U153;4_#E28X^K@JZ7K]NM:ZN#-;66R%!0-K6[*E;C#&N-8
M>4#24^36<P;;Z>P$H#T<IL"@I2&4R]9N$#C3$RVL.P&F]NY6D4B0=]M8BI#B
M%%38*EDW-NWB>%7'V4)9^@OXU<N=_94Z<G5>.W<=&"L;)]H&R)J)9NLNMO=B
M(@OA*BA%,7-TW$A-4%?AMTUGMQ,NPWY[S;J&N/44D#XD6J/DQ@A-EZ$=M:C/
M*B!F%_Y,5..U[#=M5X#Q[A&+#*?6(;;3\^,[DTY@U>D-H*L/W2"9=J=RBB[=
M-3D/+93%QO\ Z<RWYA[.)[]*R<.MN-&)!''MJYO&^+8%QW3MG*9JLAR"75B-
MHCK\>;"C"Z@/'!C ).--2 [.XC7N)$VV1/77.<RY)CR2PM5\DLD]?($ZVOW5
ML&,9$@E;OA3?B>%28WD./2<LQZ4[ L(]9%F#-C]KAR(T*+*B.0)+\$'2>;CD
M_#>5M_VO;-UHNTE45VUE9G;66P;K<C,*44.)!%P1>XOI?C4U$ CN_2Q_"DGC
MP%+=FW<8-/,X\5^RC&DJ3!=@0G+!"^I49-<S-B,B\ZRQ,B]J JJ.X*6PJNQ)
M<VWF9.VLXG(PTJ^[QQ0+Z]NE8F2R"]0-;5*?&_'57;8G:QN1I#&,3,TH[!F#
M1LSHXY#60I,:R88RL(4H)1UOY>!.!7//LEVOM]>[VT1(+/KB/2)F04D!:P5
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MP.B4]Y)4D6U(Y5$QLC,5+!2A:@.P$U5[.<KY6<R^YY,XWSFKKH]N<6-780W
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M#,$:9>EF)2#<%*U$=(T;$4W7M04V1/756MNNH-U*&M2K/J1#@QBG'1UN/?\
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M!48_L/;]O @_$_GIU,>2/+=:?MR9V(6Y-I\QE7Q0;D(*_,<5ZOGL"^'S(GR
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M(M;C=214'9+]Y#P"QQMTTY9M\A5M%7MQ?CC.[+O5/@#KU)"CJJJG3YTU!O\
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MMD5'Q[P+A+);C[Y8_EN1DP2_N]JV>4,HZNWJJMHGZ-8KGK!FCJTTR16\8_\
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M).M0DF+<5C/BB@HH/>AJB$/<B*B;_#T^.LCZA0TMI6N2H:N8/PK#!2$R9]I
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M;BKH?43;^:N?R)]EP'1))OOLDJ^\CU:@D:&7N@C=BW(F^R J8;DG>71?7?5
M"> ->3D7 +$\*\9N-*X,8[*.+S! *5RV4&N;5N/WFBHS&E6I>]_&[E<5U'%4
M?5?3NIQX"L?ZN]['C6&F*0%=?EQ(S+TEM$DS;)JK2'[".=C2&C!RVF?E[E$6
MVV45$'<5W043T4J U!%5,MA7^T,LI'?8?;7NQ52V38"OR'(*Y4)L&U@7U]%)
MYI"5%E--MY RB2"Z"K;VPIMZ=V^O/4!S%8KC6/2;NQ&1SU IT1KGD"I>1A,P
MS)"$W$%J=D#0&C2>Z@>[]>_+!I47;;O[R+9/WO5;@9E'5*JQ9&+P+@\,;B.0
M^RU*D/D#EB,*[9W,?!!0D&54XG;&()\A..FRY =[44Q7?;<NO1$^;62(\OMK
M!&W\$YHA!/L)IQP^6.7F6"?2;CELTRA"X_*Q18C N#[:BUW0LH%PC('$7=!3
MIZ(J[HE%+>;3U+20CM(-OC4<G:^W75'RG7#_ $;'^:LC^XO,:Y5*[IL%&. H
M12DOYU4!]2'9 EG,5E5VW^9>U$7UWU8<FMLB[Q2D=Y ^VB/3Q,@_X9;ZAW)4
M?LI+G^<&!T0A_,#V!0C)"W$>7L%97Y242+:SFP5%$[5_>VZ]-8RLWCFS9U]E
M/M6G^<UE,^DNZ9@)@1WW@#^JTX?L!U[J8D_[IGB/3^Z-OGT '6!57F:*QJ,P
M<#;NWV'&9UD1*G:O1$W]/QU&*WIMQM?0Y+C)5WNH_K5LL+^&[U>R31=AXB84
M\OW#HO[+H%-5W[O_ (.=4B9WF%H[LG:Q5\79P^X9;?N"ZY5-15)/TN(FHY[U
M,V:Q_P#%)5[#?[#4\S_"%_$+(^3 /I':7XZ;_P"<L'XU&>1_>U\6*1MU:O"N
M=<D<;)006<&KJ5E53TW>N<CBJ([==^S9/CMJ(D>KNS JW6M0[0/TBMNQ'\#'
MKYD&PN0Q"86?U7'0DCVD!0^!-0_;??9P=A&BH/&_/+6/)0_:FV^<8K3,-]N_
M_P!4-1V;QX.J?[N^H:7ZZ;69'^'8EK4.QO\ -71L5_X=?J6\L??^;PK#1&I;
M0\Z1W6"$_&_NJ"+_ ._3R"HRG,:\=,.@QVC4&SO<UR6T,^B[$OY7CU4TH[IU
MV+46[ZY=0_PT(WY=1_FM6[X__P .)QQ?_P!;W4AMK_U499-O<O\ FJ%K3[X'
ME]D<*0]BV%<(8RZV[V=CN/Y3=F +U0@>L,I:;=)!]$]KU]=03_KIEQ?HC-UT
M/&_^'5Z=-H F9;,K(XD*8 /?8BX![+W%5SR/[Q/W K/WVVN4</Q9K<Q0:?B[
M$8[J*.RJD=^RC6[ZJB>F^^K$GU:W7)UB%E%QPN/YZVK%?P'>@N/'3EHV3D']
MKSB"?\VP^ J%;/[C/G=>^Y^;^3G)\7ZQ1]DJ6738NP@+NK@HE-2UP"G9Z=JH
MNH*9ZE;RDCI9DA/O KH^(_A%_AWPZ_-B;=CR56_T[DA0^"E6OWU$^8>2O.>8
M(V%CSOS5?RNT7'PF<IYDVP[LJ=P.-+<-,>V7IT'6N)W;NV3=*\A(X_M'\E=
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M;5-_AK$;]:=V9!?E1XT5 [[ VY=E;2S_  <[%@H2YE,GFG.\.-6)YVN#8?E
MJ++;R^\N83Q>YG,2O'N+V5H\(Q6+[2$'9W]]S#N"<=[.B*2JO1%^&H/(^JN\
MQXDH;9 YG0?EK<L+_"3Z+6*7(\E]1Y^?XO>$VJ*KKRB\D[4":L.>,X9D1G#<
M1N#-K:XP%Y54NP*6EK7&W/A\BJB)Z:UL^HN\#K]3\#6[8O\ AH]&\825X0.
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MOBZ;)UK'<W;55:;$NXD[BW7]O7JG32L+H7V'X5BDA+W&8M[[+VJ*;*BK\?\
M#5^Z;<16%(2HG0$TG,@:J\9+W@B[M[BG1?3;;;?;7JL9]A)2+:T.;BB*VX@J
MN^Z**'NB?@B^B(NL@*':*B),4GD:\W%5!143NW7X*B)^E>O35VXJ,D13;4:V
MK$<5H%[S/9%5!W]>OH/IZ)OJ1!'2*CI$,V%@?A5GO$!I$Y4SUT57<O%/S4[]
MR54[4\3N8.J)OT74IA2GZR3K_P#"/?\ NU5S??\  +6%A)MJK(8C\N29_/7Z
M;^(PQ<JG55EV0/YQD)(K" *BJWUJA"ZBL*BIM\=UZZ^D8[B#P(K\@TD= U'
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M.KVBF_<NS<M!N0\_)CHJ _(B/ :1E;#?<FWFT[B/;X)KR919),H]0->BXAP
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M\O730MN,?):<(BG"W,BFB[=C7%^:?3J*_ ]ZAOM3]FL1&T=Y/1S%7%F!!_\
M5+ ^SE6<SZV>B4;5&<QI5_\ -,_UZ2)/#7D&T+*-<#<Q*ZA ;QQN+\L)LU_W
MMNZG[NB:P?\ A]NW@(LO_5+_ #5*C^(#T7XG.8W_ +TS_7J0WN-^;V*B/(9X
M%Y<EV@ (DPO%N9JXBMHFQ*14PAW+^OU36S#:^Z(V-Z$XYU65Y+\I7NUM6L'U
MG]'OKRRK<D'Z8F]Q*:MKVGKM4>9#PWY'Y*RRXO"W,-<:"O<'],,T0VTW]!4:
MA>Y5VZIJ#>VOOIV2%2L<\L=OE+/\U;/$]=O1.%%4E&>QI43_ +VS?_SZ:S?
M_D<;C;!<(<T $041V27%F8]LTDZ_)O4*OS)^C7D["WB3?Z%RW_9J_-4D/XB/
M1<#3=6-O;AUM?UJPYWCWY)S+%AQO@_FAN!T)Q&N,LP8<0AZJ)]U,I$*I^&VJ
M#9&\_IB/H'>J_P#=*O\ 97M/\1?HRE-ANO&_Y[7YZ3;'QB\A[*;]5.X3YDF,
M15]R/$3C#- )>U=Q%3*J4"5-MMNG35K\&;^_W%VUO[M7YJJG^(KT82--UXT>
MQ3/]:DMWQ?\ ("3);GM^.G+T54-4?:E<7YB9$@JB=S8A5>WNJ==]4_!F_O\
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M_/9_K5WD>$'EVP49N-XR<WG]+O[,G^FN9&2JI=V[C+=:C:=R_JVU[_">\O\
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M]82_;J\]50^SP[\B^Y5W15XMR941?T;1/35\;1W)_NLG_5K_ #5=_P"8?T=
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MUQ%MWHC8J?NH"@NZE*_''%WF7SYY/8W9^:7$/"0\ <$<@<C\V>.-SB@7V/\
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<4LW^ZG[O[H_N_JTI7II2C2E&E*-*4:4HTI7_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
